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Abstract 
Primary infection with both cytomegalovirus (CMV) and varicella zoster virus (VZV) 
usually occurs at an early age, followed by lifelong persistent infection (latency phase). 
Indeed, frequent reactivation of latent viruses, particularly CMV, can be a major burden 
to the immune system and can play a role in configuration of the immune system.  
This thesis set out with the aim of understanding the balance between different arms of 
the immune system and CMV and also to find out the impact of immune modulation by 
this virus on the sequelae of coincident coronary artery disease (CAD). Meanwhile, the 
purpose of the VZV study was to determine the importance of adaptive immunity in 
protection against VZV reactivation in children with acute lymphocytic leukaemia 
receiving chemotherapy.  
The most obvious finding of the current CMV study is that the CMV-seropositive cohort 
exhibited a remarkable increase in the frequencies of CD28low CD4+, CD28low CD8+ T 
cells, NKG2Cpos NK Cells and Vδ2neg γδ T cells compared to CMV-seronegative donors. 
Furthermore, it shows that the expansion of Vδ2neg γδ T cells in CMV carriers is age 
related and does not correlate with changes in the magnitude of CMV-specific CD4+ or 
CD8+ T cell frequencies within those individuals. Phenotypically, Vδ2neg γδ T cells 
were found to be highly differentiated effector memory cells and did not possess ex vivo 
immediate effector function. In the CAD study, the most striking observation was the 
differences between AMI (acute myocardial infarction) and PMI (stable post myocardial 
infarction) patients in term of the distributions of polyfunctional CMV-specific CD4+ T 
cells that were characterized by the absence of IFNγ but expression of IL-2 plus any 
other measured functions (i.e CD107a, MIP1β, and/or TNFα). This cell subset was 
significantly increased in the PMI group. 
Finally, one of the more significant findings to emerge from the VZV study was the 
significant reduction in the absolute counts of VZV-specific IFNγ+ CD4 T cells and 
inversion of the VZV-specific CD4:CD8 (IFNγ producer) T cell ratio in those leukaemic 
children who developed clinical VZV infection. Contrasting with T cell responses, 
VZV-specific IgG was detected post primary infection in most patients; however, there 
was no clear association between the VZV-specific IgG antibody titre and VZV 
reactivation. 
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In this introduction chapter, the basic virology of herpesviruses (CMV and VZV) as well 
as immune responses to both viruses will be discussed.   However, there will be more 
focus on cell-mediated immunity particularly that related to CMV infection as most of 
work in this thesis is related to this virus. 
1.1 Virology 
Herpesviruses (also called Herpesviridae) are a large group of DNA viruses. According 
to their biological function and sequence similarity, they can be classified into three 
major subfamilies, namely; Alpha (α), Beta (β) and Gamma (γ) (Arvin, 2001, Pellett and 
Roizman, 2007, Davison et al., 2009). In humans, eight different herpesviruses were 
found to cause diseases, see Table 1-1. Each one of these viruses preferentially infects a 
specific type of cell whose defence mechanisms the virus can circumvent (permissive 
cells). Virus replication in the infected cells causes cell death and lysis; therefore, herpes 
infection is described as lytic infection. Furthermore, almost all herpesviruses can 
establish dormant infection where no viral replication in blood can be detectable 
(latency) (Pellett and Roizman, 2007).  See Table 1-1. 
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Table 1-1: Summary of characteristics of herpesviruses that infect humans 
   
 
 
Name Subfamily
Cell types infected
Pathophysiology
Lytic infection Latent infection
HHV1 (HSV-1) α Epithelial cells Neurons Orofacial infections, encephalitis
HHV2 (HSV-2) α Epithelial cells Neurons Genital and neonatal infections
HHV3 (VZV) α Epithelial cells Neurons Chickenpox, shingles
HHV4 (EBV) γ
B cells, epithelial 
cells B cells
Infectious mononucleosis, 
lymphoma, carcinoma
HHV5 (CMV) β
Macrophages, 
lymphocytes, 
epithelial cells
Macrophages, 
lymphocytes, 
epithelial cells
Congenital infection, retinitis, 
hepatitis
HHV6 β CD4+ T cells
Monocytes, 
macrophages Exanthem subitum
HHV7 β T cells T cells Exanthem subitum
HHV8 γ Lymphocytes Lymphocytes Kaposi’s sarcoma
CMV, cytomegalovirus; EBV, Epstein–Barr virus; HHV, human herpesvirus; HSV, herpes simplex virus; VZV, varicella-
zoster virus.
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This thesis focuses on investigating the immunology of two common herpesviruses, 
cytomegalovirus (CMV) and Varicella zoster virus (VZV). The reasons behind this were 
an increasing appreciation of their role in configuration of the immune system during 
health and their association with morbidity and mortality during disease (Khan, 2007, 
Gluckman, 2009, Sengupta and Breuer, 2009). In addition, both of these two viruses 
have high prevalence in the UK, for instance, the CMV prevalence was found to 
increase with age from approximately 15% in those aged 1-4 years to approximately 
80% in those aged over 64 years (Vyse et al., 2009). In contrast, by the age of 5 years, 
approximately 77% of children will be VZV seropositive; meanwhile 95% of adults can 
be seropositive (Manikkavasagan et al., 2010). 
1.1.1 Herpesvirus structure  
In order to understand the immune response to CMV and VZV herpesviruses, it is 
essential to understand both the viral particle structure (virion) as well as the replication 
cycle of the virus. Starting with the virion structure, as can be seen in Figure 1.1, the 
virions of both CMV and VZV have a typical herpesvirus structure. The outside 
envelope consists of a lipid bilayer derived from the host cell endoplasmic reticular 
(ER)-Golgi intermediate compartment (ERGIC) with virus-encoded glycoprotein. In 
CMV these glycoproteins are classified into three sub groups: glycoprotein class I, 
glycoprotein class II and glycoprotein class III (gB, gH:gL and gM:gN respectively) 
(Yurochko et al., 1997, Vanarsdall et al., 2008). In VZV, there are gB, gC, gE, gH, gI, 
gK and gL as well as the putative glycoproteins gM and gN (Arvin et al., 1986, Oxman, 
2009). As will be discussed in the replication cycle (1.1.2), the main role of these 
proteins is helping attachment of viruses to host cell membranes. 
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Immediately inside the envelope, there is the tegument, which is also known as the 
matrix. It contains most of the virion proteins as well as viral and cellular RNA. In CMV 
at least 27 relatively abundant virus encoded proteins are present in the tegument, the 
most abundant protein is pp65 (product of the UL83 gene) followed by pp71 (product of 
the UL82 gene) and pp150 (product of the UL32 gene), respectively (Tomtishen, 2012).  
Meanwhile in VZV, it contains proteins encoded by open reading frames (ORF) 10, 47, 
62 and 63 (Besser et al., 2004). In addition to the structural role of tegument proteins, 
they also play an essential role during the viral replication cycle. For instance, it is 
believed that tegument proteins perform two main roles during the replication cycle; 
firstly, they modulate the host cell response to virus invasion by blocking intrinsic host 
defences and therefore optimizing the intracellular environment for virus replication. 
The second role is initiation of virion assembly and disassembly during entry stage as 
well as during the final envelopment and egress from the cytoplasm (Ostrove, 1990, 
Liesegang, 1992).  
Both CMV and VZV genomes consist of linear, double-stranded DNA. In CMV, the 
genome consists of approximately 235kBp and encodes more than 170 genes. 
Meanwhile in VZV, it is only 124kBp and encodes around 70 unique genes (ORF); most 
of them are still undefined in VZV. DNA is separated from the matrix by an icosahedral 
nucleo-capsid (Knipe and Howley, 2007) 
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Figure 1.1: Schematic of herpesvirus particle 
This figure shows a schematic representation of the herpesvirus particle. A linear double 
stranded DNA genome is covered by capsid proteins, which are surrounded by a matrix of 
protein (tegument). There are several glycoproteins embedded in the outer bilayer envelope 
membrane (Image obtained from (http://www.virology.net/big_virology/bvdnaherpes.html 
website) courtesy of Dr. Marko Reschke, Marburg, Germany).  
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1.1.2 Replication cycle 
The replication cycle of CMV and VZV follows a sequential pattern of gene 
expression common to all herpesviruses. For instance, within the first 2 hours of 
infection, transcripts classed as immediate-early (IE) genes are made. The IE 
products, IE-1 and IE-2, are transcription factors that drive the expression of early 
(E) genes and, much later, the expression of late (L) genes. Therefore, the replication 
cycle can be divided into three different phases; Figure 1.2 summarises these steps. 
I. Virus adsorption and entry, uncoating, transportation of the capsid to 
the nucleus and release of the viral DNA into it,  
II. Viral gene transcription and translation as well as synthesis of viral 
DNA and  
III. Assembly of new virions, enveloping and egress.  
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Figure 1.2: Replication cycle of herpesviruses. 
This Figure illustrates the replication cycle of herpesviruses. Specific glycoproteins in the viral 
envelope help in attachment to the host cell membrane. Penetration is achieved when the viral 
envelope fuses with the cell membrane releasing the nucleo-capsid directly into the cytoplasm. 
To ensure transport and docking of the virion at nuclear pores, after uncoating some encoded 
viral glycoproteins and tegument proteins modulate the cell environment and prevent internal 
cell defence against the virus. In the nucleus, viral DNA is replicated into many copies. The viral 
DNA is then transcribed into the late mRNAs, which exit to the cytoplasm for translation into 
the late (nucleo-capsid and envelope) proteins. At the same time, the capsid proteins encapsidate 
the newly replicated genomes. The envelope proteins are imbedded in the nuclear membrane. 
The nucleo-capsid is enveloped by budding through the nuclear membrane, as well as 
endoplasmic reticulum and Golgi apparatus. Finally, the mature viruses are released from the 
cell into intercellular spaces.  Figure adapted from (Paludan et al., 2011) 
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1.1.3 Transmission and Epidemiology 
1.1.3.1 Cytomegalovirus (CMV) 
In the context of CMV infection, it is important to emphasize that the term ‘CMV 
latency’ here does not mean that the virus is completely in an inactive mode. In fact, 
there is a continuous but low level of virus replication that is usually undetectable but 
cannot escape the immune system surveillance. Supportive evidence of this comes from 
the possibility of isolating virus particles from a variety of body fluids. For instance, in 
addition to semen and vaginal secretions, CMV was detected in 61% of saliva samples, 
10% of uterine secretions and 37% of urine samples (Gautheret-Dejean et al., 1997). 
Therefore CMV infection can be transmitted by several means including blood 
transfusion, transplantation, nursing and sexual contact. Another possible route of CMV 
transmission is the vertical transmission from mother to child, particularly during 
delivery. Although CMV is found throughout all geographic locations and 
socioeconomic groups, incidence is higher in developing countries and among low 
socio-economic classes. Furthermore, the prevalence of infection is found to be age-
dependent, where the proportion of seropositivity increases with advancing in age 
(Gautheret-Dejean et al., 1997, Staras et al., 2006).  
1.1.3.2 Varicella zoster virus (VZV) 
Compared to CMV, primary VZV infection is usually acquired during childhood. This 
might be explained as primary infection is highly contagious from child to child by 
direct contact, breathing aerosols from vesicular fluid of skin lesions, or infected 
respiratory tract secretions that are aerosolized by the transmission of virus. In contrast 
the incidence of reactivation (herpes zoster) increases with age, for instance, nearly 40% 
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to 50% of the one million new cases that appear annually are individuals over 50 years 
of age who develop zoster (Gauthier et al., 2009). Conversely to primary infection, 
secondary infection is also transmitted from person to person by direct contact, because 
of its respiratory transmission. Nevertheless the risk of transmission of zoster infection is 
less than that of chickenpox infection. 
1.1.4 Clinical presentation of CMV and VZV infection  
1.1.4.1 CMV clinical manifestation 
In healthy subjects, infection with CMV is typically self-limiting with very mild flu-like 
symptoms and usually passes without complication. However, in immunocompromised 
subjects, including patients with congenital and acquired immunodeficiency, CMV can 
cause a wide range of clinical syndromes. This might include retinitis (which may cause 
blindness), pneumonitis, cholangitis, hepatitis, gastrointestinal ulcerations, colitis, 
abdominal pain, encephalitis, fever and weight loss (Knipe and Howley, 2007). 
Although the majority of CMV infections are attributed to reactivation of latent virus, 
the acquisition of new infection is of equivalent importance. For instance 30% of 
seronegative recipients receiving kidneys from seropositive donors become seropositive, 
and mortality was as high as 80-90% in such groups before the development of anti-viral 
drugs (Vancikova and Dvorak, 2001).  
. 
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1.1.4.2 VZV clinical manifestation  
Varicella-zoster virus (VZV) infection is usually a symptomatic disease. It has two 
clinically different forms of the disease; primary infection with VZV results in varicella 
(chickenpox), characterized by vesicular lesions in different stages of development on 
the face, trunk, and extremities. Meanwhile, herpes zoster (HZ), which also is known as 
shingles, results from reactivation of endogenous latent VZV infection within the 
sensory ganglia. Clinically HZ is characterized by a painful unilateral vesicular eruption, 
which usually occurs in a restricted dermatome distribution, see Figure 1.3. 
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Figure 1.3: Primary VZV infection (chickenpox) and VZV reactivation (herpes zoster)  
Represents the two different diseases associated with VZV infection. Primary infection VZV in 
children on the left hand side and secondary VZV herpes zoster that emerges in elderly people 
on the right hand side. The figure was modified from, Lancet 2006 368: 1365–76, and  Arvin 
AM. Varicella-zoster virus. In: Knipe DM, Howley PM, eds. Fields Virology. Vol 2. 4th ed.  
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1.1.5 Hazards of congenital and neonatal infection by CMV or VZV 
CMV is the most common infectious cause of congenital defects and it is important to 
appreciate the hazards of this virus. Congenital CMV infection takes places when 
pregnant women experience a primary infection or to a lesser extent a reactivation 
during pregnancy (Grant et al., 1981). It has been reported that the incidence of primary 
CMV infection in pregnant women in the UK varies from 1% to 3%, whereas more than 
40% of neonates from such women will suffer no symptoms at birth. Meanwhile less 
than 10% are symptomatic, which may range from mild hearing loss to severe mental 
retardation and disability (Peckham et al., 1983, Stagno and Whitley, 1985b, Stagno and 
Whitley, 1985a, Freij and Sever, 1988, Pass et al., 2006). Somewhat surprisingly, the 
incidence of congenital CMV is found to be slightly higher in developed countries 
compared to developing countries. This can be explained by the fact that in developed 
societies the sero-prevalence of CMV is much lower than that in developing ones, where 
more women of child-bearing age are already CMV-seropositive (Malm and Engman, 
2007). In other words, most mothers in developing countries already have high titres of 
anti–CMV antibodies that can protect their foetuses from being harmed by the virus. In 
contrast, in developed countries if mothers catch the virus for the first time during 
pregnancy they will not have enough time to develop a humoral immune response to 
CMV. Thus, the virus will be transmitted at a higher rate than development of the 
protective antibodies, and greater severity of foetal tissue damage may occur. 
Nevertheless, the presence of antibodies in the urine of 1% of healthy neonates reveals 
that, as in adults, the disease often passes unnoticed (Peckham et al., 1983, Pass et al., 
2006). 
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Since most women would be naturally immunized against VZV by childbearing age, 
then the risk of congenital varicella is quite low and the overall risk of infection is quite 
small compared to herpesviruses. However, most cases of congenital varicella syndrome 
occur in infants whose mothers were infected between 8 and 20 weeks of gestation. The 
risk seems to be approximately 2% if the infection occurs before 20 weeks of gestation 
and less than 1% if it occurs before 13 weeks (Enders et al., 1994, Pastuszak et al., 
1994). 
1.2 Immunology  
Although both innate and adaptive immune responses are involved in controlling CMV 
and VZV infection, in this review more focus is given to cellular elements of the 
adaptive immune system as it is more related to the work in this thesis. In the following 
sections, the role of the innate immune system in recognition and presentation of viral 
antigen to cells of the adaptive immune system will be discussed in more detail. 
1.2.1 Recognition of herpesviruses by the innate immune system  
Briefly, the innate immune system is activated when the infection is sensed by pattern 
recognition receptors (PRRs), through detection of specific components of the virion 
known as pathogen associated molecular patterns (PAMPs). Several PRRs are involved 
in recognition of CMV and VZV infection, however among PRRs the most studied are 
Toll Like Receptors (TLRs) (Takeuchi and Akira, 2010). Of particular importance is 
TLR2 that is integrated in the plasma membrane and can sense gB or gH of CMV and 
virion components in VZV (Wang et al., 2005, Boehme et al., 2006). In addition, 
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herpesvirus genomic DNA can be recognised by cytoplasmic TLRs such as TLR9 
(Tabeta et al., 2004), as well as by endosomal TLRs that can sense nucleic acids.  
Besides TLRs, there are other PRRs that can recognize RNA produced during 
herpesviral replication, which involve RIG-I like receptors (RLRs) and retinoic acid-
inducible gene I (RIG-I) (Paludan et al., 2011). Upon sensation of herpes infection, 
almost all PRRs induce intracellular signalling pathways that lead to expression of pro-
inflammatory cytokines such as type I IFN (IFNα and IFNβ). These cytokines have an 
important role in blocking of local spread of virus through inducing a state of viral 
resistance in adjacent non-infected cells. Furthermore, as will be seen later, these 
cytokine are important for the activation of the adaptive immune system.  
1.2.1.1 Role of natural killer (NK) cells in immunity to CMV and VZV  
In the innate antiviral immune response, type I IFN and natural killer (NK) cells have 
key roles in protection against CMV and VZV infections. For instance, observations 
from the murine model of CMV infection and to a lesser extent from human clinical 
reports demonstrate the importance of NK cells in early control of CMV infection. An 
example of this is certain strains of mice that are resistant to mCMV (Murine 
Cytomegalovirus) that become susceptible to infection upon interference with NK cells, 
either by NK cell depletion or through genetic modification of NK cell function (Brown 
et al., 2001). This also seems to be true in humans where several reports have shown that 
recurrent CMV infection can occurs in patients with NK cell deficiency, this reviewed in 
great details by Orange (Orange, 2002). Similarly, an association between severe VZV 
infections and NK cell deficiency has been reported (Notarangelo and Mazzolari, 2006). 
In addition, NK cells were found to be able to lyse VZV-infected targets (Ihara et al., 
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1991) and blocking of IFNα, for which NK cells can be one of its sources, was 
associated with spread of VZV in the skin (Ku et al., 2004). 
The mechanisms that are used by NK cells to defend the body against herpesviruses are 
still not fully understood. However, the principle of self-recognition and altered self-
state are thought to be involved. It is known that NK cells possess two types of surface 
receptors: activating receptors such as CD94/NKG2C and inhibitory receptors such as 
CD94/NKG2A and Killer-cell Immunoglobulin-like Receptors (KIR). The activity of 
NK cells is determined by the balance between the activities of these receptors. In 
normal circumstances, when host cells are healthy, the inhibitory receptors recognize 
MHC class-I (MHC-I) alleles, and send an inhibitory signal, and therefore the NK cells 
are prevented from being activated (Farrell and Davis-Poynter, 1998, Tortorella et al., 
2000, Khan, 2007). Nevertheless, as a strategy of CD8 T cell evasion many viruses 
including the herpesviruses have the ability to down regulation of MHC-I. However, this 
loss of MHC-I would deprive these cells of the inhibitory effect of MHC-I/NK 
inhibitory receptors and render these cells vulnerable to NK cell mediated lysis 
(Wilkinson et al., 2008). How the herpesviruses avoid detection by NK cell will be 
discussed late in section 1.2.5. 
1.2.2 Recognition of herpesviruses by the adaptive immune system  
Collectively, B cells (humoral immunity) and T cells (cell-mediated immunity) are 
called ‘the adaptive immune system’. The hallmarks of adaptive immunity are antigen 
specificity and memory, which provide unique mechanisms for better protection. Indeed, 
both humoral immunity and cell-mediated immunity are required for effective response 
against herpesvirus infections. However, since intracellular infection is obligatory for 
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herpesvirus infection, cell-mediated immunity seems to be more important for clearance 
of established viral infection. Therefore, in this review more attention will be paid to 
cell-mediated immunity.  
1.2.2.1 Cell mediated immunity in herpesvirus infection. 
Unlike antibody, which can recognize complete viral antigens, conventional αβ T cells 
(CD4 and CD8 T cells) cannot recognize intact viral proteins. Instead, their T cell 
receptors (TCR) sense only special epitopes of the short viral peptides that are presented 
by antigen presenting cells (APCs) in association with major histocompatibility complex 
(MHC) molecules. In addition, involvement of non-conventional T cells such as γδ T 
cells in responses against herpesviruses, particularly CMV, has become evident. For 
appropriate understanding of cell-mediated immunity, the classification of T cells 
according to the TCR structure will be discussed in the next section.  
1.2.2.2 T cell receptor structure (TCR) 
Generally the TCR consists of two heterodimer chains that are disulphide-linked and 
anchored to the cell membrane (Figure 1.4). Each chain is composed of a Variable (V) 
region and a Constant (C) region. The Constant region anchors the TCR to the cell 
membrane, including a short cytoplasmic tail, while the extracellular Variable region 
binds to the antigen:MHC complex. As its name indicates, the TCR of αβ T cells is 
composed of alpha (α) and beta (β) chains; meanwhile, in a minority of cells, the 
receptor is formed by γ and δ chains, and thus referred as γδ T cells.  
The propagation of signal from activated TCR into the intracellular compartment is 
facilitated through accessory molecules. These include; two pair of Zeta chains (ζ) and 
CD3, which possesses three distinct chains (γ, δ, and ε). Together The CD3- and ζ-
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chains with either αβ-TCR or γδ-TCR, form what is known as the T cell receptor 
complex. Furthermore, according to expression of CD4 or CD8 co-receptor the αβ T cell 
is classified into CD4+ and CD8+ T cells respectively.  
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Figure 1.4: T cell receptor complex structure 
This illustrates the T cell receptor complex structure. TCR is composed of two protein chains 
(α/β or γ/δ) and each chain is composed of a Variable (V) region and a Constant (C) region. The 
TCR-complex includes αβ-TCR or γδ-TCR plus signal transduction molecules. These accessory 
molecules consist of two pairs of Zeta chains (ζ) and CD3, which possesses three distinct chains 
(γ, δ, and ε). In addition, αβ T cells express either CD4 or CD8. 
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1.2.2.3 Comparison between αβ and γδ T cells  
 Contrasting with αβ T cells, γδ T cells are predominantly CD4− CD8− double negative 
(Raulet, 1989, Chien and Bonneville, 2006). Table 1-2 below shows more comparisons 
between αβ and γδ T cells. In the peripheral circulation, γδ T cells are a small subset of 
T cells, approximately 2-10% of total T cells. However, in gut mucosa γδ T cells form a 
higher proportion of the intra-epithelial lymphocyte population, where they reach 10-
50% of the T cell pool (Raulet, 1989, Deusch et al., 1991, Hayday, 2000). Notably, there 
is also another sub-population of γδ T cells that reside in the epidermal compartment of 
the skin, which are known as Dendritic Epidermal γδ T cells (DETC), better 
characterised in mice. 
Table 1-2: Comparison between αβ and γδ T cells 
 
Table modified from (Girardi, 2006) 
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Feature αβ  T cells γδ  T cells 
Phenotype CD3+ 
CD4+/- 
CD4 CD25+ 
CD8+/- 
CD3+ 
CD4-CD8- (double negative) 
 
Distribution 90 -95% of peripheral blood 
lymphocytes 
2-10% of peripheral blood 
lymphocytes, however 10-50% of 
intraepithelial lymphocytes. Also in 
epidermis (DETC). 
Antigen 
recognition 
Recognize peptide antigens that are 
processed and presented via the MHC-I 
or II of antigen presenting cells (APC) 
 
Can recognize lipid & phosphorylated 
antigens directly and independent of 
MHC 
Function CD4 T cell mainly helper 
CD8 T cells mainly cytotoxic 
CD4 CD25+ regulatory 
 
Seems to have important role in 
defence against bacterial, parasites and 
viral infection. 
As well as regulatory function 
Repertoire 
diversity according 
to TCR V (D) J 
gene segments 
recombination 
Vast repertoire due to high number of 
genes that are available for 
recombination; 
Vα= 41 Vβ= 30 
Jα= 61 Dβ= 2 
 Jβ= 14 
 
Relatively limited repertoire with less 
genes available for recombination; 
 
Vδ= 3 Vγ= 5 
Dδ= 3 Jγ= 3 
Jδ= 4  
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Our understanding of γδ T cell biology spans definitions of both innate and adaptive 
immune responses. For instance, after acute response to infection, γδ T cells are found to 
develop a memory phenotype resembling that of B and T lymphocytes (Hoft et al., 
1998). Besides, they can rearrange TCR genes to produce junctional diversity, which 
again is a typical characteristic of cells of the adaptive immune system. On the other 
hand, the recognition of common microbial molecules by using restricted T cell receptor 
(TCR) as pattern recognition receptor is, indeed, one of the common features of innate 
immune system cells.     
Based on which TCR gene segment is expressed, γδ T cells can be classified into several 
subclasses. However, for simplicity in this thesis they will be divide into two main 
subclasses; Vδ2 positive γδ T cells (Vδ2pos γδ T cell) and Vδ2 negative γδ T cells 
(Vδ2neg γδ T cell). One of the most common Vδ2pos subclasses in peripheral blood is 
Vγ9/Vδ2 T cells, which represents approximately 70% of γδ T cells in peripheral blood. 
These cells can proliferate significantly in many acute infections. This proliferation is 
particularly clear in the early stages of infection, when the proportion of Vγ9/Vδ2 T 
cells even may exceed that of other lymphocytes such as in tuberculosis, listeriosis and 
malaria infections. Furthermore, they are able to kill tumour cells such as myeloma and 
lymphoma cell lines (Ferrarini et al., 2002).  
In contrast, Vδ2neg γδ T cells are referred to as γδ T cells that do not express a Vδ2 chain. 
Instead, they usually express a Vδ1 chain and to a lesser extent Vδ3 with any Vγ chain 
combination, see Figure 1.5. These cells are mainly located in peripheral tissues, 
particularly in spleen and the intra-epithelial compartment with very low percentages in 
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peripheral blood.  Furthermore, Vδ2neg γδ T cells were found to express spontaneously 
high levels of granzyme-B and perforin, which could explain their ability to kill CMV-
infected cells and hence the ability to inhibit CMV propagation.  
Though the particular mechanism of how γδ T cells can respond against various 
pathogens is not fully understood, a recognition of small non-peptide common microbial 
compounds was proposed (Bonneville and Fournié, 2005). For instance, Vγ9/Vδ2 T 
cells can recognize (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), 
which is formed during biosynthesis of isopentenyl pyrophosphate (IPP) by the non-
mevalonate pathway. The IPP compound is vital to most pathogenic microbes including 
Mycobacterium tuberculosis and malaria, but not found in humans (Morita et al., 2007). 
Therefore it is not surprising to see no response of Vγ9/Vδ2 T cells towards those 
microbes that synthesise IPP depending on the classic mevalonate pathway, where no 
HMB-PP is formed. Typical examples of microbes that do not activate Vγ9/Vδ2 T cells 
are streptococcus, staphylococcus and borrelia.  
Several ligands and receptors have been proposed for Vδ2neg γδ T cells activation. These 
include stress-induced antigens expressed on epithelial tumour cells, some leukaemias, 
and lymphomas, examples of these are UL16-binding proteins (Catellani et al., 2007) 
and MHC class I-related chains (MICA and MICB) (Zhao et al., 2006). Both of them 
can serve as ligands for an activating Natural killer-G2D receptor (NKG2D). Moreover, 
very recently, Knight and colleagues have showed Vδ1pos γδ T cell cytotoxicity against 
myeloma cells was mediated in part through the T cell receptor (TCR) in addition to 
involvement of NKG2D, DNAX accessory molecule-1 (DNAM-1), intracellular cell 
adhesion molecule (ICAM)-1, CD3 and CD2 receptors (Knight et al., 2012). 
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Furthermore, Vδ1pos γδ T cells can directly mediate killing of leukaemia cell lines and 
chronic lymphocytic leukaemia patient neoplastic cells through natural cytotoxicity 
receptors (NCRs) including NKp30, NKp44 and NKp46 (Correia et al., 2011)  
Although, the role of Vδ2neg γδ T cells, in CMV infection has become evident, the exact 
molecules responsible for activation of Vδ2neg γδ T cells have not been precisely 
identified. However, the mechanism of recognition of CMV-infected cells is thought to 
be mediated by the γδ TCR, as the effect could be blocked using anti-TCR antibodies. 
Furthermore, similar to other sub-classes of γδ T cells, Vδ2neg γδ T cells do not require 
MHC-I presentation; nevertheless direct contact may be needed for killing activity. 
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Figure 1.5: Percentage of different types of γδ T-cell expansion in CMV+ kidney recipients  
This figure shows that in CMVpos kidney recipients, the γδ T-cell expansion involves Vδ1+ and 
to a lesser extent Vδ3+ T cells. Results are expressed as mean ± SEM of absolute numbers of 
positive cells per microlitre of blood for each γδ T-cell subset determined in 12 CMVneg patients 
(filled bars) and 28 CMVpos patients (hatched bars). Quoted from Dechanet et al, 1999.  
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1.2.2.4 Initiation of anti-viral immune responses by the adaptive immune system 
As mentioned in section 1.2.1, the initial immune response against viral infection starts 
when pathogen associated molecular patterns (PAMPs) of viral particles are recognized 
by the PRRs of the innate immune system. Among the most important cells of the innate 
immune system are professional antigen-presenting cells (APCs), which upon activation 
through their PRRs start to migrate to the regional lymph node (LN).  During migration, 
APCs undergo a process of maturation in which they lose most of their ability to engulf 
other pathogens and develop an ability to communicate with T cells. This includes up 
regulation of their co-stimulatory molecules and processing of viral antigens (Takeuchi 
and Akira, 2010).  
In the lymph node, APCs interact with naïve CD4+ and CD8+ T cells, which can 
recognize short viral derived peptide on MHC-II and MHC-I respectively (Wubbolts et 
al., 1997). It has been proposed that APCs are prone to viral infection including 
herpesviruses, therefore, they are capable of presenting viral peptides in association with 
MHC-I to CD8+ T cells, see Figure 1.6. It is worth mentioning that, even if APCs are 
not infected they are still capable of presenting viral antigens to CD8+ T cells through a 
process called cross-presentation (Bevan, 2006).  Furthermore, APCs can also engulf 
part of a virally infected cell and process it as exogenous antigens. Thus, APCs present 
viral peptides to CD4+ T cells through MHC-II (Klein and Sato, 2000), see Figure 1.7. 
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Figure 1.6: Presentation of intracellular antigen on MHC class I 
The left panel demonstrates the steps of peptide processing for loading onto MHC-I molecules 
(internal pathway). Following uncoating of viral particles the viral DNA enters the nucleus and 
replicates within it. The viral messenger RNA (mRNA) then enters the cytosol and is transcribed 
into proteins. These proteins are unfolded with the help of specialized molecules called 
chaperones. This is followed by degrading the polypeptide chains into short peptides by 
proteasomes. Selected peptides are then transported into the endoplasmic reticulum, where they 
are loaded onto newly synthesized MHC-I molecules. Through the Golgi apparatus, the MHC–
peptide complexes are then exported to the surface of the cell. In the right panel, the structure of 
MHC-I Molecules is shown. It consists of one light chain called Beta2-microglobulin (β2m) and 
one heavy chain called α chain. The α chain has two peptide-binding domains (α1 and α2), and 
an immunoglobulin-like domain (α3). The α chain is connected to cytoplasm by the trans-
membrane region (TM), and the cytoplasmic tail. Modified from(Klein and Sato, 2000) 
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proteins interact to form a channel for transporting
peptides across the membrane of the endoplasmic
reticulum. Peptides released by proteasomes bind to
the cytosolic surface of the TAP molecule and are fer-
ried through this channel. On the luminal surface of
the endoplasmic reticulum, queuing up like trucks
waiting to be loaded with cargo, are the class I mol-
ecules (Fig. 3A). The two polypeptide chains of the
class I molecules, the 
 
a
 
 chain and the beta
 
2
 
-micro-
globulin, are manufactured separately on ribosomes
attached to the cytosolic surface of the endoplasmic
reticulum, but as they come off the assembly line,
they thread through special channels to make their
way to the luminal surface of the endoplasmic retic-
ulum. There, the emerging chains are attended by a
suite of molecular chaperones — calnexin, calreticu-
lin, endoplasmic reticulum p57, TAP-binding pro-
tein (also referred to as tapasin), and perhaps others
— which ensure that the polypeptides do not fold
prematurely, that they are properly glycosylated, that
the 
 
a
 
 chain meets beta
 
2
 
-microglobulin at the appro-
priate time, and that when this moment comes, the
union proceeds without a hitch. A class I molecule
is then pinioned by the TAP-binding protein to the
TAP molecule for loading. When a suitable peptide
emerges from the TAP channel, the peptide-binding
groove (Fig. 2) of the waiting class I molecule snags
it. The loaded molecule then undocks from the com-
plex of TAP-binding protein and TAP and sets off
on a journey to the surface of the cell. There, the
class I molecule remains anchored in the plasma mem-
brane by the transmembrane region of the 
 
a
 
 chain.
In this position, it displays the bulk of the 
 
a
 
 chain
(the 
 
a
 
1, 
 
a
 
2, and 
 
a
 
3 domains shown in Fig. 2), the
peptide, and the associated beta
 
2
 
-microglobulin to
other cells.
In the meantime, the class II molecules are also
preparing to receive peptides generated by the en-
docytic protein-processing pathway (Fig. 3B).
 
5
 
 Like
the two chains of class I molecules, those of class II
molecules are manufactured separately on the cyto-
solic surface of the endoplasmic reticulum and then
brought together, folded, and assembled on the lu-
minal surface of the structure with the assistance of
chaperones. Unlike class I molecules, however, class
II molecules are not loaded with peptides in the en-
doplasmic reticulum. Instead, they associate with a
protein produced in the endoplasmic reticulum, the
invariant chain, part of which acts as a stopper for
the peptide-binding groove and thereby precludes
premature loading of peptides. Enclosed in membra-
nous vesicles, the complexes of class II molecules and
invariant chains journey to the region of the cytoplasm
in which they intersect with endosomes with their car-
go of exogenous proteins.
 
5
 
 The transporting vesicles
and the endosomes fuse to form the MHC class II
compartment, in which proteases degrade the exog-
 
Figure 2.
 
 Structure of HLA Class I and Class II Molecules.
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Figure 3 (facing page).
 
 Antigen Processing.
Panel A shows the principal pathways of generating peptides for loading onto HLA class I molecules. Worn-out or defective proteins
in the cytosol are degraded into peptides in proteasomes. Selected peptides are then transported into the endoplasmic reticulum,
where they are loaded onto newly synthesized class I molecules. The HLA–peptide complexes are exported by way of the Golgi
apparatus to the surface of the cell. In tissues infected with a virus, viral particles are taken up by cells and uncoated. The viral DNA
or RNA enters the nucleus and replicates within it. The viral messenger RNA (mRNA) then enters the cytosol and is transcribed
into proteins. Some of the proteins are subsequently degraded in proteasomes, and the peptides are delivered into the endoplasmic
reticulum, where they are loaded onto class I molecules for export to the surface of the cell. Panel B shows the processing of ex-
tracellular proteins. Self or foreign proteins are taken up by endocytosis (or phagocytosis) and sequestered into endosomes. Class
II molecules synthesized in the endoplasmic reticulum are delivered by way of the Golgi apparatus into primary lysosomes, which
fuse with the early endosomes to form the major-histocompatibility-complex (MHC) class II compartment. Enzymes brought into
this compartment by the lysosomes degrade the engulfed proteins into peptides. HLA-DM molecules synthesized in the endoplasmic
reticulum and delivered into the MHC class II compartment by transport vesicles help load the peptides onto the class II molecules.
The HLA–peptide complexes are then exported to the surface of the cell.
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Figure 1.7: Presentation of extracellular antigen on MHC class II 
This illustrates the external pathway for processing of extracellular proteins. APCs have the 
ability to engulf foreign proteins and sequester them into cytoplasmic vacuoles called early 
endosomes by an endocytic process. Simultaneously, Class II molecules, which are synthesized 
in the endoplasmic reticulum, are transported by way of the Golgi apparatus into primary 
lysosomes. Both primary lysosomes and endosomes fuse to form the MHC-II compartment. 
Enzymes brought into this compartment by the lysosomes degrade the engulfed viral protein into 
peptides. HLA-DM molecules, which are synthesized in the endoplasmic reticulum, are 
delivered into the MHC-II compartment by transport vesicles. The function of HLA-DM is to 
help in loading of the peptides onto the class II molecules. Finally, The MHC-II/peptide 
complexes are then exported to the surface of the cell. The right panel displays the composition 
of MHC-II molecules. They have two polypeptide chains; α and β chains, each chain consists of 
four domains; the peptide binding domain (α1 and β1), immunoglobulin-like domain (α2 and β2) 
and trans-membrane and cytoplasmic tail. Modified from (Klein and Sato, 2000) 
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1.2.2.5 T cell priming by professional antigen presenting cells  
Following interaction between naïve CD4+ T cells and APCs, the CD4+ T cells undergo 
numerous divisions and can become polarized into distinct effector T helper (TH) cells. 
In the context of herpesvirus infection most polarized CD4+ T cells will have a TH1-type 
phenotype. That means they can produce large amounts of IFNγ, TNFα and IL-2 
(Constant and Bottomly, 1997). Although priming of CD8+ T cells can occur in the 
absence of viral-specific CD4 T cells, it seems that early priming of CD4+ T cells has a 
crucial role in generating optimal antiviral CD8+ T cell responses (Fayolle et al., 1991). 
For instance, an absence of CD4+ T cells has been found to compromise the formation 
of appropriate cytotoxic T lymphocyte (CTL) responses against herpesvirus (Smith et 
al., 2004). In addition, chemokines that are produced following the interaction between 
CD4+ T cells and APCs have an important role in attraction of CD8+ T cells towards 
APCs (Castellino et al., 2006). Moreover, interaction between CD40L of CD4+ T cells 
with the CD40 receptor on APCs can protect APCs from CTL-mediated death (Mueller 
et al., 2006), which might lead to more efficient CD8+ T cell priming. Generation of 
specific antiviral effector CD4+ and CD8+ T cells (also called priming of naïve T cells) 
is illustrated in Figure 1.8.  
Three models have been proposed for CD4+ T cell-mediated help to CD8+ T cells, 
which include the indirect model, the licence model, and the direct model. Starting with 
the indirect model, which is also called the classical pathway, here the main role of 
CD4+ T cells is to help CD8+ T cells through secretion of certain cytokines such as IL-
2, which can promote expansion of CD8+ T cells. The licensing model proposes that the 
activation of CD8+ T cell by APCs requires prior licensing of APCs through interaction 
 49 
with CD4+ T cells. In other words, activated APCs in turn can interact with CD8+ T 
cells, delivering help in the form of co-stimulatory signals. However, in the context of 
viral infection, licensing of APCs by CD4+ T cells can be bypassed. For instance, in 
some viral infection the APCs can be activated efficiently only through interaction 
between PRRs and virus receptor and thus obviating the need for CD4+ T cell licensing 
of APCs (Johnson et al., 2009). Finally, the direct model suggests that ligation of 
CD40L on CD4+ T cells with CD40 on naïve CD8+ T cells plays an important role in 
generation of memory CD8+ T cells (Azadniv et al., 2011).  
In addition to the role of CD4+ T cells during acute infection, it has been demonstrated 
that CD4+ T cells are crucial for developing memory CD8+ T cells. This role is 
attributed to the ability of CD4+ T cells to down-regulate some death regulatory 
legend/receptor on the CD8+ T cells. Two examples are down regulation in the 
expression of TNF-related apoptosis-inducing ligand (TRAIL) (Janssen et al., 2005) and 
programmed cell death protein 1 (PD1) (Fuse et al., 2009) . 
Contrasting with αβ T cells, as it was mentioned early in section (1.2.2.3), the exact 
triggering molecules and mechanism of γδ T cell activation is still an area of intense 
research. Nevertheless, it is believed that γδ T cells do not seem to require antigen 
processing and MHC presentation of peptide epitopes, although they can recognize non-
classical MHC in the absence of conventional antigenic peptides (Weintraub et al., 
1994). Furthermore, there is other clear formal evidence that, in contrast to recognition 
of MHC-bound peptide antigens by αβ T cells, human γδ T cells can recognize naturally 
occurring small non-peptide antigens (Tanaka et al., 1995).  
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Figure 1.8: Generation of antiviral T cell responses  
(A) Uptake of viral antigens by antigen-presenting cells (APCs) in infected tissue, followed by 
activation of APCs through pattern-recognition receptor (PRR) ligation, and the migration of 
these cells to draining lymph nodes. (B) Recognition of antigen-bearing APCs by naive CD4+ T 
cells results in the generation of TH1 cells owing to the presence of type I interferons (IFNs) and 
IL-12. However, TH17, TH2 and regulatory T (TReg) cell populations may also be generated. (C) 
CD4 T cell-mediated help in the generation of CD8+ T cell effectors involves the provision of 
interleukin-2 (IL-2) and the activation, known as 'licensing', of antigen-presenting cells (APCs) 
via CD40L–CD40 interactions. Figure modified from (Swain et al., 2012). 
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the priming milieu10, although TH1 cell responses are
generated in response to certain viruses independently 
of IL-12 or type I IFNs11–13, suggesting that other fac-
tors can also contribute to TH1 cell polarization. IL-12 
and type I IFNs promote TH1 cell differentiation both 
directly and indirectly (by repressing the development 
of other TH cell subsets), and can even influence effector 
T cells that are already polarized. For example, polar-
ized TH2 cells that were transferred to hosts infected 
with lymphocytic choriomeningitis virus (LCMV) 
acquired a mixed TH1/TH2 cell phenotype, which was 
characterized by high levels of IFNγ production and 
diminished IL-4 production. Interestingly, most IFNγ-
producing cells in the TH1/TH2 cell population co- 
produced IL-4 or IL-13, and IL-12 and type I IFNs were 
shown to drive this mixed TH1/TH2 cell phenotype14. 
In vivo, IL-12 can also reprogramme in vitro-polarized 
TH17 cells to a TH1-type phenotype15,16.
Originally, it was thought that IL-4-producing TH2 
cells were needed to drive optimal humoral immune 
responses. Thus, the predominance of TH1 cells over 
TH2 cells during viral infection was somewhat surpris-
ing, given the important role of neutralizing antibodies 
in viral clearance and in providing long-term immunity 
to re-infection. However, adoptive transfer of either TH1 
cells or TH2 cells was shown to provide efficient help for 
the generation of neutralizing antiviral IgG responses17,18. 
The signature TH1-type cytokine, IFNγ, enhances IgG2a 
class switching, and this explains why IgG2a is usually the 
dominant isotype in IgG responses generated against 
viruses19. In fact, several studies have found that, far from 
promoting antiviral responses, TH2 cell-associated media-
tors (and IL-4 in particular) have a strong negative impact 
on immune protection and drive immuno pathology 
during infection with many viruses, including influenza 
virus20,21, respiratory syncytial virus (RSV)22, herpes 
simplex virus (HSV)23 and vaccinia virus24. Instead, it is 
now clear that IL-4-producing TFH cells provide much of 
the help required for IgG1 production (see below).
The roles of TH17-type effector responses during viral 
infection are not well understood, but virus-specific 
IL-17-producing CD4+ T cells have been detected in 
mice following infection with mouse cytomegalovirus 
(MCMV)25, HSV26, vaccinia virus27, Theiler’s murine 
encephalomyelitis virus28 or influenza virus16, although 
at levels lower than those of TH1 cells. The generation 
of polarized TH17 cells during viral infection has been 
correlated with high levels of IL-6 and may also be 
influenced by transforming growth factor-β (TGFβ)28. 
TH17 cells are implicated in driving harmful inflamma-
tion during autoimmunity, and IL-17 may contribute 
to immunopathology during responses against viruses, 
as demonstrated in studies using influenza virus or 
vaccinia virus27,29. However, in some cases, TH17 cells 
contribute to host protection against viruses16. One pro-
tective mechanism mediated by TH17 cells might be the 
promotion of enhanced neutrophil responses at sites 
of infection. IL-17 upregulates CXC-chemokines that 
promote neutrophil recruitment30, and neutrophils can 
contribute to protection against certain viruses, includ-
ing influenza virus31. We expect that other roles for 
TH17 cells will be identified in futur  studies, as TH17 
cells often produce significant levels of IL-21 and IL-22 
in addition to IL-17 (REF. 16). Although n t extensively 
studied in viral systems, IL-22 production by TH17 
cells could be involved in regulating the expression of 
defensins, and could also play an important part in tissue 
repair (reviewed in REF. 32). IL-21 production may also 
regulate aspects of the innate immune response during 
viral infection. Moreover, IL-21 is involved in sustaining 
CD8+ T cell responses during chronic viral infection, as 
discussed below.
Figure 1 | Generation of antiviral effector CD4+6|EGNNUThe crucial initial steps  
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IL-1α, IL-1β, IL-6, IL-12p40, CC-chemokine ligand 2 
(CCL2), CXC-chemokine ligand 9 (CXCL9) and 
CXCL10. By contrast, TH2-type and non-polarized 
(TH0) memory T cells have a minimal impact on 
pulmonary inflammation following influenza virus 
challenge. To induce innate inflammatory responses, 
memory CD4+ T cells must recognize antigens on 
CD11c+ APCs. These APCs become activated during 
interactions with memory CD4+ T cells, and this results 
in the upregulation of MHC class II and co-stimulatory 
molecule expression by the APCs. Activated APCs con-
tribute to the subsequent innate inflammatory response 
through the production of pro-inflammatory cytokines, 
such as IL-6 and IL-1β. By contrast, the naive CD4+ 
T cell response in vivo does not have an appreciable 
impact on the tissue inflammatory response at 48 hours 
post-infection132. In other studies, naive CD4+ T cells 
could actually downregulate tissue inflammation fol-
lowing mouse hepatitis virus infection133. The ability 
of TH1-type and TH17-type memory CD4+ T cells, but 
not TH2-type or non-polarized memory T cells, to pro-
mote an early inflammatory response may help to explain 
why transfer of virus-specific TH1 and TH17 effector cells, 
but not transfer of TH2 or non-polarized T cells, pro-
motes early control of viral loads in mice infected with 
influenza virus16,86,132. A similar impact of memory CD4+ 
T cells on early viral control during secondary influenza 
infection was recently reported by Chapman et al.134, 
and this also correlated with a dramatic enhancement 
of innate immune responses against the virus. However, 
this effect has not yet been studied in other models of 
viral infection.
We suggest that the early activation of innate immune 
mechanisms by memory CD4+ T cells serves to lessen 
the ‘stealth phase’ of infection, during which titres of the 
virus are still too low to generate robust inflammatory 
responses135. This would prevent viru es from gaining a 
‘foothold’ in the host by infecting and replicating in cells 
at a level that is below immune detection. Importantly, 
the induction of early innate immune responses by 
memory CD4+ T cells do s not require PRR activa-
tion132 and could therefore be important for enhancing 
protection against viral pathogens — such as vaccinia 
virus and influenza virus — that can actively antagonize 
key components of innate recognition pathways, such as 
dsRNA-dependent protein kinase (PKR)136.
One intriguing finding is that memory CD4+ T cells 
specific for ovalbumin enhance antiviral immunity when 
ovalbumin is co-administered with an influenza virus 
that does not express ovalbumin132. Thus, we hypoth-
esize that the nducti n of innate i une responses 
by memory CD4+ T cells could have an adjuvant effect, 
which could be exploited (and substituted for PRR stim-
ulation132) to promote immune responses to vaccines 
that do not contain live viruses. For example, a vaccine 
could activate the innate immune system through 
antigen-specific stimulation of memory CD4+ T cells 
that are known to be widespread in the human popula-
tion (for example, most individuals have memory CD4+ 
T cells pecific for tetanus toxin). This method could 
possibly enhance the immunogenicity of ‘weak’ vaccines.
Heterologous memory responses. Heterologous viral 
immunity occurs when emory T cells that were gen-
erated in response to a particular virus cross-react with 
epitopes expressed by other, unrelated viruses. It has 
recently become clear that this is quite a widespread 
phenomenon that is likely to be important in the 
human population, as humans are exposed t  numer-
us antigens as a result of infection and vaccination137. 
REVIEWS
144 | FEBRUARY 2012 | VOLUME 12  www.nature.com/reviews/immunol
© 2012 Macmillan Publishers Limited. All rights reserved
B cell
a  B cell help
b  T cell help
Plasma cell
Virus
Antibody
Nature Reviews | Immunology
Germinal centre 
formation, isotype 
UYKVEJKPICȰPKV[
maturation
CD8+ T cells 
proliferate and 
migrate to 
infected tissue
Cytotoxi  
CD8+ T cells 
kill infected 
cells
%QPVTCEVKQPQHGȭGEVQT
T cell population to 
TRAIL– memory population
Cytotoxic
CD8+ T cell
Memory
CD8+ T cell
Production of 
neutralizing 
antibodies
B cell
BCR
Virus
BCR
TCR
TCR
TCR
CD4CD8
CD27
CD70
MHC
class II
MHC class I
MHC
class II
Virus-derived peptide
Virus-derived
peptide Virus-deriv d
peptide
CD40L
CD40L
CD40L
CD40
CD40
CD40
OX40
IL-2, IL-4,
IL-21, IFNγ
OX40L
ICOSICOSL
TFH cell CD8+ T cell TH cell
IL-2
TCR
CD8
MHC
class I
Perforin,
granzymes
Virus-infected cell
(KIWTG^ Helper functions of CD4+6|EGNNUa | The canonical function of CD4+6|EGNNUKUVJGRTQXKUKQPQHJGNRHQT$|EGNNUKP
IGTOKPCNEGPVTGHQTOCVKQPKUQV[RGUYKVEJKPICPFCHHKPKV[OCVWTCVKQPQHCPVKDQF[TGURQPUGU(QNNKEWNCTJGNRGT 6
6(*) cel s  
are a specialized subset of CD4+6|EGNNUVJCVRTQXKFGJGNRVQ$|EGNNUVJTQWIJDQVJEGNNsEGNNKPVGTCEVKQPU
OQUVPQVCDN[ 
%&.s%&KPVGTCEVKQPU CPFVJGTGNGCUGQHE[VQMKPGU6JGIGPGTCVKQPQHPGWVTCNK\KPICPVKDQFKGUKUCETWEKCNEQORQPGPV
QHRTQVGEVKQPCICKPUVOCP[XKTCNRCVJQIGPUCPFVJGIQCNQHOQUVXCEEKPGUVTCVGIKGUb | T e best-characterized pathway of 
CD4+6|EGNNOGFKCVGFJGNRKPVJGIGPGTCVKQPQH%&+6|EGNNGHHGEVQTUKPXQNXGUVJGRTQXKUKQPQHKPVGTNGWMKP
+.CPFVJG
CEVKXCVKQPMPQYPCUnNKEGPUKPIoQHCPVKIGPRTGUGPVKPIEGNNU
#2%UXKC%&.s%&KPVGTCEVKQPU+VKUQHVGPWPENGCTYJGVJGT
CD4+6|EGNNOGFKCVGFJGNRJCUCTQNGKPVJGKPKVKCNIGPGTCVKQPQHCPVKXKTCN%&+6|EGNNGHHGEVQTTGURQPUGURTGUWOCDN[DGECWUG
XKTWUGUECPVTKIIGTRCVVGTPTGEQIPKVKQPTGEGRVQTUCPFKPFGRGPFGPVN[CEVKXCVG#2%U*QYGXGTCENGCTTQNGHQT%&+ 
6|EGNNOGFKCVGFJGNRKPVJGIGPGTCVKQPQHHWPEVKQPCNOGOQT[%&+6|EGNNUJCUDGGPFGOQPUVTCVGFFWTKPIXKTCNKPHGEVKQP
&QYPTGIWNCVKQPQH60(TGNCVGFCRQRVQUKUKPFWEKPINKICPF
64#+.GZRTGUUKQPQP%&+6|EGNNUKUCRTQOKPGPVHGCVWTGQH 
%&+6|EGNNUVJCVJCXGDGGPJGNRGFCPFCVNGCUVKPRCTVHCEKNKVCVGUVJGKTTQDWUVTGECNNTGURQPUGFWTKPIUGEQPFCT[KPHGEVKQP
$%4$|EGNN TGEGRVQT+%15KPFWEKDNG6|EGNNEQUVKOWNCVQT+%15.+%15NKICPF6%46|EGNNTGEGRVQT6*6|JGNRGT
REVIEWS
140 | FEBRUARY 2012 | VOLUME 12  www.nature.com/reviews/immunol
© 2012 Macmillan Publishers Limited. All rights reserved
B
B cell
a  B cell help
b  T cell help
Plasma cell
Virus
Antibody
Nature Reviews | Immunology
Germinal centre 
formation, isotype 
UYKVEJKPICȰPKV[
maturation
CD8+ T cells 
proliferate and 
migrate to 
infected tissue
Cytotoxic 
CD8+ T cells 
kill infected 
cells
%QPVTCEVKQPQHGȭGEVQT
T cell population to 
TRAIL– memory population
Cytotoxic
CD8+ T cell
Memory
CD8+ T cell
Production of 
neutralizing 
antibodies
B cell
BCR
Virus
BCR
TCR
TCR
TCR
CD4CD8
CD27
CD70
MHC
class II
MHC class I
MHC
class II
Virus-derived peptide
Virus-derived
peptide Virus-derived
peptide
CD40L
CD40L
CD40L
CD40
D40
CD40
OX40
IL-2, IL-4,
IL-21, IFNγ
OX40L
ICOSICOSL
TFH cell CD8+ T cell TH ell
IL-2
TCR
CD8
MHC
class I
Perforin,
granzymes
Virus-infected cell
(KIWTG^ Helper functions of CD4+6|EGNNUa | The canonical function of CD4+6|EGNNUKUVJGRTQXKUKQPQHJGNRHQT$|EGNNUKP
IGTOKPCNEGPVTGHQTOCVKQPKUQV[RGUYKVEJKPICPFCHHKPKV[OCVWTCVKQPQHCPVKDQF[TGURQPUGU(QNNKEWNCTJGNRGT 6
6(*) cel s  
are a specialized subset of CD4+6|EGNNUVJCVRTQXKFGJGNRVQ$|EGNNUVJTQWIJDQVJEGNNsEGNNKPVGTCEVKQPU
OQUVPQVCDN[ 
%&.s%&KPVGTCEVKQPUCPFVJGT NG UGQHE[VQMKPGU6JGIGPGTCVKQPQHPGWVTCNK\KPICPVKDQFKGUKUCETWEKCNEQORQPGPV
QHRTQVGEVKQPCICKPUVOCP[XKTCNRCVJQIGPUCPFVJGIQCNQHOQUVXCEEKPGUVTC GIKGUb | The best-characterized pathway of 
CD4+6|EGNNOGFKCVGFJGNRKPVJGIGPGTCVKQPQH%&+6|EGNNGHHGEVQTUKPXQNXGUVJGRTQXKUKQPQHKPVGTNGWMKP
+.CPFVJG
CEVKXCVKQPMPQYPCUnNKEGPUKPIoQHCPVKIGPRTGUGPVKPIEGNNU
#2%UXKC%&.s%&KPVGTCEVKQPU+VKUQHVGPWPENGCTYJGVJGT
CD4+6|EGNNOGFKCVGFJGNRJCUCTQNGKPVJGKPKVKCNIGPGTCVKQPQHCPVKXKTCN%&+6|EGNNGHHGEVQTTGURQPUGURTGUWOCDN[DGECWUG
XKTWUGUECPVTKIIGTRCVVGTPTGEQIPKVKQPTGEGRVQTUCPFKPFGRGPFGPVN[CEVKXCVG#2%U*QYGXGTCENGCTTQNGHQT%&+ 
6|EGNNOGFKCVGFJGNRKPVJGIGPGTCVKQPQHHWPEVKQPCNOGOQT[%&+6|EGNNUJCUDGGPFGOQPUVTCVGFFWTKPIXKTCNKPHGEVKQP
&QYPTGIWNCVKQPQH60(TGNCVGFCRQRVQUKUKPFWEKPINKICPF
64#+.GZRTGUUKQPQP%&+6|EGNNUKUCRTQOKPGPVHGCVWTGQH 
%&+6|EGNNUVJCVJCXGDGGPJGNRGFCPFCVNGCUVKPRCTVHCEKNKVCVGUVJGKTTQDWUVTGECNNTGURQPUGFWTKPIUGEQPFCT[KPHGEVKQP
$%4$|EGNNTGEGRVQT+%15KPFWEKDNG6|EGNNEQUVKOWNCVQT+%15.+%15NKICPF6%46|EGNNTGEGRVQT6*6|JGNRGT
REVIEWS
140 | FEBRUARY 2012 | VOLUME 12  www.nature.com/reviews/immunol
© 2012 Macmillan Publishers Limited. All rights reserved
TH1 cell
TH17 cell
TH2 cell
TReg cell
Nature Reviews | Immunology
CD4+ T cell activation, polarization 
and population expansion
'ȭGEVQT6EGNNUOKITCVG
to infected tissue
Cytokines 
in priming 
environment
'ȭGEVQT
E[VQMKPGU
Type I IFNs
IL-12
IFNγ
TNF
IL-17A
IL-17F
IL-22
IL-4
IL-5
IL-13
IL-10
TGFβ
IL-6
TGFβIL-4
APCs take up viruses 
or virus-infected 
cells and are 
activated via PRRs
#2%UOKITCVGVQ
FTCKPKPIN[ORJ
nodes and present 
viral peptides to 
CD4+ T cells
APC
Virus
Processed viral 
peptides
MHC class II
TCR CD28
Naive CD4+ 
T cell
CD80 or CD86Virus-derived
peptide
the priming milieu10, although TH1 cell responses are 
generated in response to certain viruses independently 
of IL-12 or type I IFNs11–13, suggesting that other fac-
tors can also contribute to TH1 cell polarization. IL-12 
and type I IFNs promote TH  cell differentiation both 
directly and indirectly (by repressing the development 
of other TH cell subsets), and can even influence effector 
T cells that are already polarized. For example, polar-
ized TH2 cells that were transferred to hosts infected 
with lymphocytic choriomeningitis virus (LCMV) 
acquired a mixed TH1/TH2 cell phenotype, which was 
characterized by high levels of IFNγ production and 
diminished IL-4 production. Interestingly, most IFNγ-
producing cells in the TH1/TH2 cell population co- 
produced IL-4 or IL-13, and IL-12 and type I IFNs were 
shown to drive this mixed TH1/TH2 cell phenotype14. 
In vivo, IL-12 can also reprogramme in vitro-polarized 
TH17 cells to a TH1-type phenotype15,16.
Originally, it was thought that IL-4-producing TH2 
cells were needed to drive optimal humoral immune 
responses. Thus, the predominance of TH1 cells over 
TH2 cells during viral infection was somewhat surpris-
ing, given the important role of neutralizing antibodies 
in viral clearance and in providing long-term immunity 
to re-infection. However, adoptive transfer of either TH1 
cells or TH2 cells was shown to provide efficient help for 
the generation of neutralizing antiviral IgG responses17,18. 
The signature TH1-type cytokine, IFNγ, enhances IgG2a 
class switching, and this explains why IgG2a is usually the 
dominant isotype in IgG responses generated against 
viruses19. In fact, several studies have found that, far from 
promoting antiviral responses, TH2 cell-associated media-
tors (and IL-4 in particular) have a strong negative impact 
on immune protection and drive immuno pathology 
during infection with many viruses, including influenza 
virus20,21, respiratory syncytial virus (RSV)22, herpes 
simplex virus (HSV)23 and vaccinia virus24. Instead, it is 
now clear that IL-4-producing TFH cells provide much of 
the help required for IgG1 production (see below).
The roles of TH17-type effector responses during viral 
infection are not well understood, but virus-specific 
IL-17-produci g CD4+ T cells have been detected in 
mice following infection with mouse cytomegalovirus 
(MCMV)25, HSV26, vaccinia virus27, Theiler’s murine 
encephalomyelitis virus28 or influenza virus16, although 
at levels lower than those of TH1 cells. The generation 
of polarized TH17 cells during viral infection has been 
correlated with high levels of IL-6 and may also be 
i fluenced by transforming growth factor-β (TGFβ)28. 
TH17 cells are implicated in driving harmful inflamma-
tion during autoimmunity, and IL-17 may contribute 
to immunopathology during responses agai st viruses, 
as demonstrated in studies using influenza virus or 
vaccinia virus27,29. However, in some cases, TH17 cells 
contribute to host protection against viruses16. One pro-
tective mechanism mediated by TH17 cells might be the 
promotion of enhanced neutrophil responses at sites 
of infection. IL-17 upregulates CXC-chemokines that 
promote neutrophil recruitment30, and neutrophils can 
contribute to protection against certain viruses, includ-
i g influenza virus31. We expect that other roles for 
TH17 cells will be identified in future studies, as TH17 
cells often produce significant levels of IL-21 and IL-22 
in addition to IL-17 (REF. 16). Although not extensively 
studied in viral systems, IL-22 production by TH17 
cells could be involved in regulating the expression of 
defensins, and could also play an important part in tissue 
repair (reviewed in REF. 32). IL-21 production may also 
regulate aspects of the innate immune response during 
viral infection. Moreover, IL-21 is involved in sustaining 
CD8+ T cell responses during chronic viral infection, as 
discussed below.
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1.2.3 Immunodominance during herpesvirus infection  
Priming of T cells is followed by marked clonal expansion of viral-specific CD8+ T 
cells that acquire different effector functions, to eliminate the virus-infected cells. This is 
followed by a contraction phase, in which more than 90% of expanded clones will 
undergo apoptosis and persistent cells will form the memory pool (Bousso and Robey, 
2003). This initial expansion of viral-specific CD8+ T cells has wide diversity in terms 
of epitope specificity. However, an ordered hierarchy can occur as some epitopes 
provoke more abundant responses compared to other epitopes which give subdominant 
responses (Kedl et al., 2003). During a re-infection with the same virus or reactivation of 
latent virus there will be an expansion of effector cells from the memory pool, which 
involves rapid expansion of the cell subsets that have a high affinity for specific epitopes. 
Similar to the primary infection, upon controlling of the second infection, certain 
expanded effector cells will become memory cells. Accordingly, with each viral 
reactivation the pool of memory cells will have higher epitope specificity and less clonal 
diversity.  In immunology this phenomenon is known as immunodominance (Kim et al., 
2011), see Figure 1.9.  
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Figure 1.9: Changes in T-cell immunodominance 
T cell response that is elicited during a primary herpesvirus infection consists of heterogeneous 
viral epitope–specific T cells. These responses are not necessarily equal and in the example 
depicted the T cells specific for the ‘green’ epitope are immunodominant following the primary 
infection. This pattern of immunodominance is maintained during the memory phase. However, 
re-exposure to the virus might result in shifting of immunodominance towards another epitope 
(portrayed as red dots) that has more T cell avidity. Therefore, the more frequent exposure to the 
same immunogenic epitope the higher memory T cell pool frequency with less heterogeneity. An 
asterisk indicates when exposure to the virus occurred. Figure modified from Encyclopedia of 
Virology, Third Edition (2008), vol. 3, pp. 73 
 
 
extracellular sources. These exogenous antigens can
include viral particles and also remnants of virally infected
cells. Following uptake by professional antigen-presenting
cells, these antigens are degraded into peptide fragments
within acidified endosomes. Alternatively, if the antigen-
presenting cell is actively infected with the virus, then
intracellular vesicles containing viral proteins can serve
as a source of peptides for associating with MHC class II
complexes. Once at the cell surface these presented anti-
gens can be detected by, and activate, CD4 T cells which
express TCRs that are capable of specifically recognizing
the peptide–MHC class II combination.
Immunodominance
Individual viruses encode multiple potential T-cell epi-
topes; therefore T-cell responses elicited during viral
infections are not monoclonal or monospecific. Instead,
oligoclonal subsets of cells are induced and, although each
individual T cell is responsive to only one particular
peptide–MHC combination, the overall pool of cells is
sufficiently diverse to ensure that numerous epitopes can
be detected. The kinetics, magnitudes, phenotypic and
functional traits, as well as the stability of T responses
to each individual virally encoded epitope can differ.
Consequently, an ordered hierarchy can emerge as certain
epitopes elicit more abundant, or immunodominant
responses, whereas others are less prevalent and give rise
to subdominant responses (Figure 2).
Our understanding of the precise determinants of
immunodominance is incomplete; however, the hierarchy
of T-cell responses is likely to be shaped by many factors.
The magnitude of responses to individual viral epitopes is
influenced by properties of the host’s T cells including
precursor frequencies and the avidity of the T cells for the
presented viral antigen, as well as viral related factors
including the ability of viral peptides to bind MHC com-
plexes, the abundance of presented antigen, the kinetics of
viral protein synthesis, and the types of cells which present
the viral antigens. Changes in the patterns of immuno-
dominance have been reported most notably during the
course of persistent viral infections, as well as following
secondary exposures to viruses which have been previously
controlled (Figure 2). In the case of lymphocytic chorio-
meningitis virus (LCMV) infection of C57BL/6 mice, the
NP396 epitope is co-dominant following well-controlled
acute infections, and CD8 T cells specific for this epitope
respond most vigorously during secondary exposures to
LCMV. By contrast, during persistent LCMV infections,
responses to this usually dominant epitope can become
completely undetectable. During Epstein–Barr virus
(EBV) infections shifting patterns of immunodominance
are observed as responses to immediate early and early
viral proteins are initially detected, but as viral latency
becomes established responses to lytic cycle proteins
decline and responses to latent viral proteins predominate.
These observations demonstrate that not all antiviral
T cells respond equally and suggest that certain specifi-
cities of T cells may be more effective at combating par-
ticular viral infections.
Induction of Cell-Mediated Immunity
during Viral Infections
As a virus infection becomes established in the host, a
series of molecular and cellular signals are initiated which
activate cell-mediated immune responses. These signals
include the production of interferons, other cytokines,
and inflammatory mediators, in addition to the mobiliza-
tion of local dendritic cells. Dendritic cells are thought to
provide a critical cellular link for priming naive CD4 and
CD8 T cells (Figure 3). It has been proposed that these
cells are especially prone to infection by viruses which
facilitate their role as cellular sensors for signaling the
occurrence of an infection. Even if dendritic cells are not
p rmissive to active infection with particular viruses, they
can also resent antigens through cross-priming to CD8
T cells, as well as to CD4 T cells via the classical exo-
genous antigen processing pathway.
The primary activation events which induce cell-
mediated immunity predominately occur in secondary
lymphoid organs including regional lymph nodes and the
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Figure 2 Changes in T-cell immunodominance can occur
during primary and secondary immune responses following
acute viral infections. Viruses elicit T-cell responses to a range of
individual viral epitopes. These responses are not necessarily
equal and in the example depicted the T cells specific for the
‘green’ epitope are immunodominant following the primary
infection. This pattern of immunodominance is maintained
during the memory phase but secondary exposure to the virus
result in an anamnestic recal response during which the ‘red’
epitope-specific T cells predominate. Asterisk indicates when
exposure to the virus occurred.
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In the context of herpesvirus infection, the immunodominant response to specific 
epitopes can be shifted according to the viral infection stage. For instance, in the early 
stage of infection (lytic cycle), the initial response will be dominated by immediate early 
(IE) and early (E) viral proteins. However, upon establishing viral latency the response 
will be shifted to latent (L) viral antigens. In other words, the herpesvirus’s replication 
cycle is associated with expression of a wide range of viral proteins that includes; 
immediate early (IE), early (E) and late (L) proteins. Though the T cell response is 
mainly attributed to recognition of IE-1 proteins, there are other multiple proteins that 
can be targeted by T cells throughout the virus replication cycle. For instance pp65, 
which is one of the structural tegument proteins of CMV, is a major target for both 
CD4+ and CD8+ T cells where it is believed to be responsible for high percentage of the 
total CD8+ T cell antiviral response (Wills et al., 1996a, Sylwester et al., 2005). Besides 
pp65 there are other structural proteins such as pp50, pp28, gH, and gB that are thought 
to be of high importance in activation of T cells in the early stages of infection 
(Elkington et al., 2003). See Figure 1.10 for more information about the other antigen 
types and their representation in activation of CD4+ and CD8+ T cells.  
Contrasting with CMV, less data are available on VZV immunodominance. However, 
several VZV antigens have been identified as targets of CD4+ T cells compared to the 
partial understanding of VZV-specific CD8+ T cell specificity. For instance, during 
VZV early infection the immunodominant CD4 T cell response was toward immediate 
early antigens, such as IE62, IE63, ORF4, and ORF10, while in latency it shifted to late 
antigens that included gB, gC, gI, and gH surface glycoproteins (Arvin et al., 1986, 
Bergen et al., 1991, Arvin et al., 2002).  
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Figure 1.10: Strength of CD8+ and CD4+ T cell responses against cytomegalovirus 
antigens  
This figure illustrates a schematic representation of the strength of CD8 and CD4 T cell 
responses against cytomegalovirus antigens in healthy virus carriers. Relative reactivity for each 
protein (shown on the left axis) is indicated on the basis of strength of T cell responses (Gandhi 
and Khanna, 2004).  
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specific cytotoxic T lymphocyte immunity. Neither
cytomegalovirus viraemia nor cytomegalovirus-associated
disease developed in any of the 14 patients (although nine had
an R–/D+ transplant and were thus at low risk for infection).
Until recently, much of our understanding of the CD8+
cytotoxic T lymphocyte response to cytomegalovirus has been
based on the pp65 and IE-1 antigens, and little was known
about T-cell control over other antigens expressed during the
different stages of infection.108–110 However, the development of
ex-vivo T-cell assays—eg, enzyme-linked immunospot assay
(ELISPOT) and MHC-peptide tetramers—in combination
with predictive bioinformatics has allowed rapid profiling of
T-cell responses to a large panel of cytomegalovirus antigens
expressed during different phases of replication.111 These
studies show that CD8+ T-cell responses to the virus often
contain multiple antigen-specific reactivities, which are not
constrained to pp65 or IE-1 antigens. These observations have
been confirmed by Manley and colleagues112 who noted that a
large fraction of CD8+ cytomegalovirus-specific cytotoxic T
lymphocytes in healthy seropositive donors recognise viral
antigens other than pp65 and IE-1, which were perceived to
be immunodominant targets for the cytotoxic T lymphocyte
response.
Various important conclusions can be drawn based on
these studies: (1) T-cell reactivity against pp65, pp50, IE-1,
glycoprotein B, and IE-2 seems to form a substantial part of
cytomegalovirus-specific cytotoxic T lymphocyte responses
in a high proportion of healthy virus carriers (figure 2);
(2) subdominant or occasional T-cell reactivity is directed
towards pp28, pp150, pp71, and US proteins (figure 2); 
(3) pp65 and IE-1 constitute only 40% of the total T-cell
responses, while 60% of the CD8+ T-cell response is directed
towards other antigens; (4) immunodominant CD8+ T-cell
reactivity is restricted through a limited number of HLA
class I alleles such as HLA A1, HLA A2, HLA A23/A24, HLA
B7, HLA B8, HLA B35, HLA B40, and HLA B57/B58 (a
comprehensive list of the T-cell epitopes mapped108–111,113–123 is
shown in figure 3); and (5), these studies indicate that
successful cytomegalovirus-specific immune control in
healthy virus carriers is dependent on a strong T-cell
response towards a broader repertoire of antigens than
previously thought. 
Role of CD4+ T cells
Although much emphasis has been placed on the role of
MHC class I-restricted CD8+ T cells in the recognition of
infected cells, there is increasing evidence that CD4+ T cells
also play an important part in the control of infection. The
CD4+ T-cell response against individual cytomegalovirus
proteins has been analysed in healthy virus carriers, with
strong proliferative responses to pp65 in all patients.
Furthermore, responses to glycoproteins B and H, IE72,
IE86, and UL69 were noted in some individuals.124 Several
pp65-specific !-interferon producing CD4+ T-cell epitopes
have also been identified.125 In otherwise healthy children
who have acquired cytomegalovirus, prolonged viral
Review Human cytomegalovirus
Infectious Diseases Vol 4  December 2004    http://infection.thelancet.com
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Figure 2. Schematic representation of strength of CD8+ and CD4+ T-cell responses against cytomegalovirus antigens in healthy virus carriers. Relative
reactivity for each protein is indicated on basis of strength of T-cell responses detected by ex-vivo (ELISPOT and/or MHC-peptide tetramers) and/or in-
vitro (T-cell expansion and cytotoxicity) assays.
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1.2.4 T cell phenotyping  
One feature that characterises cell-mediated immunity is the diversity in the function and 
phenotype of T cells. Moreover, even T cells specific for the same epitope might have 
this diversity.  Several phenotypic schemes have been proposed to link certain cell 
function to specific phenotype.  In this thesis, the combination of isoform of CD45R 
with a mixture of cell-surface markers such as homing receptor, co-stimulatory, and 
activation markers were adopted.  
Generally, naïve T cells are characterized by expression of CD45RA, CC-chemokine 
receptor 7 (CCR7), the lymph-node homing receptor CD62L (L-selectin) and co-
stimulatory molecules CD27 and CD28 (Hamann et al., 1997). In contrast, memory T 
cells can be identified by expression of CD45RO (or absence of CD45RA) with 
heterogeneous expression of other markers (Klein and Sato, 2000) such as high levels of 
Lymphocyte function-associated antigen 1 (LFA-1; CD11a-CD18) (Okumura et al., 
1993). Furthermore, memory T cells can be subcategorized into different cell subsets. 
For instance, memory cells expressing CD45RO will be termed ‘central memory’ (TCM) 
if they express CCR7 as well. Their name comes from the ability of this cell subset to 
respond to secondary lymphoid tissue chemokine (SLC; CCL21), and thus migrate 
centrally towards lymph nodes. However, CD45RO+ cells with a CCR7- phenotype 
express other kinds of chemokine receptors and adhesion molecules that allow them to 
migrate to the site of infection (Klein and Sato, 2000). In addition, CD45RO+ CCR7- 
memory T cells have a superior ability to secret cytokines, particularly IFNγ, and thus 
they are termed effector memory T cells (TEM). Furthermore, according to the combined 
expression of CD27 and CD28, CD8+ T cells can be classified into early memory 
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(CD27+ and CD28+), intermediate memory (CD27- and CD28+), and late memory 
(CD27- and CD28-) subsets (Appay et al., 2002).  
In addition to surface markers, the expression of perforin and granzyme B is used to 
identify effector cell subsets. Contrasting to effector cell subsets generated during acute 
infection, which also express perforin and granzyme B, effector memory cells have a 
CD27- and CD28- phenotype.   
It is important to mention that CD45RA can be re-expressed at a later stage of 
differentiation. This cell subset is called Effector Memory CD45RA Expressing T Cell 
(TEMRA). For instance, in CMV chronic carriers CMV-specific CD8+ T cells have a 
CCR7-, CD27-, CD28-, and CD45RA+ phenotype (Gobeil and Leib, 2012). 
Interestingly, this phenotype is also seen in total CD8+ T cells and is correlated to 
CMV-seropositivity but not that of other herpesvirus infections. Figure 1.11 
demonstrates phenotypic changes in CMV specific CD8+ T cells from acute to latent 
infection.  
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Figure 1.11: Phenotypic changes of CMV-specific T cells from acute infection to the latent 
state.  
It shows a schematic representation of the steps of CMV-specific CD8 T-cell development. T-
cell differentiation during infection with virus is characterized by the successive loss of 
expression of CD45RA, CC-chemokine receptor 7 (CCR7), CD27 and CD28, followed, in the 
recovery phase, by re-expression of CD45RA. Note, PCR indicates viral load that was measured 
by polymerase chain reaction. Figure reproduced from (van Lier et al., 2003).  
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CD27– T cells only appeared two months after infection
with CMV, but not HIV, and the percentage of which
increased in the months thereafter46. Finally, during
recovery, an increasing portion of EBV- and CMV-
reactive T cells expressed CD45RA39,45,46 (FIG. 2).
In the early phase of infection with EBV, CMV and
HBV40,46,49, virus-specific T cells express perforin and
can mediate specific cytotoxicity and therefore, can be
referred to as effector T cells. So, in contrast to the situa-
tion described earlier in healthy individuals, in the acute
immune response, CD8+ cytotoxic effector T-cell func-
tions are not associated with a CD27–CD28– phenotype.
Moreover, early CD8+ T cells can secrete IFN-γ in an
antigen-specific manner46,49, although it has been
reported that at the earliest timepoint after infection
with HCV, CD8+ T cells might fail to do this and have a
so-called ‘stunned’ phenotype48. The ability of antigen-
specific T cells to secrete IFN-γ was acquired in the
recovery phase of infection after viraemia had declined.
Virus-specific T cells in the memory stage
In contrast to the low number of longitudinal studies on
the phenotypic development of virus-specific CD8+
T cells during the acute phase of infection, numerous
studies have been published on the phenotypes of T cells
in the memory or latent phase of infection. Together,
these studies indicate that although there is marked
inter-individual variability, CD8+ T cells that are specific
for a particular virus tend to have a predominant phe-
notype when many epitopes in large groups of donors
are compared50,51 (TABLE 1). Recently, it has been shown
that the TCR-β repertoire differs between different
CD8+ T-cell subsets52.As variations in the TCR repertoire
probably represent differences in antigen specificity, this
supports the notion that particular CD8+ T-cell subsets
are enriched for T cells that are specific for certain
viruses or virus-derived epitopes. With regard to the
different markers used to distinguish functional subsets
of CD8+ T cells, expression of CCR7 is detected on
influenza-specific memory T cells22. No data are avail-
able on CCR7 expression by influenza-specific T cells
during acute disease, but it is possible that to migrate to
the lung they lose expression of CCR7 and have to express
other chemokine receptors that direct them to the site of
infection. Assuming that the CCR7+ memory T cells
develop from the effector population this would mean
that, in the absence of antigen, human CD8+ T cells
would re-acquire lymph-node homing properties 
consistent with what has recently been described for
LCMV-reactive mouse T cells23.
Based on the combined expression of CD28 and
CD27 by the total CD8+ T-cell population, Appay et al.50
proposed a linear differentiation model for memory
CD8+ T cells, in which cells with a CD27+CD28+ pheno-
type are termed ‘early’, CD27–CD28+ cells termed ‘inter-
mediate’ and CD27–CD28– cells termed ‘late’ memory 
T cells. The putative transition of T cells through these
distinct stages agrees with the longitudinal analysis 
of virus-specific cells in primary infection (FIG. 2).
This implies that the phenotype of virus-specific
memory T cells is determined by their developmental
Specific CD8+ T cells in acute viral infection
With the emergence of tools — in particular MHC CLASS I
TETRAMERS loaded with CD8+ T-cell epitopes for relevant
viruses38 — it is now possible to study virus-specific
CD8+ T-cell populations in humans during different
stages of viral infection by assessing the expression of
the previously mentioned markers and their relation to
T-cell function. However, the analyses of acute virus-
specific immune responses in humans have two restric-
tions. First, as mentioned earlier, the exact moment of
infection is generally unknown and therefore sampling
cannot be standardized as in mouse models. Further-
more, measurements of virus-specific T-cell phenotype
and function are carried out on blood-derived T cells.
It cannot be ruled out that the antigen-reactive cells in
the secondary lymphoid organs or at the site of infection
are qualitatively different from the circulating pool.
Specific T cells that occur during acute viral infection
have been characterized in infections with Epstein–Barr
virus (EBV), HIV, CMV, hepatitis B virus (HBV) and
hepatitis C virus (HCV)39–49, and in this phase, overall
similarities between T cells that recognize different
viruses predominate. Most virus-specific T cells in acute
infection are activated and proliferating as evidenced
by the cell-surface expression of the activation markers
CD38 and HLA-DR, and the intracellular presence of
Ki67 — a nuclear antigen found in dividing cells.
Furthermore, most of these CD8+ T cells express
CD45R0, but not CD45RA. Only a minority of these
virus-specific T cells express CCR7 (REFS 42,45,46,49),
indicating that, in response to the viruses studied so far,
downmodulation of CCR7 expression is a relatively
early event. Early in immune responses to HIV, EBV
and CMV39,43,44,46, a marked proportion of the specific
T cells express CD28, but, especially for HIV and CMV,
this gradually decreases when the infection wanes.
MHC CLASS I TETRAMERS
Fluorescent-labelled tetravalent
complexes of MHC class I or
class II molecules complexed
with antigenic peptide. They 
can be used to identify antigen-
specific T cells by flow
cytometry.
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Figure 2 | Phenotypic changes of virus-specific T cells from acute infection to the latent
state. A schematic representation of the steps of virus-specific CD8+ T-cell development is
shown. T-cell differentiation during infection with virus is characterized by the successive loss of
expression of CD45RA, CC-chemokine receptor 7 (CCR7), CD27 and CD28, followed, in the
recovery phase, by re-expres ion of CD45RA. In re ponse to cytomegalovirus (CMV), the virus-
specific T-cell population progresses through this pathway, whereas for HIV-reactive T cells,
development generally does not proceed beyond the CCR7–CD27+CD28–CD45R0+ stage44,46. 
In all stages, CMV-specific T cells produce interferon-γ (IFN-γ) and contain perforin, and can lyse
target cells in an antigen-specific manner. For other viruses, detailed longitudinal analyses have
yet to be carried out. Furthermore, it is impossible to determine whether the ordered changes in
phen t pes refle t ctual ha ges that occur in individual cells or alterations of the composition 
of the virus-specific T-cell population. The correlation with viral load, as analysed by polymerase-
chain reaction (PCR), is based on REF. 46.
 58 
1.2.5 Immunological burden of herpesviruses infections   (CMV and VZV) 
So far, it is clear that the control of these viruses necessitates contributions from almost 
all arms of the immune system. Therefore, frequent reactivation of latent viruses would 
be associated with frequent activation of the immune system, which, indeed, can be a 
major burden to the immune system. The ability of these viruses to establish latent 
infection is still an area of potential research. However, the ability of these viruses to 
evade recognition by the immune system has been proposed as a key factor in their 
ability to remain latent. How CMV and VZV can evade various parts of the immune 
system will be discussed in the following sections.  
1.2.5.1 Evasion of the immune system by CMV  
Despite CD8+ T cells recognizing many CMV antigens, CMV has adopted strategies of 
avoiding discovery by CD8+ T cells. The key strategy to achieve this is by preventing 
MHC-I expression via several different mechanisms, more details are shown in Figure 
1.12. The question here is that if CMV has capabilities for evading CD8+ T cells by 
preventing MHC-I expression then it would be reasonable to argue that CD8+ T cells 
play only a minor role, if not at all, in immunity to CMV. However, clear evidence 
against this claim comes from the clinical observations in humans and experiments in an 
animal model of CMV, murine CMV (mCMV), where it has been confirmed that 
depletion of CD8+ T cells is associated with a remarkable increase in morbidity after 
mCMV infection (Wills et al., 1996a, Sester et al., 2002b).  
In other words, it is beyond doubt that CD8+ T cells are very important in CMV 
immunity. Therefore, regardless of the ability of CMV to avoid detection, the immune 
system, particularly CD8+ T cells, has ways to counter this evasion by CMV. Two 
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theories can explain this; firstly, CMV interference with the MHC-I complex is not 
absolute. The first evidence is based on the cross-priming phenomenon. This involves 
dendritic cells, which are professional antigen presenting cells (APCs) that capture 
antigens from infected cells in tissues, and then migrate to lymph nodes and present 
them to CD8+ T cells as exogenous antigens on MHC-I molecules. Further support for 
overcoming viral evasion tactics comes from the knowledge that MHC antigen 
presentation can be enhanced by type I (IFNα and IFNβ) and type II interferon (IFNγ), 
which are produced in high concentration by infected cells and lymphocytes respectively. 
It is believed that the IFNγ induces increased expression of MHC proteins that 
overwhelm the viral inhibition (Geginat et al., 1997, Hengel et al., 1998). Therefore, the 
immune system can counter some of the evasion mechanisms of CMV that has 
developed to evade T cell recognition (Tabi et al., 2001).  
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Figure 1.12: Evasion of CD8+ T cells by CMV 
This figure illustrates the strategies CMV uses to evade recognition by CD8 T cells. Immediately 
after virus particles enter the cytoplasm of the host cell, a tegument glycoprotein (pp65) 
phosphorylates newly formed immediate early proteins such as IE-1 and thus protects them from 
being degraded by cytoplasmic proteasomes (Gilbert et al., 1996). Thereafter, the expression of 
the CMV encoded US6 protein occurs. US6 binds the TAP complex at lumen, and prevents 
translocation of other processed CMV antigens into the endoplasmic reticulum (ER), where 
newly synthesised MHC molecules are located. Another mechanisms of interference with MHC-
I expression includes retaining of newly synthesized MHC-I heavy chain inside the ER as result 
of US3 binding (Lehner et al., 1997). Furthermore, CMV proteins US2 and US11 induce both 
components of MHC-I (the retained MHC heavy chain and B-2 microglobulin) to be transported 
to the cytosol where they are degraded by the proteasome (Wiertz et al., 1996a, Wiertz et al., 
1996b). 
!
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Indeed, the ability of CMV to down regulating MHC-I renders the cell impervious to T 
cell-mediated immunity. Nevertheless, loss of MHC-I would deprive these cells of the 
inhibitory effect of MHC-I/NK inhibitory receptors and render these cells vulnerable to 
NK cell mediated lysis (Abendroth and Arvin, 2001, Eisfeld et al., 2007, Wilkinson et 
al., 2008) Moreover, expression of CMV UL111a during latency, which is a viral 
homologue of IL-10, has been demonstrated to down regulate expression of MHC-II 
molecules (Cheung et al., 2009). 
To escape this susceptibility to NK cell lysis, CMV has a number of viral gene products 
that block NK cell mediated recognition and thus cell lysis (Wilkinson et al., 2008). Two 
main strategies are used for this purpose. One of these strategies is through blocking NK 
cell stimulating receptors via an increase in the expression of cellular HLA-E through 
the action of the CMV UL40 protein (Tomasec et al., 2000). HLA-E is a non-classical 
MHC-I molecule that in normal conditions binds a restricted set of peptides derived 
from the leader sequences of classical MHC-I (Tomasec et al., 2000). However, the 
presence of CMV US6 protein prevents entry of these leader sequences of classical 
MHC-I to the endoplasmic reticulum (ER) and therefore also prevents expression of 
HLA-E (Lehner et al., 1997). Indeed this situation does not suit survival of CMV, so to 
overcome this, CMV UL40 signal peptide (SPUL40) contains a nonameric sequence with 
exact sequence identity to an endogenous HLA-E–binding peptide. Therefore, it can led 
to upregulate HLA-E independently of TAP function (!!! INVALID CITATION !!!), 
and thereby, it gives a false signal (via the inhibitory receptor CD94/NKG2A) to NK 
cells that the cell is healthy. Very recent Prod’hommes’ group has validated this model 
and  gained insight into the molecular processes involved (Prod'homme et al., 2012). 
 62 
 Another way to stimulate the inhibitory receptors of NK cells is via expression of 
UL18, which is an MHC-I homologue. UL18 was demonstrated to bind NK cell 
inhibitory receptor LIR1 with 1000-fold higher affinity than HLA-I molecules (Willcox 
et al., 2003). Nonetheless, Prod’homme et al showed that while the expression of UL18 
can inhibit LIR1pos NK cells, it also could stimulate LIR-1neg NK cells (Prod'homme et 
al., 2007). This study might imply an additional LIR-1neg independent interaction in 
which UL18 expression promotes NK cell recognition. 
Another strategy in evading NK cells is by preventing the activation of NK cell 
stimulatory receptors. For instance, UL16 is found to interfere with expression of some 
host molecules such as MICB (MHC class I polypeptide-related sequence B), ULBP1 
(UL16 binding protein 1) and ULBP2 (UL16 binding protein 2), which are known to be 
potent NK cell stimulatory ligands. Thus, CMV prevents the NK cell stimulatory 
receptors from binding to their ligands (Dunn et al., 2003, Rolle et al., 2003). In 
addition, UL142 was found to downregulate cell surface expression of the MICA (MHC 
class I polypeptide-related sequence A) (Chalupny et al., 2006).   
Furthermore, UL141 was found to play a major role in NK cell modulation by HCMV 
(Tomasec et al., 2005). It was demonstrated to act by preventing up regulation of ligand 
CD155 and CD112, which are main ligands for NK cell activating receptors CD226 
(DNAM-1) and CD96 (Prod'homme et al., 2010). See Figure 1.13.  
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Figure 1.13: Evasion of NK cells by CMV 
This illustrates mechanisms of NK cell recognition inhibition by CMV-infected cells.  Typically, 
T cells can recognize and kill virus-infected cell (A). However; CMV encodes several genes that 
can block the expression of MHC-I (see Figure 1.12). It also secretes UL111a (IL-10 analogues), 
which down regulates MHC-II  (B). The down regulation of MHC-I can make the infected cell 
susceptible to NK cell mediated lysis (C). Nonetheless, CMV uses the host HLA-E pathway to 
inhibit NK cells via the CD94/NKG2 inhibitory receptor. It also expresses a viral homologue of 
cellular MHC Class I, UL18. 
T- cell 
Killing  
CMV peptide -HMC 
complex 
CMV 
US2,US3, 
US6,US11 
Bl
oc
k 
T- cell 
UL 111a 
CMV 
CMV-peptides 
ER 
A B 
NK##
Killing  
IFNs 
Perforin & 
Granzymes 
g#
CMV#
MHC-E 
UL 18 
UL 111a 
NK##
C D
 64 
1.2.5.2 Evasion of the immune system by VZV infection 
As explained early in section 1.2.1, the innate immune system plays a major role in 
protection against herpesvirus infection.  This role contributes to the establishment of an 
antiviral state in non-infected cells through secretion of a variety of interferons and 
cytokines (Muller et al., 1994, Sadler and Williams, 2008). VZV has two strategies to 
prevent this antiviral response. The first strategy is by inhibiting expression of IFNα, 
through expression of ORF63 (Ambagala and Cohen, 2007). The second strategy is by 
impairing the antiviral signaling of IFNγ that might involve ORF66 (Schaap et al., 2005).  
The exact mechanisms by which these molecules can modulate the immune system are 
not fully understood. 
In addition, ORF66 seems to be important in down-regulation of MHC-I expression via 
preventing MHC-I transportation to the cell surface by the Golgi apparatus (Abendroth 
et al., 2001). Furthermore, VZV encodes an immune-modulatory function, which can 
directly interfere with MHC-II expression at the transcription level (Abendroth et al., 
2000). This effect seems to be due to inhibition of IFNγ expression (Black et al., 2009).  
The interactions between VZV infected cells and NK cell receptors have not been 
extensively studied. For instance, how VZV can evade recognition by NK cells as a 
consequence of MHC-I down regulation on infected cell surfaces via the viral protein 
kinase ORF66 have not been demonstrated (Eisfeld et al., 2007). Likewise, to the best of 
our knowledge, no mechanisms of VZV interference with NK cell activating ligands 
have been reported. 
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1.2.6 Studies on CMV-specific immune responses 
The influence of cytomegalovirus carrier status on lymphocyte subsets and natural 
immunity was noticed since the late eighties (Gratama et al., 1987).  In this context there 
are several studies that confirm the importance of CD8+ T cells in controlling CMV 
disease, particularly in primary infection. For instance, subsets of CD8+, CD57+ cells in 
normal, healthy individuals were found to correlate positively with human CMV carrier 
status, phenotypic and functional analyses (Wang et al., 1993, Wang and Borysiewicz, 
1995). Furthermore, Sester and colleagues demonstrated that during primary infection, 
the cellular immune response is mainly dominated by CMV-specific CD8+ T cells 
(Sester et al., 2002b). This was also established by Reusser’s group, who showed that 
the delay in restoration of CMV-specific CD8+ T cells after bone marrow 
transplantation (BMT) increased the risk of developing severe CMV disease (Reusser et 
al., 1991). Furthermore, transfer of CMV-specific CD8+ T cell clones derived from the 
donor bone marrow led to improvement in outcome with regards to CMV infection in 
recipients (Walter et al., 1995).  
In recent years, there has been an increasing literature on the role of CD4+ T cells in 
controlling CMV infection. For instance, studying the characteristics of CMV-specific 
CD4+ and CD8+ T cells during primary CMV infection in renal transplant recipients 
demonstrated that formation of CD8+ T cells alone was not sufficient for controlling 
infection; effector memory CD4+ T cells were shown to be essential for recovery of 
CMV infection (Gamadia et al., 2003). This is also true in the case of BMT patients, 
where reconstitution of cellular immunity against CMV required both CMV-specific 
CD8+ and CD4+ T cells (Walter et al., 1995). Further evidence of the importance of 
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CD4+ T cells in defence against CMV is the ability of CMV-stimulated CD4 cells (from 
CMV-seropositive but not CMV-seronegative donors) to suppress CMV gene expression 
in CMV encephalitis (Cheeran et al., 2000). 
It is believed that the chief function of CD4+ T cells is to give help to CMV-specific 
CD8+ T cells, particularly in maintaining the memory response. The initial suggestion 
that CD4+ T cells are playing this important role comes from the observation that 
cytotoxic CD8+ T cell activity declined in patients deficient in CD4+ T-helper cells 
specific for CMV, which indicates that CD4+ helper cell function is essential for the 
persistence of CD8+ T cells (Walter et al., 1995). However, the murine model of CMV 
infection suggests this role is only important during the primary phase of infection; in 
other words, the depletion of CD4+ T cells during recall responses has minimal or no 
effect on the memory CD8+ T cell response, meanwhile depletion during the priming 
phase (acute stage) is associated with a remarkable reduction in responses by memory 
CD8+ T cells to re-infection (Shedlock and Shen, 2003). 
Besides giving help to CD8+ T cells, CD4+ T cells can directly kill CMV-infected cells. 
It is proposed that in primary CMV infection, cytotoxic CD4+ T cells appear after 
cessation of the viral load. These cells are characterized by a loss of CD27 and loss of 
CD28, and upregulation of CD57, which indicates an advanced stage of cellular 
differentiation. They also have cytolytic molecules such as granzyme B and perforin, 
which might be used in killing of CMV-infected cells (Appay, 2004). The triggering of 
killing potential of these CD4+ T cells can be via direct recognition of endogenous 
antigen in addition to exogenous antigens (the normal pathway for CD4+ T cell 
activation), as shown by studies of the CMV-gB protein, which is processed and 
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expressed efficiently by MHC-II of the infected cells (Hegde et al., 2005). Although the 
response of CD4+ T cells can be demonstrated against a wide range of CMV antigens, 
the main responses are found to be against pp65 and glycoprotein B, which are also 
strong antigens for CD8+ T cells. IE1, though a strong antigen for CD8+ T cells, is less 
stimulatory than pp65 and gB for CD4+ T cells (Sylwester et al., 2005). This may be 
because IE-1 does not access the class II processing pathway as readily as pp65 and gB, 
which are both structural components of the virus particle and more classical exogenous 
antigens.  
Furthermore, Casazza et al showed that acquisition of direct antiviral effector functions 
by pp65-specific CD4+ T cells with cellular maturation (Casazza et al., 2006). This 
included acquiring a highly differentiated effector memory phenotype, that was 
characterized by the relatively low frequency of IL-2–producing CD4+ T cells compared 
with IFN-γ, TNF-α, and MIP-1β production. Indeed, this suggests that the primary role 
of CMV pp65-specific CD4+ T cells during chronic infection is not solely one of 
supplying CD4+ T cell help. 
Although it seems that the cooperation between NK cells on one hand, and B cells and 
αβ T cells on the other hand are sufficient to prevent most infections, γδ T cell 
deficiency is found to be associated with immune deficiency (Chung et al., 2006). 
Besides that, a remarkable expansion of γδ T cells can be demonstrated during bacterial 
as well as some viral and parasitic infestation. For instance, γδ T cell proportions 
increase considerably following infection with intracellular pathogens such as 
Mycobacterium tuberculosis (Janis et al., 1989), influenza (Carding et al., 1990), 
Epstein Barr virus (De Paoli et al., 1990), and Plasmodium (Worku et al., 1997). 
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Furthermore, clinical studies in transplant recipients showed that CMV infection 
resolves better when circulating γδ T cells expand (Dechanet et al., 1999b). Based on 
these and other observations that indicate the presence of interaction between different T 
cell subsets (Vincent et al., 1996), there is a strong belief that γδ T cells play a very 
important role in immune pathology of infectious disease including CMV infection. The 
percentage of Vδ2neg γδ T cells in peripheral blood has ben shown to remarkably 
increase in renal transplant patients with active CMV infection (Dechanet et al., 1999b). 
Moreover, the resolution of CMV viremia was found to be directly proportionate to the 
expansion of the Vδ2neg γδ T cell population (Lafarge et al., 2001). Indeed, these 
observations strongly indicate the important role of Vδ2neg γδ T cells in combating CMV 
infection. Supporting this proposal, Halary and colleagues generated γδ T cell clones 
from renal transplant patients (Halary et al., 2005). They demonstrated that Vδ2neg γδ T 
cells specifically react with CMV-infected cells by producing the pro-inflammatory 
cytokine, tumour necrosis factor –α (TNFα). 
1.2.7 Influence of CMV chronic infection on the immune system of elderly 
subjects  
As discussed above, the frequent reactivation of CMV latent infection can be a major 
burden on the immune system. In recent years, there has been an increasing interest in 
latent CMV infection as a key factor in immunosenescence.  
By definition, the term ‘immunosenescence’ refers to the steady decline of immune 
system function by natural age advancement. This includes deterioration in both the 
capability to fight infections and ability to detect and eliminate transformed cells, in 
addition to poor development of long-term immune memory (Koch et al., 2007). 
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Therefore, it is considered as a major contributor to high morbidity and mortality among 
the elderly. Although immunosenescence can be attributed to an aging process that 
naturally affects most of the body’s systems, other factors such as continuous 
challenging of the immune system by different antigens might play a very important role 
in accelerating this phenomenon (Franceschi et al., 2000). 
Although the effects of immunosenescence involve all parts of the immune system, this 
review focuses mainly on alterations of the adaptive immune system, particularly T cell 
function, because functions of B cells depend on an appropriate function of helper T 
cells (Marc E. Weksler, 2002). Although most functions of the innate immune system, 
including antigen presentation by APC, are well preserved in the elderly, it should be 
emphasized that the innate immune system is also affected by aging associated changes. 
For instance, mortality and morbidity can be predicted according to NK cell status 
(Solana et al., 2006). Furthermore, elevation in pro-inflammatory factors in the elderly is 
partially attributed to the innate immune system ageing (Franceschi et al., 2007). The 
main differences in immune phenotype between young and elderly are shown in Figure 
1.14. 
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Figure 1.14: Changes in the proportions of Naive and memory T cells with ageing 
Summary of changes in proliferation capacity, immune-phenotype and cytokine profile with 
advancing age. Homing chemokine receptor (CCR7) and phosphatase isoform (CD45RA) were 
used to determine the differentiation status of lymphocytes, the less expression of CD45RA/ 
CCR7 the higher the differentiation. While low differentiation status is associated with high 
proliferation capacity, the cytotoxic function (measured by IFNγ production) is remarkably 
increased in highly differentiated cells. The main difference between elderly and young seems to 
be the size of the naive and effector memory cell pools. Modified from(Koch et al., 2007). 
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1.2.8 Explanation of the Immune Risk profile in context of CMV infection  
A large body of data demonstrates the contribution of chronic CMV infection to 
immunosenescence (Looney et al., 1999, Khan et al., 2002a, Ouyang et al., 2003a, 
Ouyang et al., 2003b). For instance, besides the clonal expansions of CD8+ T cells that 
are characteristically associated with chronic CMV infection, the phenotypic changes in 
these cells are found to be very similar to those associated with age-related alterations 
(Looney et al., 1999, Olsson et al., 2000), which indeed emphasises the impact of CMV 
on the ageing of the T cell immune system.  
One of the best known studies that addressed the changes in the immune system with 
age advancing is the Sweden Octogenarian longitudinal study (OCTO) (Olsson et al., 
2000). The result of this longitudinal study suggests a set of immunological parameters 
as an indicator of morbidity and mortality in healthy elderly subjects (≥85 years). These 
parameters include: low numbers of naive T cells with remarkable reduction in the 
diversity of the T cell receptor (TCR) repertoire and an increase in the absolute numbers 
of memory T cells. There is also an inversion in the CD4: CD8 T cell ratio with a low 
number of B cells. Recently, CMV seropositivity has been added to these criteria, and 
this is known as Immune Risk profile (IRP), see Figure 1.15. 
Interestingly, the contribution of CMV to this IRP seems to exceed the anticipation. For 
example, the inverted CD4:CD8 ratio in this profile can be explained by continuous 
challenging of T cells by reactivation of CMV until they reach replicative senescence 
(proliferation exhaustion). At this stage, CD8+ T cells become apoptosis resistant while 
CD4+ T cells become more susceptible to apoptosis (Pawelec et al., 1996, Effros and 
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Pawelec, 1997). Therefore, CD8+ T cells accumulate, CD4+ T cells decrease and the 
CD4: CD8 ratio becomes inverted. Support for this notion is that the clonal expansion of 
T cells is found to be predominantly of CMV specific CD8+ T cells (Khan et al., 2002b, 
Khan et al., 2004). It is worth noting that the majority of these cells are non-functional. 
However, the high absolute number of these cells could be the cause of an imbalance in 
the cytokine production profile in the elderly (Almanzar et al., 2005), see Figure 1.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
Figure 1.15: Explanation of the immune risk profile in the context of chronic CMV 
infection.  
 
The increases in susceptibility to infection with a poor response to vaccines in addition to the 
high incidence of pro-inflammatory diseases are the main changes that occur with advancing 
age. Collectively these changes are called the immune risk profile (IRP).  Impact of chronic 
CMV on the immune system such as, expansion of CMV specific CD8+ T cells with inversion 
of CD4:CD8 ratio and low number of B cells can be the reason behind these changes. Modified 
from. (Pawelec et al., 2009) 
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Figure 1.16: CD8 T cell memory pool in CMV seropositive healthy young and elderly 
donors  
This demonstrates the effects of chronic cytomegalovirus infection on the size of the repertoire 
of both naive and memory T cells. The high lymphocytosis that is seen in the elderly can be 
attributed to repeated reactivation of latent CMV or even re-infection with CMV. Each time 
more naive T cells become CMV-specific effector and memory T cells. This will lead to a 
decrease not only in the naive T cell repertoire but also to accumulation of CMV-specific CD8+ 
T cells that are apoptosis resistant, causing inversion of the CD4:CD8 ratio and increase in pro-
inflammatory cytokines that characterizes the immune profile of the elderly.  
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1.2.9 VZV in immunocompromised subjects 
Although VZV causes self-limiting disease, this can be extremely dystrophic in certain 
categories of patient, such as malignancy, immunosuppressed individuals and neonates. 
Furthermore, the development of chickenpox in immunocompromised children is not 
only associated with considerable morbidity but also with a significant increase in 
mortality rate. The typical example where VZV has devastating sequelae is in children 
under chemotherapy due to cancer. For instance, the overall mortality rate from varicella 
in children with cancer has been reported in the late 1980’s to be as high as 7% 
(Feldman et al., 1975, Feldman and Lott, 1987). However, the subsequent introduction 
of therapeutic acyclovir shortens the cutaneous course of the infection and reduces the 
risk of dissemination and a more serious illness (Feldman and Lott, 1987, Nyerges et al., 
1987). 
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1.3 Aims and objectives  
Primary infection with both CMV and VZV usually occurs at an early age, followed by 
lifelong persistent infection (latency phase). Until now, the precise mechanisms of 
herpesvirus latency are not fully understood. However, it is clear that the immune 
system has a crucial role in keeping replication of these viruses in check. Indeed, this 
immune response seems to multifaceted, with central roles for different subset of T cells 
(αβ and γ𝛿 T cells), besides the importance of antibody and NK cells. Indeed, frequent 
reactivation of latent viruses, particularly CMV, can be a major burden to the immune 
system. In addition, contribution of all of these arms of the immune system to just 
keeping these viruses in a latent state rather than eradicating them must have its impacts 
on the configuration of the immune system.  Therefore, the main aim of this thesis was 
to understand the immune responses against chronic infection with these two common 
herpesviruses, namely CMV and VZV infections. To achieve this aim several objectives 
were proposed to investigate the following: 
• Influences of chronic CMV carriage on the immune system of healthy subjects. 
• Role of unconventional (γ𝛿) T cells in CMV infection. 
• Impact of CMV infection on the sequelae of other concurrent diseases. Here any 
association between CMV and ischemic heart disease (IHD) morbidity was 
investigated.  
• Immunological defects behind the reactivation of VZV infection during acute 
lymphocytic leukaemia (ALL) were examined. 
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2 Materials And Methods 
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2.1 Donors 
Blood samples were collected from three different donor groups. The first group 
involves healthy donors; these are workers in the Duncan building in the University of 
Liverpool. In the second group, patients with ischaemic heart diseases were recruited 
from the Cardiology Department, Newcastle Freeman Hospital. Meanwhile, the third 
group of donors consisted of children with acute lymphocytic leukaemia, who were 
admitted to the oncology unit in Alder Hey hospital. Since there were considerable 
variations among these donors groups, the characteristics of each group were discussed 
in more details with each related results chapter. All samples were obtained with 
informed consent of the donor to participate in the study. The work in this thesis was 
approved by Research Ethics Committee (REC). REC number for each group of donor is 
summarized below.. 
 
2.2 Peripheral blood mononuclear cell (PBMC) preparation 
Approximately 20ml of peripheral blood was taken from each donor by venipuncture. 
This blood was transferred immediately into a tube containing anti-coagulant (600ul of 
preservative-free heparin), and then it was diluted with an equal volume of RPMI 1640 
media (Sigma, UK). Each diluted sample was then divided into two equal amounts 
Chapter Donors Research Ethics 
Committee (REC) Number
3 and 4 Healthy REC 2k/175
5 Patients with Ischaemic Heart Diseases REC 09/H0905/50
6 Patients with Acute Lymphocytic Leukemia  REC 08/H1002/83 
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(usually 20ml). Peripheral blood mononuclear cells (PBMC) were isolated by density 
gradient centrifugation using Ficoll-PaqueTM Plus (GE Healthcare Bio-sciences AB, UK). 
Blood was gently layered onto an equal volume of Ficoll-PaqueTM Plus and centrifuged 
at 503g (equivalent to 1800rpm) for 20 min at room temperature in a bench-top 
centrifuge with the brake off, see Figure 2.1. 
Next, PBMC were harvested from the interface and washed twice with RPMI. In the 
first wash 20ml of RPMI was used (centrifugation at 1800rpm =503g for 10min with 
brake on 9). In the second wash, 40ml of RPMI was used at 1200rpm (=302g) centrifuge 
speed and brake rate 9. Then, after removing supernatants, cell pellets were resuspended 
in 10ml of growth medium (RPMI 1640 medium supplemented with 10% heat 
inactivated foetal calf serum [FCS], 2mM Glutamine, 50µg/ml Penicillin and 50µg/ml 
Streptomycin) and counted using a haemocytometer to calculate the number of the cells. 
2ml of plasma was also removed from each separated blood sample for serological 
testing. 
Aiming to avoid multiple bleeding of donors any extra-PBMC cell yield was preserved 
at -80°C in freezing media (FCS containing 10% DMSO). Each time cryo-preserved 
PBMC were used, they were firstly thawed, and then washed twice in FACS buffer 
(PBS containing 0.1% bovine serum albumin [BSA] and 2mM EDTA). EDTA was used 
to disaggregate any cells that were clumped or that were adherent to the plastic. 
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Figure 2.1: Blood layering and Ficoll Centrifugation - 
It demonstrates the steps of separation of peripheral human blood by density gradient 
centrifugation.  The two tubes demonstrate different layers before and after spin. 
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2.3 Serology  
2.3.1 ELISA 
2.3.1.1 Anti-CMV ELISA (IgG) test 
Donors’ plasma samples were quantitatively analyzed for anti-CMV antibody titre using 
a commercial cytomegalovirus (CMV) IgG ELISA kit (EUROIMMUN AG). Briefly, 
1µl of plasma was diluted in 100µl sample buffer and added to micro-titer plate wells in 
duplicate. To create a standard curve from which the concentration of antibodies can be 
calculated, three calibrators of known concentration (provided by the kit) were included. 
In addition negative and positive control samples were also used. The plates were 
incubated at room temperature for 30 minutes. Plasma samples were then discarded and 
each well was washed 3 times with wash buffer and then incubated with 100µl of CMV 
antigen-enzyme conjugate for 30 minutes at room temperature. Unbound antigen was 
discarded and wells washed again 3 times with wash buffer. Then 100µl of 
chromogen/substrate was added to each well. Plates were left for 15 minutes at room 
temperature to allow colour development, followed by adding 100µl of stop solution. 
Finally photometric measurement of the colour intensity was made at the wavelength of 
450 nm within 30 minutes of adding the stop solution. To determine the concentration of 
antibodies in plasma the Relative Unit (RU) of antibody concentration was calculated 
using the calibration curve, see Figure 2.2. The interpretation of results was carried out 
according to EUROIMMUN AG recommendation see Table 2.1. 
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Figure 2.2: Calibration curve 
The standard curve was created by point-to-point plotting of the extinction values measured for 
the 3 calibration sera against the corresponding units. The Y-axis indicates the extinction reading 
while the X-axis denotes the concentration in relative units (RU/ml).  
 
 
Table 2-1: Interpretation of CMV status according to the CMV- specific antibody titer 
CMV-antibody estimated concentration CMV status 
<16 RU/ml Negative 
≧ 16to<22 RU/ml Borderline 
≧22 RU/ml Positive 
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2.3.1.2 Avidity determination of IgG antibodies against CMV in plasma 
Identification of primary CMV infection is usually based on the detection of virus-
specific IgM antibodies. However, this approach sometimes is unreliable due to 
persistence of high titre of IgM even in long standing infection. In addition false-positive 
IgM antibody tests for CMV can be found in patients with acute Epstein-Barr virus 
infection (Miendje Deyi et al., 2000). In recent years additional determination of 
antibody avidity has become a proven method for differentiation between relatively 
fresh and long-standing infection. Initially the immune system reacts to an infection by 
forming low-avidity IgM antibodies. With continued disease duration, IgG that are more 
precisely adapted to the antigens are produced and the avidity increases. Therefore, 
detection of high avidity antibodies indicates that infection is at a late stage. 
According to the manufacturers’ protocol of the cytomegalovirus (CMV) IgG ELISA kit 
(EUROIMMUN) 1µl of plasma was diluted in 101µl sample buffer and added to micro-
titer plate wells in duplicate. For controls, the provided negative and positive samples 
were used. The plates were incubated at room temperature for 30 minutes to allow 
antibodies to coat the well surface. Plasma samples were then discarded and each well 
was washed   with wash buffer and then incubated for 10 minutes (room temperature) 
with 200µl of urea solution into each of the first micro plate wells and 200µl of 
phosphate buffer into each well of the second micro-titer strip. This was followed by a 
washing step and then addition of CMV antigen-enzyme conjugate for 30 minutes at 
37°C. Unbound antigen was discarded and wells washed again 3 times with wash buffer. 
Then 100µl of tetramethylbenzidine (TMB) substrate was added to each well. Plates 
were left for 10 minutes at room temperature to allow colour development, followed by 
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adding 100µl of stop solution. Finally the photometric measurement of the colour 
intensity was made at the wavelength of 450 nm within 30 minutes of adding the stop 
solution.  
The presence of low avidity antibodies in a donor’s serum has been proved if the ELISA 
extinction value is considerably reduced by urea treatment. In order to quantify the 
results a relative avidity index (RAI) is calculated as follows: 
 
The cut-off value of low avidity antibodies recommended by EUROIMMUN is 40%. 
Table 2-2 summarizes the interpretation value. 
Table 2-2: Cut-off value of low avidity 
Relative Avidity Index 
(RAI) 
Antibodies Avidity CMV infection 
<40% Low-avidity Fresh infection 
40% - 60%         Equivocal       Unknown 
>60%? High-avidity Log-standing infection 
 
 
 
 
Extinction of sample with urea treatment 
Extinction of sample without urea treatment 
x 100 = relative avidity index (RAI) in %
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2.3.1.3 Qualitative detection of IgG antibodies to Varicella-Zoster Virus (VZV) 
Aiming to determine if the donors were immune to VZV, a special ELISA kit (Diamedix 
Immunosimplicity Is-VZV IgG EIA Test System; catalog No 720-380 - 96 Tests) was 
used.  Basically, the protocol was very similar to that of the CMV ELISA where donors’ 
samples were prepared by adding sample diluent at 1:101 ratio. This was followed by 
transferring 100µl of Calibrator, Controls and diluted samples into the antigen wells. The 
protocol included use of Calibrator and Controls. Also one well was reserved for reagent 
blank (100µl of Sample Diluent). This was followed by incubation at room temperature 
(18-30°C) for 30 minute. After discarding contents of the wells they were washed 3 
times with Wash Solution. Next 100µl of Conjugate was added to each well and the 
plate was incubated at room temperature (18-30°C) for 30 minutes, followed by a wash 
step as above. Subsequently 100µl of Substrate Solution was added to each well and 
incubated at room temperature for 30 minutes. Finally 100µl Stop Solution was added to 
each well and the absorbance was read at 450/600-630 nm. The results were presented as 
EU/ml (ELISA Units/ml), which can be calculated using the following formula: 
 
Results can be interpreted according to the following values 
Table 2-3: Interpretation of VZV –ELISA values  
EU/ml                   Interpretation 
<15.0 EU/ml Nonreactive (Negative) for anti-VZV IgG: Presumed non-immune to VZV 
15.0-19.9 EU/ml Equivocal No conclusion on the immunity of VZV ≧20.0 EU/ml Reactive (Positive) for anti-VZV IgG: Presumed immune to VZV 
 
EU/ml of sample =
EU/ml of Calibrator
Absorbance of Calibrator
X Absorbance of sample
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2.3.1.4 Qualitative detection of IgG antibodies to herpes simplex virus (HSV) type 1 and /or type 2   
Here results were obtained with the Diamedix immunosimplicity Is-HSV 1 & 2 IgG EIA 
Test System (Catalog No. 720-340 – 96 Tests) all steps of procedure were exactly the 
same as that for VZV ELISA mentioned above.   However the interpretation of results 
was slightly different.  
 
Table 2-4: Interpretation of HSV –ELISA values  
 
 
 
 
 
 
 
 
 
 
EU/ml of sample =
EU/ml of Calibrator
Absorbance of Calibrator
X Absorbance of sample
EU/ml Interpretation 
<16.0 EU/ml Negative for anti-HSV 1&2 IgG 
 
16.0-19.9 EU/ml Equivocal for anti-HSV 1&2 IgG 
 ≧20.0 EU/ml Positive for anti-HSV 1&2 IgG 
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2.3.2 Real Time PCR to quantitatively determine CMV DNA 
This protocol was adapted from the Clinical Microbiology Laboratory at the Royal 
Liverpool University Hospital after permission of Dr Mark Hopkins. Principally, the 
protocol is based on the assay described by Boeckh and colleagues (Boeckh et al., 2004) 
where double primer sets were used in conjunction with a Roche Lightcycler 480 Probe 
Master mix to amplify regions of the UL55 and UL123 CMV genes. FAM labeled 
Taqman probes was used to detect CMV amplicons in the relevant fluorimeter channel 
of the Roche LC480 instrument. In addition a second heterologous amplification system 
was used to identify possible PCR inhibition. Herein, EXO-DNA was used as internal 
control (IC), which was detected with HEX labeled probe in a different fluorimeter 
channel. Note in addition to EXO-DNA all the primers and probes were purchased from 
Eurofins MWG Operon. The standard curve for measuring the CMV virus load was 
created by using serial dilutions of UL55 and UL123 plasmid clones. An Invitrogen 
pCRII-TOPO TA cloning kit was used to generate plasmid sizes (including the PCR 
product) of 4039 and 4059 bases for UL55 and UL123 respectively. See Table 2-5 for 
probe and primer specifications.  
Table 2-5: Primers and probes for Quantitative Detection of Cytomegalovirus DNA in 
Plasma by Real-Time PCR 
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Liverpool University Hospital after permission of Dr Mark Hopkins. Principally, the 
protocol is based on the assay described by Boeckh and colleagues (Boeckh et al., 2004) 
where double primer sets were used in conjunction with a Roche Lightcycler 480 Probe 
Master mix to amplify regions of the UL55 and UL123 CMV genes. FAM labeled 
Taqman probes was used to detect CMV amplicons in the relevant fluorimeter channel 
of the Roche LC480 instrument. In addition a second heterologous amplification system 
was used to identify possible PCR inhibition. Herein, EXO-DNA was used as internal 
contro  (IC), which was detected with HEX labeled probe in a different fluorimeter 
channel. Note in addition to EXO-DNA all the pri ers and probes were purchased from 
Eurofins MWG Operon. The standard curve for measuring the CMV virus load was 
created by using serial dilutions of UL55 and UL123 plasmid clones. An Invitrogen 
pCRII-TOPO TA cloning kit was used to generate plasmid sizes (including the PCR 
product) of 4039 and 4059 bases for UL55 and UL123 respectively. See Table 2-5 for 
probe and primer specifications.  
Table 2-5; Primers and probes for Quantitative Detection of Cytomegalovirus DNA in 
Plasma by Real-Time PCR 
Primer 
set  Region 
Amplicon 
size (bp) Forward primer Reverse primer 
Probe  
(Fluorochrome) 
CMV 
CMV-
UL123-
exon4 
84 
TCC CGC TTA 
TCC TCR GGT 
ACA 
TGA GCC TTT 
CGA GGA SAT 
GAA 
TCT CAT ACA TGC 
TCT GCA TAG TTA 
GCC CAA TAC A   
 (FAM) 
CMV CMV-UL55 68 
TGG GCG AGG 
ACA ACG AA 
TGA GGC TGG 
GAA GCT GAC 
AT 
TGG GCA ACC 
ACC GCA CTG 
AGG 
 (FAM) 
EXO-
DNA EXODNA 89 
GCC TGG TGC 
AAA AAT TGC 
TTA 
TCG TTC ATT 
TGT TCT TTT 
GTG GAA 
CAG CTA TTG 
CAA ACG CCA 
TCG CAC 
 (HEX) 
RT-PCR Procedure  
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RT-PCR Procedure  
2.3.2.1 Nucleic acid extraction 
DNA was harvested from 100µl of blood. A QIAamp DNA Mini Kitkit (Qiagen, product 
number; 69504) was used and the protocol supplied by the manufacturer was followed. 
Basically, 100µl of whole blood was placed in a microcentrifuge tube containing 20µl of 
proteinase K, and 200µl of lysis buffer. The mixture was vortexed and incubated for 10 
minutes at 56°C. After the incubation period, 200µl of 98-100% ethanol was added to 
the mixture and the tube inverted. After that, the mixture was pipetted into a QIAamp 
Mini spin column placed in a 2ml collection tube and centrifuged for 1 minute at 6000g 
(8000rpm) then the flow-through and collection tube were discarded. 
The mini spin column was placed in a new 2ml collection tube and washed twice with 
washing buffers (labeled as AW1 and AW2) for 1 minute at 6000g (8000rpm) and for 3 
minutes at 20,000g (14000rpm) respectively. The flow-through and collection tube were 
discarded and the DNeasy mini spin column was placed in a new 2ml collection tube. 
Finally, 200µl of buffer AE (elution buffer) was added to the mini spin column and 
incubated for 1 minute at room temperature and then centrifuged for 1 minute at 6000g 
(8000rpm); this step was repeated to increase the overall of DNA yield, see Figure 2.3 
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Figure 2.3: Summary of steps for DNA extraction from blood utilizing a QIAamp DNA 
Mini Kit 
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Mix by pulse-vortexing for 15 s
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Centrifuge at 6000 x g 
(8000 rpm) for 1 min 
Step 17 
Storage at –20°C.
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Step 1 
20 µl QIAGEN Protease (or proteinase K)
100 µl sample ( blood)
200 µl Buffer AL to the sample
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Step 9 
Centrifuge at 6000 x g 
(8000 rpm) for 1 min
Step 10 
Carefully open the QIAamp 
Mini spin column and add 
500 µl Buffer AW1
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Step 11 
Centrifuge at 6000 x g 
(8000 rpm) for 1 min
Step 12 
Add 500 µl Buffer AW2
Step 13
 Centrifuge at full speed 
(20,000 x g; 14,000 rpm) for 3 min.
Step 14 
Add 200 µl Buffer AE or 
distilled water
Step 15 
Incubate at room temperature 
(15–25°C) for 1 min
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Step 5
Add 200 µl ethanol (96–100%) to the sample
Step 8
Carefully apply the mixture from
 step 7 to the QIAamp Mini 
spin column
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Step 4
Briefly centrifuge the 1.5 ml 
microcentrifugetube to remove drops 
from the inside of the lid.
Step 3
Incubate at 56°C for 10 min
Step 2
Mix by pulse-vortexing for 15 s
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Step 7
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2.3.2.2 Preparation of primers and probes   
New primers were re-hydrated with nuclease-free water to a stock concentration all at 
100µM. Regarding the working solution the CMV primers (UL55F, UL55R, UL123F, 
and UL123R) were all adjusted to 10µM.  Meanwhile, working concentration for the 
internal control primers (IC) was 5µM for EXO315R and 2.5µM for EXO186F.  
New taqman probes were re-hydrated with TE buffer (10 mM Tris-Cl, pH 7.5 and 1 mM 
EDTA) to stock concentrations of 100µM. The concentration of working aliquots of the 
CMV probe mix (UL55-FAM and UL125-FAM) was 10µM and for the internal control 
(EXO-HEX) was 5µM. To avoid repeated freeze/thaw of primers and probes aliquots 
were prepared and stored in separate tubes at -20C and only mixed during the 
preparation of master mix, see Figure 2.4. 
 
 
Figure 2.4: Preparation of primer and probe aliquots  
The primers for CMV (UL55FUL55R, UL123F, and UL123R) and IC (EXO315R and 
EXO186F) and their taqman probes (FAM and HEX respectively) were prepared and kept 
separate until the time of master mix preparation. 
 
50µl of UL55   F
50µl of UL55   R
50µl of UL123 F
50µl of UL123 R 
25µl of EXO 315R
12.5µl of EXO 186F
262.5µl d H2O 
+
+
CMV PRIMER
500µl
25µl of UL55-FAM
25µl of UL123-FAM
12.5µl of EXO-HEX
187.5µl d H2O 
+
+
CMV PROBE
250µl
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2.3.2.3 Master mix preparation 
The amount of master mix prepared each time was dependent on the number of samples 
proposed, see Table 2-6: 
 
Table 2-6: Master mix preparation 
Component 1* 2* 4* 
Roche probe master 12.5 25 50 
CMV primer mix 1 2 4 
CMV probe mix 0.25 0.50 1.00 
H2O 1.25 2.50 5.00 
*Indicates number of samples. 
All volumes are measured in µl 
15 µl of this master mix will be added to 10µl of patient purified DNA sample.                        
 
Note; to check for PCR inhibition the internal control was included in each well 
therefore 0.25µl of water was substituted by Exo DNA (106 copies/ml) in 15µl of LC480 
master mix prior to addition of 10µl purified sample. 
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2.3.2.4 Amplification setup 
An LC480 Roche instrument and software were used to run the sample and set up to 
read multicolour hydrolysis of probes (FAM and HEX). The protocol that was used is 
shown in the Table 2-7: 
Table 2-7: Amplification protocol  
Protocol Temperature 0C 
Time at temp  
(min:ss) 
Ramp rate 
(Co/sec) 
Acquisition 
mode 
Pre-incubation  95 05:0 4.4 None 
Amplification  
45 cycles of  
95 00:10 4.4 None 
60 00:45 2.2 Single 
72 00:10 4.4 None 
Cool 40 00:30 2.2 None 
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2.4 Cellular work  
2.4.1 Cell surface staining with monoclonal antibodies  (mAb) 
 For optimal mAb staining in all types of sample used (freshly isolated or cryo-preserved 
PMBC), the cells-to-media volume ratio was corrected. The ideal concentration for 
optimal antibody staining was chosen to be 0.5-1x106 cells per 30-50µl media. This was 
based on the recommendation of mAb supplier companies. To obtain this concentration 
cell pellets were firstly pelleted by centrifugation at 1500rpm for 5 minutes with 4-5ml 
of FACS buffer. Then the pellet was re-suspended in the appropriate volume of FACS 
buffer, so that 50µl media will contain at least 0.5×106 PBMC.  This was followed by 
incubation of PBMC with fluorochrome-conjugated monoclonal antibodies in ice for 20-
30 minutes. Lastly cells were washed by FACS buffer and to prevent the flow cytometer 
from blocking all samples were filtered through a 70µm Nylon cell strainer (BD Falcon) 
just before flow cytometric analysis was carried out. 
Note, the quantities of monoclonal antibodies were adjusted according to fluorescent 
brightness, concentration of the antibodies and density of target molecules on the cell 
surface. Therefore, each antibody was independently titred to give the optimal staining 
quality before carrying out the actual experiments. Also mouse isotype monoclonal 
antibodies were usually included with each experiment set.   
Since stimulation of PBMC is known to cause alteration in the expression level of some 
cell surface activation markers such as co-stimulatory molecules, therefore, most 
phenotyping studies were carried out using unmanipulated cells (not ex-vivo stimulated).  
Panels of monoclonal antibodies including the type of fluorescent dyes (fluorochrome) 
conjugated, and quantities that are used in each experiment are summarized in Table 2-8. 
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All incubations of surface staining were on ice and for 25 minutes followed by a 
washing step with FACS buffer and centrifugation (400g) for 5 minutes. However, 
staining with tetramer/pentamer was slightly different, see section 2.4.2 for detailed 
tetramer/pentamer staining and for panels that include an intracellular staining step see 
section 2.4.3. 
Table 2-8: Monoclonal antibody staining panel for lymphocyte phenotype profile 
Tube  Purpose 
 
FITC 
(Green) 
PE 
(Yellow) 
PerCP-Cy5.5  
(Far red) 
APC 
(Red) 
1 Unstained None None None None 
2 FITC control 1µl /CD8  None None None 
3 PE control None 1µl /CD8  None None 
4 PeCy5.5 Control None None 1µl /CD8  None 
5 APC control None None None 1µl /CD8  
6 αβ T cell profile 1µl /CD27  1µl / CD8 1µl / CD28 1µl/ CD4  
7 NK cell profile 2µl / CD16  1µl / NKG2C 1µl / CD3  1µl/ CD56  
      
 
This table summarizes the surface-staining panel of monoclonal antibodies that are used to 
identify different lymphocyte phenotypes. Each column in the table was given the colour 
corresponding to the colour of antibody-conjugated fluorochrome. The volumes (µl) denote the 
quantity of each antibody used per 50 µl of cell suspension (approx. 0.5x106 PBMC) 
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Table 2-9: Summary of 𝛾𝛿 T cells surface and intracellular monoclonal antibody staining 
panel. 
Tube  Purpose FITC 
(Green) 
PE 
(Yellow) 
PerCP-Cy5.5 
(Far red) 
APC 
(Red) 
1 Unstained None None None None 
2 FITC control 1µl /CD8  
 
None None None 
3 PE control None 1µl /CD8  None None 
4 PeCy5.5 
Control 
None None 1µl /CD8  None 
 
5 APC control None None None 1µl /CD8  
 
6 γδ T cell 
subsets 
1µl / TCR Vδ1 1µl / TCR Vδ2  None 1µl/ TCRγδ  
 
7 αβ & γδ T cell 
profile 
3µl /TCR αβ  1µl / TCR Vδ2 None 1µl/ TCRγδ  
 
8 Differentiation 
status 
1µl / CD27  1µl / TCR Vδ2 1 µl / CD28  1µl/ TCRγδ  
 
9 Naive/memory 
status 
1µl / LFA-1  1µl / TCR Vδ2 1µl / CD45RA  1µl/ TCRγδ  
 
10 T cell 
regulation 
2µl / TCR Vδ2 1µl / PD-1 1µl / CD28 1µl/ TCRγδ  
 
11 Proliferative 
ability 
1µl / IL7R  6µl / IL15R  1µl / TCR Vδ2 1µl/ TCRγδ  
 
12 Cytotoxic 
ability 
5µl / Perforin  1µl /Granzyme 
B  
1µl / TCR Vδ2 1µl/ TCRγδ  
 
 
This table summarizes the design of experiments that used surface staining as well as internal 
staining of PBMC by monoclonal antibodies. In colour control tubes (tubes from 1 to 4) there 
was 0.5x106 PBMC incubated with only one specific anti-human monoclonal antibody. 
Meanwhile in tube 5 to 10 cells were incubated with combinations of different coloured 
conjugated anti-human monoclonal antibodies. 
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2.4.2 Tetramer/Pentamer staining of CMV–specific CD8+ T cells  
Tetramer/pentamer staining was conducted on Human Leucocyte Antigen (HLA) 
matched donors. Thus 2 ml blood from CMV positive donors was sent to the tissue-
typing unit in the Royal Liverpool Hospital for HLA typing. Based on availability of 
tetramer/pentamer, only donors with HLA-A*01, HLA-A*02, HLA-B*07, or HLA-
B*08 (the most common European alleles) were considered for this analysis. The 
tetramer/pentamer selected for this purpose was loaded with CMV epitopes known as 
the most immunodominant, which involves pp65, and IE2 matrix protein of CMV, 
(Wills et al., 1996b, Kern et al., 2002, Khan et al., 2004).  
Note, tetramer was freshly prepared by Dr. Khan, where appropriate monomers of 
alleles that were loaded with CMV epitopes were conjugated to an APC or PE 
fluorescently labelled streptavidin molecule via biotin. N.B, the detailed method for 
tetramer preparation is described elsewhere (Altman et al., 2010).  
For tetramer staining the following protocol was followed; PBMC were isolated (as 
discussed in section 2.1) and cells suspended at approx. 106 cells per 100µl growth 
media. 2 µl of tetramer was added per tube and incubated at 37°C for 20mins, then 
washed in PBS (650xg for 5min). Cells were then surface stained with CD8 and any 
other antibodies indicated and/or intracellular stained in accordance with protocols in 
sections 2.4.1 or 2.4.3 respectively.  
Pentamers were purchased from ProImmune under the name of Pro5® MHC Pentamers, 
see Table 2-10. Besides their stability Pro5 MHC Pentamers are unlabeled therefore 
there was flexibility in choice of fluorescent label (here called Fluorotag), in this thesis 
PE and APC- Fluorotags were used. Note that the protocol was similar to the tetramer 
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staining protocol mentioned above, however, the only difference is to add the 
appropriate amount of fluorotag during the CD8 surface staining step.    
Table 2-10: combination of pentamers allele and CMV-peptide sequence 
ALLELE PEPTIDE SEQUENCE EPITOPE ORIGIN 
A*01:01 VTEHDTLLY HCMV pp50 245-253 
A*02:01 NLVPMVATV HCMV pp65 495-504 
B*07:02 TPRVTGGGAM HCMV pp65 417-426 
B*08:01 QIKVRVDMV HCMV IE1 88-96 
   
 
2.4.3 Intracellular cytokine staining (ICS) 
It is known that incubation of PBMC with viral lysate (or pool of purified peptides) 
induces pro-inflammatory cytokine production (Radha et al., 2005). Based on this, 
frequencies of virus-specific CD4+ T cells and CD8+ T cells were measured by 
determining the increase in production of intracellular cytokine, which in our study one 
or all of the following cytokine were targeted; IFN-γ, TNFα and/or IL-2. Steps of 
intracellular staining are summarized in Figure 2.5. 
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Figure 2.5: Steps for intracellular mAb staining  
Showing the action of each step of the stimulation assay. In the first step the cells were 
stimulated by viral-Ag and this antigen enhances the cells to secret the cytokine such as, IFNγ. 
After two hours of incubation the secreted molecules were inhibited by Brefeldin A. After 6-18 
hours the cells were labeled by fluorochrome–conjugated anti-CD4 and/or anti-CD8. Then the 
cells were fixed and permeabilized for intracellular staining such as, IFN-γ. Ultimately, the cells 
were analyzed by flow cytometry. 
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1. Cells are stimulated with antigen at 37°C. The cells produce 
IFN-! 
 
     2. After 2hrs, brefeldin A was added to stop releasing proteins  
    3. After 6 to 16 hrs, surface staining for CD4 or CD8 
   4. Fix and permeabilise with intracellular stain for IFN-! ,TNF-α, 
and/or IL2 
CD4&CD8 T cell 
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2.4.3.1 T cell responses to CMV 
Aiming to determine CMV-specific CD4+ T cells responses, 0.5-1×106 freshly isolated 
PBMC were incubated with lysate of CMV-infected fibroblast or mock lysate (made 
from non-infected fibroblasts “negative control”) at 37°C for a total of 6-14 hours. 
Meanwhile, to stimulate CD8+ T cells, cocktails of known immunogenic CMV peptides 
(made commercially by Invitrogen, UK) were used. The antigens selected were IE1, 
pp65 and a combination of pp50 and gB peptides (VTE/DYS).  Collectively, these 
antigens have been shown to stimulate responses in the main percentage of previously 
infected persons. More details about peptide are shown in Table 2.11. At the end of the 
second hour of incubation, 400µl of Brefeldin A was added at 10µg/ml final 
concentration. The aim of this step is to prevent the export of cytokine into the 
extracellular environment, so that it accumulates within the cell and allows detection 
using intracellular antibody staining later. After incubation for the remaining hours, cells 
were washed with FACS buffer. Then, they were incubated with monoclonal antibodies 
(mAb) for surface staining of CD4 and/or CD8.  
To fix the surface antibodies and prevent them from being removed during the 
permeabilization step, samples were washed by FACS buffer, and then incubated with 
80µl fixation reagent (intraprep reagent 1; Beckman Coulter, UK) in the dark for 20 
minutes at room temperature. To allow entry of antibodies to the cytoplasm, cells were 
incubated for 5 minutes with 80µl of permeabilizing agent (intraprep reagent 2; 
Beckman Coulter, UK). Without washing away the permeabilizing reagent, cells were 
incubated with anti fluorochrome-conjugated anti-cytokine (IFNγ, TNFα, and/or IL-2) 
mAb for 30min at room temperature, before a final wash.   
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Table 2-11: Immunogenic CMV Peptides and the class I HLA alleles they are  
bound by  
 
 
 
CMV antigen Peptide HLA type 
 
 
 
IE1 MIX 
 
 
 
VLEETSVML A2 
CRVLCCYVL B7 
ELRRKMMYM B8 
QIKVRVDMV B8 
KEVNSQLSL B40 
EEAIWYTL B44 
FPKTTNGCSQA B55 
EVISVMKRR A68 
ATTFLQTMLR A68 
KRKMIYMCY B27 
 
 
 
 
 
 
 
 
pp65 MIX 
NLVPMVATV A2 
TPRVTGGGAM B7 
RPHERNGFTV B7 
IPSINVHHY B35 
FPTKDVAL B35 
QPSLILVSQY B35 
YSEHPTFTSQY A1 
QYDVPAALF A24 
QVVKVYLESF A24 
YTPDSTPCHR A68 
DTPVLPHETR A68 
PQYSEHPTRTSQYRIQ DR11 
FTSQYRIQGKLEYRHT DR11 
KYQEFFVDANDIYRI DR52 
IIKPGKISHIMLDVA DR4/DR53 
AGILARNLVPMVATV DR3/DR11 
VTE/DYS MIX 
VTEHDTLLY A1 
DYSNTHSTRYV DR7 
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2.4.3.2 Quality of CMV-specific T cell responses in patients with coronary artery disease (CAD) 
Referring to chapter 5, the aim was to determine differences in the magnitude of T cell 
responses to CMV in patients with coronary artery disease and age-matched healthy 
volunteers.  A BD LSR II flow cytometer was utilized to define the frequency of 
CMV-specific T cells that are capable of exhibiting multifunctional properties. Here a 
slightly modified intracellular staining protocol was used. Briefly, PBMC from CAD 
patient and healthy donors were stimulated with a mixture of IE-1 and pp65 CMV 
peptides and CMV-fibroblast lysate for approximately 10 hours in the presence of co-
stimulatory antibodies (purified anti-CD28 and anti-CD49d mAb, both from BD), 
Golgi Stop containing monensin besides brefeldin-A (BFA), and FITC conjugated anti 
CD107a (as a degranulation marker) monoclonal antibody. On day two, surface 
staining for CD4-PerCP-Cy5.5 and CD8-APC/Cy7 was carried out followed by 
intracellular staining with mAb detecting four main functions including; anti MIP1β-
PE, IFNγ-AlexaFluor700, TNFα-PE/Cy7, and IL-2-APC. Note, all of these mAb were 
purchased from BD Biosciences. 
2.4.3.3 T Cell responses to VZV antigen 
The aim here was to measure the frequency of VZV–specific T cells. Therefore, similar 
to the CMV work, ICS assays were used to detect the increase in inflammatory cytokine 
production by T cells in response to VZV antigen. The same protocol as in section 
2.1.5.1 was used and the only difference was in the stimuli which were either 1µl 
(concentration 0.72mg/ml) of VZV Rod strain inactivated cell extract (Advanced 
Biotechnologies Inc) or 10µl (concentration 103.3 PFU/0.5ml) live attenuated VZV-
varilrix vaccine (Glaxo SmithKline).  
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2.4.4 CFSE assay 
CFSE (Carboxy-Fluorescein Succinimidyl Ester) proliferation assay was utilized to 
identify the ability of T cells to proliferate in response to VZV antigen. Briefly, this 
assay is based on the ability of CFSE molecules to diffuse into cells. Therefore, when 
CFSE is incubated with live cells, endogenous enzymes such as, esterases process it and 
it tends to bind to the cytoplasmic membrane and also to nuclear proteins. Upon entering 
the cell the CFSE diffuses uniformly throughout the cytoplasm, therefore when the cells 
divide the CFSE dye is split equally between the daughter cells. Consequently the CFSE 
concentration in each cell will reduce as the cells proliferation progress. Using flow 
cytometry the amount of fluorescence emitted by each generation of cells will be 
inversely proportional to the number of divisions.  
2.4.4.1 Labelling of cells with CFSE 
PBMC were isolated in the usual way, followed by cell counting of viable cells and 
adjusting the concentration so that each ml of PBMC suspension contained 2 to 3 
million cells. CellTraceTM CFSE Cell Proliferation Kit (Invitrogen) was used to perform 
the CFSE labeling. 
Briefly, a stock solution of 5mM CFSE was prepared by adding 18µl of DMSO 
(Component B) to one vial of CFSE (Component A). A titrated amount of CFSE 
solution (2.5-5µl) was then added to PBMC, mixed gently and incubated for 10min at 
37°C. This was followed by three washing steps, each time using 10ml of cold PBS, and 
centrifugation for 10 minutes at  (400g) was used. Finally recounting of the viable cells 
was performed and cells were re-suspended in growth media at a concentration of 1-
1.5x106 per ml per well. 
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2.4.4.2 Cell stimulation 
Experiments were designed so that in addition to the VZV-antigen (1µl of purified VZV 
peptides or 15µl of vaccine) stimulated wells for each donor there were duplicates of 
positive control, Phytohaemagglutinin (PHA 0.5µl), and negative control (no stimulus) 
wells.  Eventually, the plate was incubated for 7 days at 37°C. 
2.4.4.3 Staining of cells  
On day 8, the plate was removed from the incubator and the desired number of PBMC 
was aliquoted from the cell suspension into labeled FACS tubes.  This was followed by 
washing steps, which included adding 4ml of FACS buffer to each tube and spinning at 
1500rpm for 5min in the centrifuge. Next, the supernatant was discarded and cells 
resuspended in the residual volume of buffer. Next, antibodies for surface staining to 
both test samples and control samples were added and incubated on ice for 20min. The 
staining panel involved anti-CD4/PE and anti-CD8/APC mAbs. This was followed by 
washing off unbound antibodies with 4ml of FACS buffer and spinning at 1500rpm for 
5min in the centrifuge.  
Finally, cells were resuspended in 400µl of 'FACS fix' solution (PBS containing 2% 
paraformaldehyde and 2% FCS) and mixed thoroughly by vortexing for 10-15 seconds. 
Flow cytometric analysis was done using a FACSCalibur flow cytometer where CFSE is 
detected by FL1 and CD4 and CD8 detected by FL2 and FL4 respectively. 
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2.5 Ex vivo Cell Culture  
2.5.1 Isolation of γδ T cell from peripheral blood 
Here the manufacturer’s instructions for use of the TCRγδ+ T Cell Isolation Kit 
(Miltenyi Biotech) were followed. Basically, untouched TCRγδ+cells (γδ T cells) were 
isolated by depletion of non-TCRγδ cells (non-γδ T cells). Non-TCRγδ cells, which 
include αβ T cells, NK cells, B cells, dendritic cells, granulocytes, monocytes, stem cells, 
and erythroid cells, were indirectly magnetically labeled with a cocktail of biotin-
conjugated monoclonal antibodies, as primary labeling reagent, and anti-biotin 
monoclonal antibodies conjugated to Micro-Beads, as secondary labeling reagent. The 
magnetically labeled non-γδ T cells were depleted by retaining them on a MACS 
Column in the magnetic field of a MACS Separator, while the unlabeled γδ T cells 
passed through the column. The efficiency of isolation process was calculated by 
measuring the frequency of γδ T cells pre and post selection by flow cytometry. The aim 
was to reach 95-100% purity. 
2.5.2 Establishment of γδ T cell lines 
After the frequency of γδ T cells had been enriched (as described in above) to more than 
95 % they was co-cultured with irradiated PHA-activated allogeneic PBMC as feeder 
cells and stimulated with anti-CD3 and recombinant interleukin-2 (rIL-2). Cultures were 
enriched further by depletion of αβ T cells prior to re-stimulation with feeder cells (after 
3 to 4 weeks) followed by maintenance with media containing rIL-2. The absence of αβ 
T cells was confirmed by flow cytometry. As controls CMV-specific CD8+ T cell lines 
were generated from CMV-seropositive donors after stimulation with the cocktail of 
CMV-encoded peptide epitopes.  
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2.5.3 Culturing / subculturing (passaging) of Fibroblasts  
Human fetal foreskin fibroblasts (HFFF) were all maintained in Dulbecco’s modified 
Eagle’s Medium (DMEM) supplemented with 2 mM glutamine, 100 IU of penicillin/ml, 
100 µg of streptomycin/ml, and 10% foetal calf serum (FCS). In addition, 1% 
Amphotericin B was also used to prevent fungi from contaminating cell cultures. The 
passage of HFFF was carried out whenever >90% of the flask surface became covered 
by fibroblasts. Briefly, after discarding the old media from the flask it was washed with 
PBS followed by addition of trypsin-EDTA solution and incubated in 37°C for 2-5 
minutes, rocking the flask every minute. When all fibroblasts detached the contents of 
the flask were transferred into a 50 ml tube where they were washed again with PBS and 
centrifuged. Finally fibroblasts were resuspended and counted and an appropriate 
volume of growth media was added according to cell count and the size of flasks. 
2.5.4 Infection of HFFF with human CMV 
A number of HFFF flasks were prepared as described in section 2.5.3. When the HFFF 
were at 70% confluence they could be used for infection by CMV.  After the 
maintenance media had been removed, CMV was added to each flask at the appropriate 
multiplicity of infection (MOI). The amount of virus was dependent on the proposed 
experiment, see Table 2-12.  
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Table 2-12: Multiplicity of Infection (MOI) 
 
In this thesis both AD169 and Towne strains of human CMV were used for infection of 
fibroblasts.  The virus and fibroblasts were incubated at 37°C for 90min in 5ml of media, 
the flasks were rocked every 15-20min. For mock-infected flasks media alone was added. 
This was followed by washing off of virus with media and incubating in 25ml of media 
at 37°C. The monolayer integrity of adherent fibroblasts was checked daily for 
appearance of the cytopathic effect (CPE). Supernatant collection was started upon first 
signs of CPE in sterile tubes and stored at -80°C. Fresh media was added and cells 
returned to the 37°C incubator.  This step was repeated every 3-4 days until cells showed 
extreme CPE. When HFFF showed near complete death at this stage they were removed 
by sterile scraper and transferred into a sterile tube. These cells were used for 
preparation of CMV lysate that can be used in intracellular cytokine assays. See section 
2.5.6. 
2.5.5 Preparation of CMV 
Aiming for propagation of CMV virions, the growing HFFF were infected at multiplicity 
of infection (MOI) of 0.1:1. All the supernatants collected during the culture period were 
 105 
Table 2-12: Multiplicity of Infection (MOI) 
 
In this thesis both AD169 and Towne strains of human CMV were used for infection of 
fibroblasts.  The virus and fibroblasts were incubated at 37°C for 90min in 5ml of media, 
the flasks were rocked every 15-20min. For mock-infected flasks media alone was added. 
This was followed by washing off of virus with media and incubating in 25ml of media 
at 37°C. The monolayer integrity of adherent fibroblasts was checked daily for 
appearance of the cytopathic effect (CPE). Supernatant collection was started upon first 
signs of CPE in sterile tubes and stored at -80°C. Fresh media was added and cells 
returned to the 37°C incubator.  This step was repeated every 3-4 days until cells showed 
extreme CPE. When HFFF sho ed near co plete death at this stage they were removed 
by sterile scraper and transferr  i t   t il  t . hese cells were used for 
preparation of CMV lysate that  ll lar cytokine as ays. Se  section 
2.5.6. 
Purpose Multiplicity of 
infection 
(MOI)Virus: 
Fibroblast 
 
Number of cells  
Amount of virus 
particles needed 
To propagate CMV for 
production of more viruses 
0.1:1 For 10 flasks (size 150cm
2) 
(3x106 cells each) 
3x106 
To infect of HFFF for 
preparation of CMV lysate 
for inducing T cell responses  
4:1 For 10 flasks (size 150cm
2) 
(3x106 cells each) 
12x107 
For infection of targets for 
use in T cell recognition 
assays 
Up to 10:1 Depends on number 
ofassays 
Depends on 
number of assays 
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initially centrifuged at 1500 rpm for 10min to remove any cell debris. The cleared 
supernatants were then pooled into large centrifuge pots. This was followed by 
centrifugation at high speed (12000 rpm using a GSA Sorvall) for 2 hours. Next 
supernatant was decanted and virus pellet was resuspended in about 5ml of RPMI. 
Finally, a 21G needle was used to aspirate the cloudy fluid and aliquot into sterile 
eppendorf tubes at 50-100µl per tube and transferred into a -80°C freezer. 
2.5.6 Fibroblast lysate 
Fibroblast monolayers were grown as described in section 2.5.3. We usually aimed to 
have ten 150cm2 flasks ready for infection and five flasks for mock-infected controls. 
Infection of fibroblasts with AD169 or Towne strains of human CMV was carried out at 
MOI of 4:1 as explained in section 2.5.4. The monolayer integrity of adherent fibroblasts 
was checked daily for appearance of the cytopathic effect, which was usually visible 
within 16 hours (overnight). The first harvesting of supernatant from each flask was done 
on day 8 and frozen at -80°C.  More media was added to cells and incubation at 37°C 
was continued.  Harvesting of the supernatant then continued twice weekly from then on. 
When most of the monolayer became detached from the plastic, cells were harvested, 
using a scraper if necessary. Cultures normally survived for 2-3 weeks. Next cells and 
debris were separated and the pellet retained from the supernatant by spinning in a 
separate container. To make lysate the pellets and cell debris were snap frozen in liquid 
nitrogen and reheated to 50°C several times. For safety reasons the CMV lysate was 
exposed to UV light to ascertain that any remaining virus was totally inactivated.  
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2.6 Flow cytometry  
Most analyses were carried out on a BD FACSCalibur flow cytometer (BD Biosciences). 
Multiple parameters were used to define the lymphocytes, including gating, based on 
forward scatter (FSC) and side scatter (SSC). Fluorescence emission was measured at 
different wavelengths: FL1: 519 nm (FITC), FL2: 578 nm (PE/ Cy3), FL3: 695 nm 
(PerCP-Cy5.5), and FL4: 660 nm (APC).  
Unstained cells were used to set the background levels of fluorescence so that <1% of 
cells were determined as positive for any of the colours used. Cells incubated with single 
colours; CD8-FITC, CD8-PE, CD8- PerCP-Cy5.5, and CD8-APC were used to verify 
detection of each individual colour by the flow cytometer. Colour compensation was 
carried out when false positive results were obtained. For example, if FL4 (APC) 
positive events were also observed in samples only stained with PC5.5-conjugated anti-
CD8, the flow cytometer settings were corrected – i.e. compensated to show events as 
FL4 (APC) negative. This compensation was applied for each colour in order to avoid 
false positive results in test samples, where antibodies with different colours were used. 
A BD LSR II flow cytometer was also accessible to perform some studies in chapter five 
(role of CMV in coronary heart disease). In this project the following fluorochrome-
mAbs were used; for surface staining CD107-FITC, CD4-PerCP-Cy5.5 and CD8-
APC/Cy7 while for intracellular staining anti MIP1β-PE, IFNγ-AlexaFluor700, TNFα-
PE/Cy7, and IL-2-APC monoclonal antibodies were used. In addition, Tracking and 
Compensation beads (BD Biosciences) were used for voltage setup and auto-
compensation process respectively. 
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CellQuest software and FACSDiva software (both from BD) were used for flow 
cytometer data acquisition by the FACSCalibur and LSR II, respectively. However, all 
post acquisition analysis was carried by FlowJo software (version 9.5.2 and X ; Tree 
Star, Inc).  
2.7 Statistical analysis  
Since the data from this project did not always follow a Gaussian distribution, unless 
otherwise mentioned, nonparametric tests were used for all analysis. The median with 
25th and 75th percentiles was used for the description of distributions. Meanwhile, for 
comparison purposes (P value) either the Mann Whitney test (in case of comparing two 
independent variables) or the Kruskal-Wallis test followed by Dunn’s post-test (more 
than two variables compared) were used. In addition, for association and/or correlation 
the Spearman test was also used. All P values were two-tailed and 95% significance was 
applied. 
Note all statistical analyses were performed with Graphpad Prism software (version 5-
mac, GraphPad Software Inc.). However, for appropriate analysis of polychromatic flow 
cytometry data (Chapter 5) special programs called PESTLE and SPICE v5 (Simplified 
Presentation of Incredibly Complex Evaluations, Version 5) (Roederer, 2011) were used 
to generate graphs and for statistical analysis.  
N.B, More description of statistical testes will be included in separate section with each 
chapter.  
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2.8 List of reagents and antibodies 
2.8.1 Reagents 
1 Ficoll Hypaque density gradient centrifugation (GE Healthcare, product number; 
17-1440-03). 
2 Phosphate-buffered isotonic saline (PBS) (Sigma, product number; P4417) 
3 RPMI 1640 medium (Sigma, product number; R0883) 
4 Dulbecco’s modified Eagle’s Medium (DMEM) (Sigma, product number; 
D5796)  
5 Fetal bovine serum (FBS), (Sigma, product number; F4135). 
6 Glutamine (2mM), penicillin (50u/ml), and streptomycin (Sigma, product 
number; G6784) 
7 Brefeldin A (Sigma, product number; B7651) 
8 Phytohemagglutinin-PHA-M (Sigma; product number: L8902) 
9 Bovine serum albumen (BSA) (Sigma, product number; A2153)  
10 EDTA (BDH, product number; 104245S) 
11 Ethanol (University of Liverpool) 
12 Distilled water DNAse and RNAse free (Gibco, product number; 10977-035)  
13 Leucocytic Permeabilization Reagent  (IntraPrep ; Beckman Coulter product 
number:A07803)  
 Reagent 1 (Fixation agent) formaldehyde. 
            Reagent 2 (permeability agent) saponin. 
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2.8.2 Monoclonal antibodies 
Table 2-13: Antibodies used in multiparameter T cell studies (chapter 5) 
Target  Fluorochrome Clone Isotype Concentration  Catal -Number Vendor 
IFN-γ Alexa Fluor 
700 
4S.B3Mouse  IgG1 1/50 502520 BioLegend 
TNF-α  PE-Cy7 MAb11 IgG1 1/50 557647 BD 
Biosciences 
IL-2  APC 5344111 IgG1k 1/50 341116 BD 
Biosciences 
MIP-1β  PE D21-1351 IgG1 1/50 550078 BD 
Biosciences 
CD4  eFluor 450 RPA-T4 IgG1k 2/50 48-0049-42 eBioscience 
CD8 PerCP-Cy5. 5RPA-T8 IgG1k 1.5/50 560662 BD 
Biosciences 
CD107a  FITC H4A3 IgG1k 5/50 555800 BD 
Biosciences 
 
 
 
Table 2-14: Monoclonal antibodies used in NK cell phenotype studies 
Target  Fluorochrome Clone Isotype Concentration  Cata-Number Vendor 
 CD16  FITC NKP15 IgG1k 1/50 347523 BD 
Biosciences 
 
CD3 PerCP-Cy5.5 OKT3 IgG1 1/50 45-0037-73 eBioscience 
 
 CD56 APC MEM188 IgG1 1/50 17-064-42 eBioscience 
 
NKG2C PE  IgG1 1/50 FAB138P R&D systems 
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Table 2-15: Monoclonal antibodies used in γδ T cell studies (chapter 4) 
Target  Fluorochrome Clone Isotype Concentration  Catalogue -
Number 
Vendor 
TCR γδ APC B1 IgG1k 1/50 561049 BD 
Biosciences 
 
TCR Vδ2 FITC B6 
 
IgG1 1/50  562088 BD 
Biosciences 
 
TCR Vδ2 
 
PE B6 
 
IgG1 1/50  555739 BD 
Biosciences 
 
 
TCR Vδ2 
 
PerCP B6 
 
IgG1k 1/50  331410 BioLegend 
 
TCR Vδ1 
 
FITC TS8.2 IgG1 1/50  TCR2730 Perbio 
TCR αβ FITC WT31 IgG1 1/50  347773 BD 
Biosciences 
CD11a 
(LFA-1) 
FITC G43-25B IgG2a 1/50  555379 BD 
Biosciences 
CD45RA PerCP-Cy5.5 HI100 IgG2b 1/50  304122 BioLegend 
CD27 FITC M-T271 IgG1k 1/50  555440 BD 
Biosciences 
CD28 PerCP-Cy5.5 CD28.2 IgG1k 1/50  302922 BioLegend 
IL-7Ra FITC eBioRDR5 IgG1k 1/50  11-1278-42 eBioscience 
 
IL-15Ra PE JM7A4 IgG1k 1/50  330207 BioLegend 
Granzyme 
B 
FITC GB11 IgG1 k 2/50  560211 BD 
Biosciences 
Perforin PE dG9k IgG2b 2.5/50  308105 BioLegend 
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3 Imprint Of Chronic CMV Infection On The 
Immune System Of Healthy Subjects 
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3.1 Background 
Primary CMV infection is usually asymptomatic and takes place during childhood. This 
is followed by persistent lifelong latent infection (Gandhi and Khanna, 2004). Although 
the exact mechanisms involved in CMV latency are not fully understood, it is clear that 
different arms of the immune system are involved in keeping viral replication under 
check (Polic et al., 1998). Being one of the largest known viruses, with a genome of 235 
kb, CMV elicits a very broad spectrum of immune responses. It starts with the innate 
mechanism that includes production of inflammatory cytokines by virus-infected cells 
and activation of NK cells which ultimately drives the adaptive immune system to 
produce CMV-specific antibody and generation of αβ T cells and γδ T cell responses 
(Jackson et al., 2011). The evidence that supports the importance of these different arms 
of the immune system is discussed in more details in section (1.2.6). However, here 
more focus was given to certain cell subsets, which are believed to play a direct role in 
CMV immunity.  
Imprint of CMV carriage on the immune system  
It has become more evident that chronic CMV carriage has a major influence on the 
immune system (Gratama et al., 1987). One of the obvious influences might be the 
effect of CMV on the αβ T cell repertoire. This was particularly true for CD8+ T cells 
characterised by expression of CD57; this cell subset were found to be monoclonal and 
correlated positively with human CMV carrier status in healthy individuals (Wang et al., 
1993, Wang and Borysiewicz, 1995, Wang et al., 1995). Furthermore, the CD8+ subset 
shows a double increase in its absolute number in CMV-seropositive elderly compared 
to CMV-seronegative subjects (Looney et al., 1999). Interestingly, this expansion of 
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CMV-specific CD8+ T cells can often be monoclonal (Khan et al., 2002b) and 
characterized by accumulation of highly (late) differentiated effectors memory cells 
(CD28neg CD8+ T cells) that are can be dysfunctional in the very elderly (Ouyang et al., 
2004). Similarly, but at lower frequency, there is an association between an increase in 
CD28neg CD4+ T cells and CMV seropositivity with advancing age (Pourgheysari et al., 
2007). It is important to mention that this phenotype, particularly CD28neg CD8+ T cells, 
is part of the immune-risk phenotype. In addition, the increase in CD8+ T cell frequency 
is associated with mortality in the elderly (80-90 years) and considered as a signature of 
immunosenescence (Olsson et al., 2000, Wikby et al., 2002, Pawelec et al., 2010). 
Evidence for the role of NK cells in immunity to CMV in humans comes from several 
clinical observations. For example patients with a rare NK cell disorder show frequent 
episodes of acute CMV infection (Biron et al., 1989, Gazit et al., 2004). In addition, 
recovery of NK cells post bone marrow transplant is associated with a remarkable 
decrease in incidence of serious CMV disease (Quinnan et al., 1982). Furthermore, 
encoding of several mechanisms by CMV to evade NK cells is indirect evidence 
suggesting the importance of NK cells in controlling CMV infection (Wilkinson et al., 
2008). Of particular importance, CMV was found to remarkably modify the NK 
repertoire, for instance, in healthy donors there is a significant increase in frequency of 
NKG2C+ NK cells with reductions in cells with other activating receptors (Guma et al., 
2004, Guma et al., 2006, Monsivais-Urenda et al., 2010). In addition, NK cells that were 
co-cultured ex-vivo with CMV infected fibroblasts showed an increase in the expression 
of NKG2C (Guma et al., 2006). Indeed, such observations highly suggest the 
importance of NKG2C+ NK cells in the control of CMV chronic infection. 
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Besides NK cells and αβ T cells, the role of non-conventional T cells expressing the 
gamma delta (γδ) TCR in control of CMV infection has become more appreciated 
(Lafarge et al., 2001, Knight et al., 2010, Vermijlen et al., 2010). 
 Unlike αβ T cells, γδ T cells are MHC-unrestricted in their antigen-recognition and 
normally constitute a minority of circulating T cells. According to the TCR gene usage 
the γδ T cells can be sub-classified into Vδ2pos γδ T cells and Vδ2neg γδ T cells (Xiong 
and Raulet, 2007). However, Vδ2neg γδ T cells seem to be more important in CMV 
immunology. More details about characteristics of this cell subset are reviewed in 
section (1.2.2.3). 
A Pioneering work by Dechanet and colleagues has shown that γδ T cells considerably 
expand in peripheral blood following primary CMV infection in CMV-seronegative 
transplant recipients of kidneys from seropositive donor (Dechanet et al., 1999a, 
Dechanet et al., 1999b). It is worth mentioning that the expansions were composed of 
either Vδ1pos or Vδ3pos cells but not Vδ2pos cells (Pitard et al., 2008). Furthermore, in 
vitro incubation of Vδ2neg γδ T cells with CMV infected target cells showed the ability 
of Vδ2neg γδ T cells to produce cytokines and to demonstrate cytotoxicity (Halary et al., 
2005) Indeed, such observations highly suggest the importance of Vδ2neg γδ T cells in 
CMV infection. 
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3.1 Aims  
The influence of CMV carriage on different arms of the immune system has been 
studied widely. Almost all previous studies focused on the relationship between CMV 
infection and one kind of cell subset independent of other cell subsets. Therefore, the 
main aim of the current study is to investigate the simultaneous impact of chronic 
infection with CMV on different cell subsets in the same healthy donor. Here, the 
frequencies of the following subsets: CD28neg CD4+ T cells, CD28neg CD8+ T cells, 
NKG2Cpos NK cells and Vδ2neg γδ T cells was compared in CMV-seropositive and 
CMV-seronegative donors.  
Since it is not known whether these cell subsets work independently or together to 
control CMV infection, the second aim was to investigate the existence of association 
(such as cooperation or redundancy) between these subsets. This was examined by 
calculating the correlation and linear regression between levels of these cell subsets in 
the CMV-seropositive cohort.  
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3.2 Plan of Investigation 
To achieve these aims, healthy volunteers from the University of Liverpool and the 
Royal Liverpool University Hospital (RLUH) NHS Trust were recruited. All subjects 
were mobile, did not have any cognitive impairment, were not suffering from acute or 
chronic illness, and were not on medication known to affect the immune system. All 
blood samples were obtained after formal consent from the donor to participate in the 
study. Ethical approval for this work had been given by the Liverpool Research Ethics 
committee. The main steps of the plan of investigation are summarized in Figure 3.1; 
generally it includes three main steps:   
 Determining the CMV status of the cohort. 
 Detecting CMV specific IgG antibody  (titre and avidity) by 
ELISA. 
 Measuring αβ T cell responses against CMV utilizing intracellular 
cytokine staining (ICS) and flow cytometry. 
 Phenotyping to determine the frequency of CD28neg CD4+ T 
cells, CD28neg CD8+ T cells, NKG2C+ NK cells and Vδ2neg γδ 
T cells in CMV-seropositive donors and compare it to CMV-
seronegative donors. 
 Analyzing the linear regression of all possible combinations of these 
cell subsets and calculating the correlation between them. 
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Figure 3.1: Plan for investigation steps.  
 
!
Step 1 determine CMV status 
Response to CMV antigen ELISA
Avidity Antibody titer CMV infected 
fibroblast lysate  
CMV purified 
peptides 
Low High 
Old 
infection
Recent 
infection
CMV specific CD4+ 
T cell response 
CMV specific CD8+ 
T cell response 
CMV 
positive 
CMV 
negative 
To be correlated to  
lymphocyte phenotype
Step 2 lymphocyte phenotyping 
  
αβ T cells  γδ T cells  NK cells  
CD28-neg 
CD8 T cells  
vδ2neg
 γδ T cells
NKG2C-pos 
NK cells  
CD16-neg 
NK(immature)
CD16-pos 
NK(mature)
NKG2C-pos 
NK cells  
CD28-neg 
CD4 T cells  
CD4 T cells  CD8 T cells  
vδ2-pos
 γδ T cells
Step  3 measuring linear regression   
Plotting liner regression of all possible combination of  cells subsets and calculating the correlation 
between them.
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3.3 Statistical analysis 
Since data do not follow the normal (Gaussian) distribution precisely, thus non-
parametric tests were used for all analyses. This includes the use of medians with 25th 
and 75th percentile for distribution description. Meanwhile; Mann-Whitney and 
Spearman tests were used to calculate the difference in distribution (P value) and the 
correlation, respectively. 
3.4 Results 
3.4.1 Testing blood donors for CMV carriage 
3.4.1.1 ELISA 
To address the aims, it was necessary to confirm the CMV status of the study cohort. 
This involved the use of two complementary methods to measure humoral and cellular 
immunity; IgG antibody responses against CMV measured by ELISA, and αβ T cell 
responses against CMV measured by flow cytometry. 75 consenting volunteers were 
recruited to donate 10-20 ml of blood. After separation of heparinised blood using Ficoll, 
plasma was used for quantitative anti-CMV IgG ELISA as described in 2.3.1.1. The 
ELISA results are summarised in Figure 3.2. According to this assay, out of 75 donors 
tested there were 36 CMV-seropositive donors.  
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Figure 3.2: CMV status of the study population 
This illustrates percentage of CMV seropositive (red colour) and CMV seronegative 
(blue colour) healthy subjects in current study. The total population of the study is 75 
(n=75), 36 of them were CMV-seropositive, while slightly more than the half of donors 
were CMV-seronegative.   
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3.4.1.2 Intracellular cytokine staining  (ICS) 
Simultaneously T cell responses against CMV antigen were carried out. Lysed CMV 
infected fibroblasts (for more details of CMV lysate see section 2.5.6) was used to 
measure CD4+ T cells. Meanwhile; cocktails of known immunogenic CMV peptides 
(made commercially by GPT ) were used to measure CD8+ T cell responses. The 
antigens selected were IE1, pp65 and a combination of pp50 and gB peptides 
(VTE/DYS). T cell responses were measured by staining PBMC with antibodies against 
T cell markers (CD4 and CD8) and then against intracellular Interferon-gamma (IFNγ). 
Figure 3.3 shows three representative examples of donors tested for T cell responses 
against CMV antigen. The increase in proportions of IFNγ producing CD4+ or CD8+ T 
cells was used to decide whether there was response or not, the following formula was 
used to calculate this proportion.  
 
In each case there were extremely low responses against mock antigen (0.2-0.5% of 
CD4+ T cells). However some donors appeared to respond against CMV antigen 
whereas others did not. In donors HD035 and HD195, 4.5% and 2.28% of total CD4+ T 
cells were CMV-specific (produced IFNγ) respectively. In other words, proportions of 
IFNγ production by CMV-specific CD4+ T cell have increased by approximately 90 and 
70 times respectively in response to lysed CMV infected fibroblasts. In contrast, in 
donor HD180 the CMV-specific T cells were at background levels (0.03%) with less 
than double increases in IFNγ production after stimulation.  118 
3.4.1.2 Intracellular cytokine staining  (ICS) 
Simultaneously T cell responses against CMV antigen were carried out. Lysed CMV 
infected fibroblasts (for more details of CMV lysate see section 2.5.6) and pools of 
CMV peptides (commercial) were used to measure CD4+ and CD8+ T cell responses 
respectively. T cell responses were measured by staining PBMC with antibodies against 
T cell markers (CD4 and CD8) and then against intracellular Interferon-gamma (IFNγ). 
Figure 3.3 shows three representative examples of donors tested for T cell responses 
against CMV antigen. The increase in proportions of IFNγ producing CD4+ or CD8+ T 
cells was used to decide whether there was response or not, the following formula was 
used to calculate this proportion.  
 
 
 
In each case there were extremely low responses against mock antigen (0.2-0.5% of 
CD4+ T cells). However some donors appeared to respond against CMV antigen 
whereas others did not. In donors HD035 and HD195, 4.5% and 2.28% of total CD4+ T 
cells were CMV-specific (produced IFNγ) respectively. In other words, proportions of 
IFNγ production by CMV-specific CD4+ T cell have increased by approximately 90 and 
70 times respectively in response to lysed CMV infected fibroblasts. In contrast, in 
donor HD180 the CMV-specific T ells were at background l vels (0.03%) with less 
than double increases in IFNγ production after stimulation. 
Frequency of CMV-specific CD4+ or CD8+ T cells = 
                             % IFNγpos  (CD4+ or CD8+) T cells events in response to mock.  
    Subtracted from 
     % IFNγpos  (CD4+ or CD8+) T cells events in response to CMV-antigen  
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Figure 3.3: Representative flow cytometry plots of healthy blood donor responses against 
CMV antigens.  
This figure shows 3 representative results of blood donor responses against CMV. PBMC were 
stimulated for 6 hours at 37°C followed by surface staining for CD4-FITC and then intracellular 
staining for IFNγ-PE. The frequencies shown in the upper right quadrant refer to the % of CD4+ 
T cells that produce IFNγ out of total CD4+ T cells after stimulation. 
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3.4.1.3 Measuring CD8+ T cell responses against CMV antigens in CMV carriers 
Up to this point, information was only available on CD4+ T cell responses against CMV. 
Indeed, measuring the CD8+ T cell response to CMV is required to confirm T cell 
reactivity. However, due to the inefficiency of CD8+ T cell cross priming by exogenous 
antigens, the CMV antigen (lysate) method is sub-optimal for stimulating CD8+ T cells 
(Sester et al., 2002a). Instead, an	  inclusive CMV peptide pools was used for this purpose. 
These pools spanned the entire amino acid sequences of the HCMV pp65, major 
immediate early (IE-1) proteins and DYS/VTE. They comprised of 15-amino acid 
peptides with at least nine overlaps between neighboring peptides. Besides, these 
reagents do not require further processing and can be presented efficiently to CD8+ T 
cells. Furthermore, all potential CD8+ T cell epitopes contained in these proteins were 
provided by the complete pools and, therefore, unlike with single epitopes, testing was 
somewhat independent of donor HLA type (Kern et al., 2000). Similar to the steps for 
measuring CD4+ T cell responses, production of IFNγ was exploited as an indicator of 
cellular responses. Representative examples are shown in Figure 3.4. Notably, from 
those donors who showed response to CMV lysate/peptide mix, only 10 donors were 
chosen for this purpose. Briefly, for each donor PBMC were subdivided into three equal 
amounts and the concentration was adjusted to 1x106 per ml.  Then each well was 
stimulated with a different pool of peptides namely; pp65 peptides, IE-1 peptides and 
DYS/VTE peptides. Results are shown in Figure 3.5, where the main response was by 
CD8+ T cells responding to pp65 (mean= 1.68% of total CD8 subset with Standard 
Deviation (SD) = 1.82) followed by response to IE-1 peptides (mean= 0.99% of total 
CD8 subset with SD=1.3) and then DYS/VTE mix (mean= 0.93% with SD=0.59), see 
figure 3.5. 
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Figure 3.4: CD8+ T cell responses to the different peptide antigens. 
Illustrative example of CD8+ T cell responses in a CMV- seropositive healthy donor to three 
different pools of purified CMV peptides (from top to bottom DYS/VTE, IE-1,and PP65 
peptides). The proportion of CMV specific cells is shown as a percentage in the upper right 
quadrant.  
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Figure 3.5: Mean of CMV specific CD8+ T cell responses to a mix of synthetic peptides. 
This figure demonstrates CMV specific CD8+ T cell responses of 10 CMV-seropositive donors 
to synthetic peptides (after subtracting the mock level). The highest response is toward pp65 
peptides, followed by response to IE-1 peptides and to a lesser extent to DYS/VTE peptide 
mixes (mean= 1.68 with S.D= 1.819, mean= 0.987 with S.D=1.3 and mean= 0.933 S.D=0.59 
respectively).   
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3.4.2 Phenotyping  
The influence of CMV seropositivity on the immune system of immunocompetent 
subjects has been and is still an area of research interest. Most studies focused on 
changes in each arm of the immune system separately. This includes individually 
studying the phenotype of CD4+ and CD8+ T cells, NK cells or to a lesser extent γδ T 
cells.  However, far too little attention has been paid to investigating such changes in the 
same cohort at the same time. Therefore, to have a comprehensive view, the current 
study was designed to compare simultaneously differences in frequencies of certain cell 
phenotypes in CMV positive and CMV negative healthy donors. This includes CD28neg 
CD4+ T cells, CD28neg CD8+ T cells, NKG2Cpos NK cells and Vδ2neg γδ T cells. 
3.4.2.1 Possibility of using frozen PBMC samples for Phenotyping  
During the initial optimization stages, it was worth investigating the possibility of using 
frozen PBMC samples instead of fresh blood each time. For this purpose six samples of 
blood from the same donor were used, three of the samples were fresh and three were 
recently frozen (within 10 weeks duration). Each sample was tested for both surface cell 
markers and response to antigens as explained above. A representative example is shown 
in Figure 3.6. Herein, the CD8+ T cell response to synthetic peptides was measured 
using flow cytometry and intracellular staining to detect any increase in IFNγ production 
after stimulation. No significant difference in antibody surface staining assay was 
detected. However, the functional assay was slightly weaker in frozen samples. Thus a 
decision was made to use fresh blood samples or recently frozen samples for all 
functional assays. Meanwhile old frozen cells might be used for non-functional assays 
such as antibody staining of cell surface markers. 
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Figure 3.6: Examples of CD8+ T cell responses in fresh and frozen PBMC samples  
This figure shows comparison between the response of fresh and recently frozen CD8+ T cells to 
different synthetic CMV peptides. The stored samples were cryopreserved below -70°C for 
approximately 6 weeks. From the same donor a fresh blood sample was taken and used as a 
control for the stored sample. As can be seen there is only a slight difference between the fresh 
and recently frozen cell responses to the antigens.   
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3.4.2.2 Higher frequency of CD28 negative CD4+ and CD8+ T cells in CMV-seropositive compared 
to CMV-seronegative donors. 
The role of CD28 is well established in promoting T cell proliferation, survival, 
metabolism and cytokine production; it is reviewed in detail by Acuto and Michel 
(Acuto and Michel, 2003). The down regulation of its expression by repeated 
stimulation makes it one of the indicative markers for T cell differentiation (Hamann et 
al., 1997, Appay and Rowland-Jones, 2004, Appay et al., 2008).  A representative 
example of how these subpopulations were identified is shown in Figures 3.7 and 3.8. 
Briefly, plotting size (forward scatter, FSC) versus granularity (side scatter, SSC) was 
used to identify the lymphocyte population. Upon gating on lymphocytes CD4+ and 
CD8+ T cell subpopulations were then identified. Finally, according to expression of 
CD28, both CD4+ and CD8+ T cells were dissected into early (CD28pos or CD28high) 
and late  (CD28neg or CD28low), also called highly differentiated T cells. The differences 
in the frequency of these subsets of T cells in CMV-seropositive and CMV-seronegative 
were compared in the charts below the flow cytometric plots in Figures 3.7 and 3.8.  
There was a significant (p< 0.001) increase in the frequency of CD28neg CD4+ T cells in 
CMV-seropositive donors (9.6, 2.8-15.8, n=34; median, 25th-75th percentile) compared 
to CMV-seronegative donors (0.98, 0.59-4.96, n=24; median, 25th-75th percentile). 
Similarly, there was a significant difference (p< 0.001) in the percentage of CD28-neg 
CD8+ T cells between CMV-seropositive (36.48, 29.25-41.50, n=34; median, 25th-75th 
percentile) and CMV negative groups (16.5, 11.64-36.85, n=24; median, 25th-75th 
percentile). 
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Figure 3.7: Phenotypic profile of CD4+ T cell subsets in CMV-seropositive and CMV-
seronegative donors.  
The figure shows representative data of flow cytometry analysis from CMV-seronegative (left 
column) and CMV-seropositive donors  (right column). Forward vs. side scatter was used to 
identify lymphocytes followed by gating on CD4+ and CD8+ T cells. Finally the percentage of 
CD28neg CD4+ T cells was calculated (the number within the upper left quadrant). The Chart 
below the FACS-plots summarised CD28neg phenotypic profiles of CD4+ T cells in CMV-
seropositive and CMV-seronegative donors. Error bars indicate the median, 25th, and 75th 
percentile  (9.6, 2.8 -15.8, and 0.98, 0.59-4.96; CMV-seropositive and CMV-seronegative 
respectively) with P<0.001 at 95% confidence intervals are shown. 
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Figure 3.8: Phenotypic profile of CD8+ T cell subsets in CMV-seropositive and CMV-
seronegative donors  
The figure shows representative data of flow cytometry analysis from CMV-seronegative (left 
column) and CMV-seropositive donors  (right column). Frequency of CD28neg CD8+ cells was 
calculated and summarised in the chart. There was a significant difference (p< 0.001) in the 
percentage of CD28neg /CD8+ T cells between CMV positive group (36.48, 29.25-41.50, n=34 
median, 25th-75th percentile) and CMV negative groups (16.5, 11.64-36.85, n=24 median, 25th-
75th percentile).  
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3.4.2.3 Similarity in the frequency of total NK cells in CMV positive and CMV negative subjects with 
remarkable expansion of NKG2Cpos NK cells in CMV positive donors. 
Aiming to determine the influence of chronic CMV infection on NK cells, two levels of 
flow cytometric analysis were carried out. Initially, the frequency of immature and 
mature NK cells among the lymphocyte population was identified. Thus after gating on 
lymphocytes the CD3negCD56pos population were selected, which subdivide according to 
expression of CD16 into immature and mature NK cells (CD16neg NK cells and CD16pos 
NK cells respectively), see figure 3.9. Comparison between CMV positive and CMV 
negative subjects showed similarities in the frequencies of both immature NK cells (not 
shown) and mature NK cells (Figure 3.9). 
Indeed, such similarity in frequency of total NK cells does not necessary mean similarity 
in frequency of all minor subtypes of NK cells. Therefore, a second step was carried out 
to compare certain subsets of NK cell. Though there are several activating and inhibitory 
receptors involved in NK cell CMV immunity, in this thesis, NKG2C was chosen. This 
is based on several observations that suggest the importance of NKG2Cpos NK cell in 
CMV infection (Guma et al., 2004, Guma et al., 2006, Monsivais-Urenda et al., 2010). 
Figure 3.10 is an illustrative example of gating steps to determine this population. 
Statistical analysis confirms the presence of a significantly high frequency of NKG2Cpos 
NK cells in CMV positive compared to CMV negative donors (p<0.05) at 95% 
confidence intervals. 
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Figure 3.9: Similarity in mature NK cell frequency in CMV-positive and CMV-negative 
donors.  
NK cells were classified according to expression of CD16 into mature (CD16pos NK cell) and 
immature NK cells (CD16neg NK cells). The frequency of mature NK cell populations in both the 
CMV positive and CMV negative healthy donors were compared in the chart. 
 
 
 
 
 
CD56
CD3
FSC
SSC
NK cells
Gating on 
lymphocyte 
Gating on 
NK cells 
CD16
CD56
0
10
20
30
40
50
60
70
80
90
100
Frequency of CD16 pos NK cells 
out of the total  NK cells
CMV-positiveCMV-negative
P>0.05
To
ta
l N
K
 c
el
l
 134 
 
 
 
 
 
Figure 3.10: High frequency of NKG2Cpos NK cells is detected in CMV-seropositive donors.  
Flow cytometric plots show gating steps to determine NKG2cpos mature NK cells 
(CD3negCD56pos CD16pos NK cells). Diagram shows frequencies (median, 25th-75th percentile) 
of NKG2Cpos NK cells among total NK cell populations in CMV-seropositive (6.93, 4.193-
10.40) (red squares) and CMV-seronegative donors (3.43, 1.64-7.40) (blue squares). Error bars 
signify the median and interquartile and significance (p) values at 95% confidence intervals are 
shown at the top of the diagram. 
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3.4.2.4 Remarkable increase in the frequency of Vδ2neg γδ T cells in CMV-positive donors compared 
to CMV-negative donors. 
The role of γδ T cells, particularly the Vδ2neg subset in relation to CMV in healthy 
subjects has been studied relatively recently (Pitard et al., 2008). Meanwhile, several 
studies were carried out on immunosuppressed patients with active CMV disease such as 
renal transplant and bone marrow transplant (BMT) patients (Dechanet et al., 1999a, 
Knight et al., 2010). Therefore, the aim of the current study was firstly to confirm the 
expansion of this cell subset in a healthy donor cohort in correlation to CMV status. 
Secondly to find out if there is redundancy between Vδ2neg γδ T cells and CMV-specific 
αβ T cells and NK cells.  
To determine if there is any difference in γδ T cells or in the proportions of the subclass 
Vδ2neg γδ T cells between CMV-seropositive and CMV-seronegative donors, PBMC 
were analyzed by flow cytometry. Here PBMC were stained with antibodies against αβ-
TCR, pan-γδ-TCR and Vδ2-TCR using 3-colour staining. A representative example of 
the gating steps is shown in Figure 3.13. Statistically, there was a significant increase in 
the proportion of Vδ2neg γδ T cells (P value < 0.0001) in CMV seropositive compared to 
CMV seronegative healthy donors, see chart in Figure 3.11. However, there was no 
statistically significant difference (P value < 0.1047) in the proportion of total γδ T cells 
between groups (not shown).  
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Figure 3.11: Remarkable increase in the frequency of Vδ2neg γδ T cells in CMV-positive 
compared to CMV-negative healthy donors. 
Flow cytometric plots are representative examples of characterization of Vδ2neg γδ T cells 
from CMV-seronegative and CMV-seropositive healthy donor (left plots and right plots 
respectively). Gates were designed to show the frequency of Vδ2neg γδ T cells out of total 
lymphocytes, which are then represented in the chart as median and 25th-75th percentile. In 
CMV-seropositive (red squares) the frequency was (1.94, 0.81-2.98) while in  CMV-
seronegative donors (blue squares) it was (0.633, 0.33-1.94) Error bars indicate median with 
interquartile and significance (p) values at 95% confidence intervals are shown at the top of the 
graph. 
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3.4.3 These changes in the distributions of lymphocyte subsets are 
characteristic of CMV chronic infection in healthy donors. 
Aiming to determining whether these phenotypic changes are attributed to CMV 
infection and not general phenomena of any persistent viral infection, the impact of 
herpes simplex virus (HSV) carrier status on these subsets of lymphocytes was 
investigated.  therefore, sera from the study cohort (CMV positive and CMV negative 
groups) were tested by ELISA for the presence of anti-HSV-1 and -2 IgG antibodies (see 
section 2.3.1.4). As a result there were four groups of healthy donors; CMVpos HSVpos 
(n=29), CMVpos HSVneg  (n=12), CMVneg HSVpos (n=17), and CMVneg HSVneg  (n=14). 
Frequencies of lymphocytes of interest were compared among these groups of donors 
(Figure 3.12).  
Comparing the healthy donors according to HSV status (i.e. CMVpos HSVpos vs. CMVpos 
HSVneg and CMVneg HSVpos vs. CMVneg HSVneg) showed no significant difference in the 
frequency of all kinds of cells of interest. Meanwhile, comparing cells according to 
CMV status such as, CMVpos HSVpos vs. CMVneg HSVpos demonstrated remarkable 
differences in frequencies of all kinds of lymphocytes of interest. However comparison 
between CMVpos HSVneg and CMVneg HSVneg groups showed differences only when 
considering frequency of CD28neg CD4+ T cells and Vδ2neg γδ T cells.  
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Figure 3.12: The impact of HSV infection on the distributions of different lymphocyte 
subsets in CMV- seropositive and CMV–seronegative healthy donors. 
The study population was divided according to CMV and HSV serology into four populations; 
CMVpos HSVpos (n=29), CMVpos HSVneg  (n=12), CMVneg HSVpos (n=17), and CMVneg HSVneg  
(n=14). Infection with CMV but not HSV induced the accumulation of late differentiated 
effector αβ T cells (CD28neg CD4+ T cells and CD28neg CD8+ T cells) chart A and B 
respectively.  Also the increase in frequencies of Vδ2neg γδ T cells and NKG2CposNK cells was 
related to CMV seropositivity but not HSV status (see chart C and D). Significance (p) values at 
95% confidence intervals are shown as asterisks at the top of the graph (ns= not significant, *= 
p<0.05, **= p<0.001, and ***= p<0.0001). 
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3.4.4 Dynamic monitoring of phenotypic changes 
Comparing the lymphocyte phenotype in CMV seropositive to CMV seronegative 
subjects provided only a view on the differences in the immune system pre and post 
infection with a gap in the knowledge of how long these changes had taken to develop. 
Therefore a special type of ELISA was carried out to attempt to define the CMV-
seropositive cohort into recently infected and durably (long-standing) infected subjects.  
Basically this assay works by detecting the avidity of CMV-specific IgG and hence 
donors with low IgG avidity can be considered as CMV-recent infected whereas those 
with anti-CMV IgG high avidity they must have had CMV for a long period (CMV 
long-standing infection), see section (2.3.1). According to this assay only three donors in 
the current study showed low avidity. Indeed, with such low numbers, statistically, it 
was not possible to compare the two groups. Thus another approach was tried, which 
was studying changes in the immune system during CMV symptomatic primary 
infection. 
3.4.4.1 Acute symptomatic primary CMV infection in immunocompetent patients. 
Studying CMV symptomatic primary infection is usually carried out on immune-
compromised patients such as post renal transplantation where there is a high incidence 
of CMV infection. Nevertheless because the population of this study was recruited from 
healthy donors, identification of symptomatic CMV primary infection of immune-
competent subjects was tried. Since the incidence of CMV symptomatic primary 
infection in Merseyside hospitals is approximately eight cases per year, the goal was to 
recruit 4 to 8 patients. However, only one of five patients diagnosed with primary CMV 
infection yielded samples.  
 140 
From the consented patient 20 ml of blood was taken at three different time points; T1 
blood sample was taken the second day of diagnosis (first day of acyclovir therapy), T2 
was taken 10 days after therapy initiation while T3 was taken 6 weeks later.  After 
separation of PBMC in the standard way, plasma was collected and used to measure 
both CMV specific antibody titres by ELISA and viral load utilizing Real time PCR (see 
section 2.3.2) 
3.4.4.2 Relationship between viral load and CMV-specific IgG antibody titre and changes in 
composition and frequency of effector αβ T cell subsets  
Aiming to determine the association between the anti CMV-IgG and CMV viral load on 
the one hand and the change in the phenotype of lymphocytes, the viral load and 
antibody titre were correlated to the frequency of target cell populations. Starting with 
viral load there was a remarkable drop in the number of viral DNA copies per ml of 
plasma from 472x10-2 to 1 x10-2 between T1 and T2. However, by T3 viral DNA was 
not detectable. In contrast, the level of CMV-specific IgG antibody was almost constant 
and only started to decline by T3 (Figure 3.13).  
Dynamically, αβ T cells showed an initial sharp increase in the percentage of CD28neg 
CD4+ T cells from 3.25% at T1 to 7.56% at T2, followed by a slow increase to reach 
7.97% by T3. This level seemed to be approaching that in CMV chronic infection, (see 
3.4.2.2, and Figure 3.7), where the median was 9.6 and 25th-75th percentile ranges 
between 2.8 and 15.8; respectively. In contrast, CD28neg CD8+ T cells demonstrated a 
remarkable reduction, at T3 to approximately half their frequency at T1 (T1= 61.5% T3= 
30.2%). Again this suggests that levels were approaching those of CD28neg CD8+ T cells 
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in CMV chronic infection  (36.48, 29.25-41.50, n=34: median, 25th-75th percentile) 
(section 3.4.3.2 and Figure 3.8). 
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Figure 3.13: Phenotypic changes in CD4+ and CD8+ T cells after primary CMV infection. 
Flow cytometric plots from an immunocompetent healthy donor with acute primary CMV 
infection. T1 blood sample was taken on the second day of diagnosis and first day of acyclovir 
therapy, T2 was taken 10 days after therapy initiation while T3 was taken 6 weeks later. The 
upper two panels show the frequency of CD28-negCD4+ and CD8+ T cells as % total 
lymphocytes (upper left quadrant in each plot). The chart below shows the changes in viral load 
(blue curve) and anti-CMV IgG antibody titre (red curve).  
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ig re 3.15: e oty ic c a es i      lls ft  i   i f ti . 
FACS plots from an immunocompetent healthy donor with acute primary CMV infection. T1 
blood sample was taken on the seco d day of diagnosis and first day of acyclovir therapy, T2 
was taken 10 days after therapy initiation while T3 was taken 6 weeks later. The upper two 
panels show the frequency of CD28-negCD4+ and CD8+ T cells as % total lymphocytes (upper 
left quadrant in each plot). The chart below shows t e changes in viral load (blue curve) an  
anti-CMV IgG antibody titre (red curve).  
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3.4.4.3 Alteration in the percentage of NKG2Cpos NK cells and Vδ2neg γδ T cells after primary CMV 
infection. 
The dynamic changes in the frequency of NKG2C-pos NK cells and Vδ2neg γδ T cells 
post acute primary CMV infection are illustrated in Figures 3.14 and 3.15 respectively. 
Herein, changes in the viral load and anti-CMV IgG antibody titre (displayed as blue and 
red curves, respectively) are plotted against frequencies of these cells at three different 
time points (T1, T2, and T3). Both NKG2Cpos NK cell and Vδ2neg γδ T cell frequencies 
gradually declined over time.  Table 3.1 below summarises the change in the frequency 
of each subset compared to their corresponding medians (25th-75th percentile) in CMV 
positive chronic carriers.  
Table 3-1 Cell frequencies in CMV infected patient compared to medians and means of 
healthy CMV+ carriers. 
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3.4.4.3 Alteration in the percentage of NKG2Cpos NK cells and Vδ2neg γδ T cells after 
primary CMV infection. 
The dynamic changes in the frequency of NKG2C-pos NK cells and Vδ2neg γδ T cells 
post acute primary CMV infection are illustrated in Figures 3.16 and 3.17 respectively. 
Herein, changes in the viral load and anti-CMV IgG antibody titre (displayed as blue and 
red curves, respectively) are plotted against frequencies of these cells at three different 
time points (T1, T2, and T3). Both NKG2Cpos NK cell and Vδ2neg γδ T cell frequencies 
al y declined over time.  Table 3.1 below sum arises the change in the fr quency 
of each subset compared to their corresponding medians (25th-75th percentile) in CMV 
positive chronic carriers.  
Table 3-1 Cell frequencies in CMV infected patient compared to medians and means of 
healthy CMV+ carriers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMV primary infection 
 
CMV positive chronic carriers 
 
T1 
 
T2 
 
T3 
 
Median        25th-75thpercentile 
 
NKG2Cpos NK 
cells 
 
26.9 
 
23.9 
 
21.6 
 
7.9                 5.4 - 11.2  
 
Vδ2neg γδ T 
cells 
 
2.37 
 
1.69 
 
1.42 
 
 1.94                0.86 - 3.5 
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Figure 3.14: Changes in the levels of expression NKG2C in NK cells after primary CMV 
infection. 
Dynamic changes in the frequency of NKG2Cpos NK cells (upper right quadrant) post acute 
primary CMV infection in an immunocompetent healthy donor. Time points T1, T2, and T3 
were taken on the second, 10th, and 28th day of diagnosis. The chart below displays the changes 
in viral load (blue curve) and anti-CMV IgG antibody titre (red curve).  
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Figure 3.16: Changes in th  levels of xpression NKG2C in NK cells after primary CMV 
infection. 
Dynamic changes in the frequency of NKG2Cpos NK cells (upper right quadrant) post acute 
p imary CMV infection in an immunocompetent ealthy donor. Time points 1, T2, and T3 
wer  taken on the second, 10th, and 28th day of diagnosis. The chart below displays the changes 
in vir l load (blue curve) and anti-CMV IgG antibody titre (red curve).  
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Figure 3.15: Alteration in the percentage of Vδ2-neg γδ T cells after primary CMV infection 
The panel of flow cytometric plots demonstrates frequencies of both Vδ2pos (right rectangle gate) 
and Vδ2neg (left rectangle gate) γδ T cells on the second, 10th, and 28th day post diagnosis of 
acute primary CMV infection. The chart below shows associated changes in viral load (blue 
curve) and anti-CMV IgG antibody titre (red curve).  
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Figure 3.17: Al eration in the percentage of Vδ2-neg γδ T cells after primary CMV infection 
The pane  of FACS plots demonstrates frequencies of both Vδ2pos (right rectangle t ) and 
neg (l ft rectangle gate) γδ T cel s on the second, 10th, and 28th day post diagnosi  of acute 
primary CMV infection. The chart below shows associated changes in viral load (blue curve) 
and anti-CMV IgG antibody titre (red curve).  
 
 
3.4.5 Significant positive correlation between Vδ2neg γδ T cells and CD28neg 
CD4+ T cells in CMV-seropositive healthy donors. 
A regression analysis was used to determine the presence of association (such as co-
operation/redundancy) between different lymphocyte subsets, which includes CD28neg 
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3.4.5 Significant positive correlation between Vδ2neg γδ T cells and CD28neg 
CD4+ T cells in CMV-seropositive healthy donors. 
A regression analysis was used to determine the presence of association (such as co-
operation/redundancy) between different lymphocyte subsets, which includes CD28neg 
CD4+ T cells, CD28neg CD8+ T cells, NKG2Cpos NK cells and Vδ2neg γδ T cells, in 
CMV-seropositive healthy donors. The matrix of correlations was generated by plotting 
the linear regression with the best-fit line and 95% confidence band between all possible 
cell subsets combinations. Spearman Correlation coefficient (r) and P values were used 
to test whether slopes and intercepts are significantly different. The results obtained 
from this analysis are presented in Figure 3.16.   
Starting with the association between αβ T cells and other subsets, while the linear 
regression analysis showed no significant association between levels of CD28neg CD8+ T 
cells and Vδ2neg γδ T cells in CMV-seropositive subjects (r  = 0.39 with P = 0.177), there 
was significant positive correlation between CD28neg CD4+ T cells and that of Vδ2neg γδ 
T cells (r  = 0.61 with P = 0.016). In contrast, neither CD4+ nor CD8+ T cells showed 
significant association with NKG2Cpos NK cells (r=0.34,P=0.344 and r=0.18,P=0.347, 
respectively).  
Regarding the association of NK cells with γδ T cells, though the best-fit line of linear 
regression between NKG2Cpos NK cells and Vδ2neg γδ T cells was in a positive direction, 
statistically there was no significant association between these subsets (r= 0.19 and 
p=0.463). 
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Figure 3.16: Correlations between levels of different lymphocyte subsets in CMV positive 
immunocompetent donors. 
The cluster of charts demonstrates the linear regression between different lymphocyte subsets. 
All possible combinations of cells subsets were plotted. The lines in the each chart represent the 
best-fit line with 95% confidence band.  Spearman Correlation coefficient (r) and P value are 
shown at top of each chart. 
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3.5 Discussion  
The aim of this chapter was to investigate the influence of chronic CMV infection on 
different lymphocyte subsets in immunocompetent donors. This includes examining the 
concurrent change in the frequency of lymphocyte subsets that are believed to be 
important in CMV infection. This involved determining the frequency of CD28neg CD4+ 
and CD28neg CD8+ T cells, NKG2Cpos NK Cells and Vδ2neg γδ T cells to find out if 
there is any association between these subsets. To achieve these aims, 75 healthy donors 
were recruited and classified according to detection of anti-CMV IgG antibodies and 
CMV-specific αβ T cell response into CMV negative and CMV positive subgroups 
(approximately 52% and 48% of cohort; respectively). This was followed by statistical 
comparison of the frequencies of lymphocytes of interest between both groups. 
It has become more evident that chronic CMV infection has substantial influence on αβ 
T cells; this is particularly true of CD8+ T cells where several reports demonstrate 
accumulation of monoclonal highly differentiated CD8+ T cells in CMV-seropositive 
elderly subjects (Looney et al., 1999, Khan et al., 2002b). However, far less attention 
has been given to assessing the impact of CMV on the CD4+ T cell repertoire compared 
to CD8+ T cells (Pourgheysari et al., 2007). Therefore, phenotypic analysis of CD4+ T 
cells was included in the current study. Using a panel of various surface markers such as 
CCR7, CD45RA, LFA1, CD27 and CD28 might be necessitated for appropriate 
phenotyping. For instance using these marker can categorize T cells into Naive (TN), 
Central Memory (TCM), Effector Memory (TEM), and Effector Memory CD45RA re-
expressing (TEMRA) (Appay et al., 2008). However, the limitation in the number of 
channels available for flow cytometry allowed only the use of one of these markers 
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(besides the basic markers: CD3, CD4 and CD8). The decision was made to use CD28, 
as its down regulation seems to be a highly reliable marker for identification of late 
differentiated cells (Olsson et al., 2000, Wikby et al., 2002, Acuto and Michel, 2003).  
Interestingly, the current study showed that the influence of CMV carriage was not only 
limited to a remarkable increase in the frequency of CD28neg CD8+ cells but was also 
associated with a significant increase in CD28neg CD4+ T cells. Furthermore, linear 
regression analysis indicated positive correlation between CD28neg CD4+ T cells and 
CD28neg CD8+ T cells, though it was not statistically significant. Indeed, this might 
suggest that these cells do not play a redundant role in controlling latent CMV infection. 
In other words, both of them might be needed to keep the latent virus under control. 
Nevertheless, since these cells are highly differentiated, their function and effectiveness 
in viral infection control is debatable. For instance, while some reports indicate these 
cell subsets are exhausted and nonfunctional other demonstrated that they could be re-
energized to produce robust functional responses (Waller et al., 2007, Chong et al., 
2008). 
Regardless if these cells are exhausted or not, the question here is whether their 
expansions are useful? The exact answer to this question is still an area of debate. For 
instance, some argue that these cells can play a protective role. This is supported by the 
very low incidence of severe CMV disease in immune competent subjects with 
expanded CMV-specific T cell clones. Nevertheless, appearance of donor-specific 
CD28neg CD8+ T cells in transplant recipients was found to be associated with low 
incidence of acute rejection, which suggests the suppressive function of these cells (Liu 
et al., 1998, Colovai et al., 2003). However, If CMV-specific CD8+CD28neg cells were 
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strongly immunosuppressive an increased incidence of CMV viraemia would be 
expected in subjects with expanded levels of CMV-specific clones. On the other hand, 
other reports show a correlation between the expression of PD-1, CMV infection and 
disease in liver transplant recipients (La Rosa et al., 2007) and with CMV viraemia in 
renal transplant recipients (Sester et al., 2008). Alternatively, CD8+CD28neg cells may 
simply be anergic rather than actively immunosuppressive.  
There are several subclasses of NK cells that are broadly different functionally and 
phenotypically. In addition to levels of expression of CD56, which can classifying NK 
cells into CD56dim and CD56bright populations, expression of CD16 is widely used to 
categorize NK cells into immature (CD16neg) and mature (CD16pos) cells (Caligiuri, 
2008). The present study showed no differences between CMV-positive and CMV-
negative donors regarding the frequencies of both mature and immature NK cells. 
Though there are several activating and inhibitory receptors that might be involved in 
NK cell-CMV immunity, NKG2Cpos NK cells were chosen. This was based on several 
observations that suggest the importance of this subset in CMV infection (Guma et al., 
2004, Guma et al., 2006, Monsivais-Urenda et al., 2010). Although the exact mechanism 
how NKG2Cpos NK cells can recognize CMV-infected cell has not been fully uncovered, 
the recognition of HLA-E associated with CMV infection can be proposed. This based 
on observation showed the proliferation of NKG2Cpos NK cells in the presence of IL-15 
and HLA-E. Indeed future studies are required to determine if NKG2C directly 
recognizes CMV-infected cells and if this recognition is HLA-E–dependent.  
Interestingly, a recent study has shown that the NKG2Cpos NK cells preferentially 
increased during acute CMV infection; furthermore it demonstrated that this NK cell 
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subset gradually acquired a CD57+ phenotype (Lopez-Verges et al., 2011). Considering 
that this phenotype is also expressed by CMV-specific B cells and T cells they are 
proposed to acquire immunological memory after CMV viral infection. Thus, it is 
proposed that CD57 might provide a marker of “memory” NK cells that have been 
expanded in response to infection (Lopez-Verges et al., 2011). 
 
 Nevertheless, statistically, there was no association between these cells and other 
lymphocyte subsets. Indeed such observations highly suggest that NKG2Cpos NK cells 
play a non-redundant role in controlling CMV chronic infection.  
There is growing evidence that non-conventional T-cells expressing gamma-delta (γδ) 
TCR are important in protection against CMV, an example is the role of Vδ2neg γδ T 
cells in controlling active CMV infection in immunosuppressed patients (Dechanet et al., 
1999b). Nevertheless, far too little attention has been paid to their role in CMV infection 
in immunocompetent subjects. Therefore, one of this study’s aims was to investigate the 
importance of Vδ2neg γδ T cells in controlling CMV in healthy immunocompetent 
subjects and to find out if their frequency correlates with other lymphocyte subsets in 
carriers. 
The results of this study demonstrate the presence of a remarkable increase in Vδ2neg γδ 
T cells frequencies in healthy CMV-seropositive donors compared to CMV-seronegative 
donors. Furthermore it showed the presence of an association between Vδ2neg γδ T cells 
and αβ T cells, which showed significant positive correlation in case of CD28neg CD4+ T 
cells. This might suggest the presence of cooperation between the two subsets in 
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controlling CMV. In other words there is a possibility that activated Vδ2neg γδ T cells 
might in some way induce proliferation and differentiation in naıve αβ T cells through 
presenting CMV antigen (or via cytokine production). This notion can be supported by 
previous studies on Vδ2pos γδ T cells (a major sub-population of γδ T cells) that 
demonstrated the ability of these cells to professionally present antigen directly to CD4+ 
T cells through up regulation of HLA class II molecules (Brandes et al., 2005) or to 
CD8+ T cells through cross-priming (Brandes et al., 2009, Meuter et al., 2010). In the 
case of Vδ2neg γδ T cells, more investigations are needed to prove or disprove this 
possibility. 
Up to this point, a remarkable change in the composition of lymphocyte subsets was 
demonstrated in CMV positive healthy donors. This included a significant increase in 
the frequency of CD28neg CD4+ T cells, CD28neg CD8+ T cells, NKG2Cpos NK cells and 
Vδ2neg γδ T cells in CMV seropositive healthy donors. Nonetheless, having observed 
such changes in lymphocyte phenotype it was further investigated whether these changes 
were specific for chronic CMV infection or part of a general phenomenon that can occur 
with any persistent viral infection, particularly other herpes viruses. To answer this 
question the impact of herpes simplex virus (HSV) carrier status on these subsets of 
lymphocyte was investigated. The current study suggested that infection with CMV was 
most likely the cause of accumulation of late differentiated effector αβ T cells (CD28neg 
CD4+ T cells and CD28neg CD4+ T cells) as well as being responsible for accumulation 
of Vδ2neg γδ T cells and NKG2Cpos NK cells. Meanwhile, HSV chronic infection could 
have a similar effect in advanced age. 
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Ideally, to monitor dynamic change in the phenotype that might be related to an 
infectious agent, the exact time of acute infection is needed to be known. However, since 
in most cases CMV infection is subclinical it would be impossible to exactly define the 
time of acute infection. Therefore, determining the avidity of CMV- specific IgG by a 
special type of ELISA was carried out. Accordingly, CMV seropositive donors could be 
classified into two groups, donors with low avidity (recent infection) and high avidity 
(long-standing infection). In the current study only three donors showed low avidity 
therefore statistically it was not appropriate to perform accurate comparison between the 
low and high avidity groups. Thus another approach was tried, which was studying 
changes in the immune system during symptomatic primary CMV infection. This 
approach is usually carried out in studies of immune-compromised patients such as post 
renal transplantation where there is high incidence of CMV infection. Indeed, studying 
the immune system in immune-compromised patient would not be the perfect module 
for studying the immune system of healthy subjects. Therefore the use of immune-
compromised donors was excluded from the current study. Instead, recruiting of healthy 
donors with symptomatic primary CMV infection was tried. Based on the incidence of 
symptomatic primary CMV infection in Merseyside hospitals, which was approximately 
eight cases per year, the aim was to recruit 4 to 8 patients. Unfortunately, only one out 
five patients diagnosed with primary CMV infection agreed to participate in the study.  
The striking result obtained from this patient was that the change in the phenotype of 
lymphocytes is related to the change in anti-CMV-IgG titre rather than CMV viral load. 
In addition, apart from CD28neg CD4+ T cells, which started to appear after viral 
clearance, all other cell subsets seem to be involved since the beginning of acute 
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infection. It is crucial to appreciate that this finding from a single patient might not 
reflect the real kinetics of the immune response during acute CMV infection. 
Nevertheless, shortage of information in this field made it reasonable to report this result.  
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4 The Impact Of Age And Cytomegalovirus Carriage 
On γδ T Cells In Immunocompetent Subjects 
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4.1 Background 
The results from the pilot study that was presented in Chapter 3 demonstrated that 
chronic CMV-carriage is associated with remarkable changes in the host immune system. 
This included alteration in phenotype and repertoire of NK cells, αβ T cells and γδ T 
cells. While the roles of αβ T cells, including CD4+ and CD8+ T cell in CMV immune 
responses have been studied in great detail (Wills et al., 1996b, Kern et al., 1999, 
Elkington et al., 2003), there is insufficient information about the role of other T cell 
subsets. Currently there is increasing appreciation of the role of non-conventional T cells 
expressing the gamma delta (γδ) TCR in protection against CMV. Furthermore, γδ T 
cells were found to expand or become activated in infections and in malignancy 
(Maeurer et al., 1996, Behr-Perst et al., 1999, Wang et al., 2001, Bonneville and Fournie, 
2005, Ebert et al., 2006), and also differentiate into memory cells much earlier in life 
than αβ T cells, indicating a major role in responding against pathogenic insults from 
birth (De Rosa et al., 2004).  
Normally, γδ T cells constitute a minority of circulating T cells and fall into two main 
subclasses: Vδ2 pos γδ T cells (50-90% of γδ T cells, predominant in blood) and Vδ2neg 
γδ T cells, which include Vδ1pos cells (predominant in mucosa) and Vδ3pos cells, which 
comprise 0.1% of γδ T cells in peripheral blood (Xiong and Raulet, 2007). This is 
reviewed in more detail in Section (1.2.2.3). 
Dechanet-Merville and colleagues have shown that γδ T cells are considerably expanded 
(reaching 40% of circulating T cells) following primary CMV infection in CMV-
seronegative transplant recipients of kidneys from CMV-seropositive donors (Dechanet 
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et al., 1999a, Dechanet et al., 1999b). Furthermore, an early γδ T cell reconstitution 
seems to be associated with improved control of CMV replication, and the expansions 
were composed of either Vδ1pos or Vδ3pos cells, but not Vδ2pos cells (Lafarge et al., 
2001). Similarly, Vδ2neg γδ T cell expansions have also been reported recently in CMV-
infected allogeneic stem cell transplant patients and in CMV-infected fetuses (Knight et 
al., 2010, Vermijlen et al., 2010). 
The selective expansion of Vδ2neg γδ T cells (Vδ1pos and Vδ3pos) in CMV-infected hosts 
implies that these γδ T cells are involved in immunity to CMV. Expanded Vδ2neg γδ T 
cell lines specifically secrete cytokines and demonstrate cytotoxicity after incubation 
with CMV-infected target cells in vitro, but not uninfected targets or targets cells 
infected with other herpes viruses (Halary et al., 2005). Though the ligand remains 
undefined, it was shown that Vδ2neg γδ T cells are also expanded in healthy CMV 
carriers (Pitard et al., 2008).  
 The association between CMV status and oligoclonal expansions of both CD4+ and/or 
CD8+ CMV-specific memory T cells in CMV healthy carriers is well established 
(Karrer et al., 2003, Pourgheysari et al., 2007). Furthermore, this cell accumulation 
seems to be age related, for instance, CMV specific αβ T cell levels are frequently over 
1% of the respective subset in young virus carriers, and often exceed 10% of 
CD4+/CD8+ T cells in the elderly (Khan et al., 2004, Pourgheysari et al., 2007). The 
question whether, like CMV-specific CD4+ and CD8+ T-cells, Vδ2neg γδ T cells also 
expand with age has seemingly not been addressed yet.  
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4.2 Aims 
 The persistent nature of CMV infection is thought to drive the accumulation of large 
CD4+/CD8+ T cell expansions over time. Thus the aim was to test the hypothesis that 
Vδ2neg γδ T cell expansions occur more frequently in CMV carriers of older age and also 
to test whether there are similarities between the phenotype and properties of Vδ2neg γδ T 
cells and αβ T cells in this group. 
4.3 Plan of investigation 
To achieve these aims, the investigation plan was designed to involve successive steps. 
Firstly the CMV status of the study cohort was determined by detecting CMV-specific 
IgG antibody by ELISA.  Then the study population was categorized according to age 
into three groups namely; young, middle aged, and elderly. This was followed by 
comparing the frequency and absolute number of different γδ T cells subsets between 
CMV-seropositive and CMV-seronegative subjects and also between different age 
groups. Furthermore, the Vδ2neg γδ T cell phenotype was determined and compared to 
that of αβ T cells. Finally, some functional studies of virus recognition by Vδ2neg γδ T 
cells were also carried out. Figure 4.1 summarises these steps of the investigation. 
4.4 Statistical analyses 
These were performed with Graphpad Prism software (GraphPad Software Inc.). The 
Mann Whitney test was applied with 95% confidence intervals to test differences in γδ T 
cell frequencies between different donor groups. The non-parametric Spearman’s rank 
correlation coefficient was used to assess correlations between different T cell subset 
frequencies. All P values were two-tailed.  
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Figure 4.1: Summary of investigation steps 
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4.5 Results  
4.5.1 Study volunteers 
255 healthy adult volunteers, aged 20-85 years, and two non-immunocompromised 
patients diagnosed with symptomatic primary CMV infection, were formally consented 
to donate blood samples for the study. All subjects were mobile, did not have any 
cognitive impairment, were not suffering from acute or chronic illness, and were not on 
medication known to affect the immune system. Ethical approval was obtained from the 
local Adult Research Ethics Committees. CMV status was determined using plasma 
samples with a commercial CMV IgG ELISA kit (Biocheck Inc.). Diamedix HSV IgG 
and VZV IgG kits (Launch Diagnostics) were used for herpes simplex virus (HSV) and 
varicella zoster virus (VZV) seropositivity, see methodology section 2.3.1. Absolute 
lymphocyte counts were determined by the Blood Sciences Department at the Royal 
Liverpool University Hospital NHS Trust. Table 4.1 below summarises the study 
population characteristics.  
 
Table 4-1: Study cohort characteristics  
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and VZV IgG kits (Launch Diagnostics) were used for herpes simplex virus (HSV) and 
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lymphocyte counts were determined by the Blood Sciences Department at the Royal 
Liverpool University Hospital NHS Trust. Table 4.1 below summarises the study 
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Table 4-1: study cohort characteristics  
Age group CMV-positive CMV-negative Total 
21-40 years 39 58 97 
41-60 years 43 40 83 
61+ years 43 32 75 
Total 125 130 255 
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4.5.2 Influence of CMV carriage on γδ T cell subset repertoire  
After categorizing of the study cohort into CMV-seropositive and CMV-seronegative, 
the next step was to identify frequencies of different γδ T cell subsets. Therefore flow 
cytometric analysis of PBMC utilizing a panel of monoclonal antibodies was carried out. 
This included staining with anti-panTCRγδ, anti-Vδ1 and anti-Vδ2 monoclonal 
antibodies to determine the frequency of Vδ1pos γδ T cells, Vδ2pos γδ T cells and Vδ2neg 
γδ T cells, see Figure 4.2. Furthermore, the frequency of Vδ3pos γδ T cells was estimated 
(due to lack of an anti-Vδ3 monoclonal antibody) by applying the following formula:  
 
Overall, the frequency of different γδ T cell subsets showed considerable variation; with 
some individuals Vδ1pos cells were the major γδ T cell type while in others Vδ2pos cell 
expansion was observed (see representative examples in Figure 4.2 A and B).  
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Overall, the frequency of different γδ T cell subsets showed considerable variation; with 
some individuals Vδ1pos cells were the major γδ T cell type while in others Vδ2pos cell 
expansion was observed (see representative examples in Figure 4.2 A and B).  
 
 
% Vδ3pos γδ T cells = % total Vδ2neg γδ T cells  -  % Vδ1pos γδ T cells   
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Figure 4.2: γδ T cell subsets in healthy donors  
Flow cytometry plots showing PBMC stained with pan-TCRγδ and anti-Vδ1 or anti-Vδ2 
monoclonal antibodies from 2 CMV-seronegative (A) and 2 CMV-seropositive healthy donors 
(B). Values shown in the quadrants of each plot indicate the percentage of lymphocytes staining 
for each γδ subset. 
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4.5.3 CMV carriage associated with increase of Vδ2neg γδ T cell frequency 
that is composed of Vδ1pos and Vδ3pos γδ T cells. 
Interestingly, comparison between the total γδ T cell frequency in CMV-seropositive 
and CMV-seronegative donors was very similar (Figure 4.3A). Nevertheless, Vδ2neg γδ 
T cells were significantly higher (p<0.0001) in CMV-seropositive donors than in CMV-
seronegative donors (see Figure 4.3B). This coincided with a slight reduction of Vδ2pos 
γδ T cells in CMV carriers but this was not statistically significant (Figure 4.3B). This 
study also confirmed that the Vδ2neg γδ T cell population was composed mainly of 
Vδ1pos and to a lesser degree Vδ3pos γδ T cells  (γδ T cells negative for both Vδ1 and 
Vδ2). Relative numbers of both types of Vδ2neg γδ T cell was significantly higher (Vδ1: 
p<0.0001 and Vδ3 [Vδ1neg Vδ2neg]: p=0.0238) in CMV-seropositive donors than in 
seronegatives (Figure 4.3C). 
However, to confirm that this effect was CMV-associated, other human herpes-viruses, 
HSV-1/-2, and VZV were tested for. Statistical analysis did not show any significant 
difference in γδ T cell subsets between seropositive and seronegative donors for these 
viruses (data not shown), in agreement with work published by others (Pitard et al., 
2008). 
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Figure 4.3: CMV carriage characterized by increase in the frequency of Vδ1pos and Vδ3pos 
γδ T cells. 
Charts summarising the staining results from 182 healthy donors are shown for: total γδ T cells 
(A), Vδ2pos and Vδ2neg γδ T cells (B), and for Vδ1pos and Vδ1neg δ2neg γδ T cells (C). Values on 
the y-axis indicate the percentage of total T lymphocytes represented by each subset. P values 
are shown above each plot with 95% confidence intervals applied. 
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4.5.4 Ageing may also be a factor in driving V2δneg γδ T cell expansions in 
CMV-seropositive donors.  
To test if Vδ2neg γδ T cell expansions were more evident in older CMV carriers, donors 
were separated into three age groups: young, 21-40 years old (n=97), middle-aged, 41-
60 years old (n=83) and elderly, 61 years or over (n=75). Interestingly, a significant 
increase in the frequency of Vδ2neg γδ T cells was observed in CMV carriers of all age 
groups when compared with age-matched CMV-seronegative donors. This increase was 
also significant in all age groups when expressed as absolute numbers of cells per µl of 
blood (young; p=0.009, middle aged; p=0.0003 and elderly donors; p<0.0001), see 
figure 4.4A-C.  
In contrast, Vδ2pos γδ T cells were reduced in CMV-seropositive when compared to 
CMV-seronegative subjects (Figure 4.4A-C), but this did not reach statistical 
significance. A number of middle-aged and elderly donors had Vδ2neg γδ T cell 
expansions approaching 10% (or more) of all T cells, with the highest observed 
frequency at 41% of all T cells in one healthy elderly donor. These were mainly 
composed of Vδ1pos cells (data not shown). Overall, these findings are very similar to 
that of increased CMV-specific CD4+ and CD8+ T cells in healthy old-aged virus 
carriers and suggest that persistent infection results in multiple cell types being 
expanded even in healthy carriers. Table 4.2 summarizes the influence of age and CMV 
carriage on γδ T cell subsets. 
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Figure 4.4: The effects of ageing and CMV carriage on γδ T cell subsets  
Charts summarising the frequencies of circulating Vδ2pos and Vδ2neg γδ T cells after inclusion of 
elderly donors and separation into age groups. Young; 21-40yrs (A), middle age; 41-60yrs (B) 
and elderly 61yrs and over (C). Values on the y axis indicate the percentage of the total T cell 
repertoire (histograms panels on the left side) and absolute numbers of cells per µl of blood 
(histograms panels on the right side). All data were derived from a single blood sample. 
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Table: 4-2 Summary of the influence of ageing and CMV carriage on γδ T cell subsets 
  
Note, values denote means and standard error for each subset as a percentage of total T cells and, 
in brackets, absolute numbers per µl of blood. 
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Summary of the influence of ageing and CMV carriage on γδ T cell subsets 
 
Age 
group 
 
 
T cell 
Subset 
 
CMV-pos 
 
 
CMV-neg 
 
 
P value 
(Mann-
Whitney) 
 
21-40yrs 
  
(N=39) 
 
(N=58) 
 
 Vδ2neg 2.04% +/- 0.3 
(29.71+/-5.75)  
1.21% +/- 0.08 
(14.58+/-1.5) 
0.036 
(0.009) 
 
 Vδ2pos 2.62% +/- 0.37 
(35.5+/-6.4) 
3.37% +/- 0.38 
(39.5+/-4.7) 
0.134 
(0.385) 
 
 
41-60yrs 
  
(N=43) 
 
(N=40) 
 
 Vδ2neg 2.44% +/- 0.46 
(40.14+/-9.87)  
0.85% +/- 0.1 
(11.42+/-1.32) 
<0.001 
(0.0004) 
 
 Vδ2pos 2.17% +/- 0.44 
(29.62+/-5.9) 
2.44% +/- 0.32 
(34.8+/-5.1) 
0.085 
(0.09) 
 
 
60+yrs 
  
(N=43) 
 
(N=32) 
 
 Vδ2neg 3.67% +/- 1.03 
(58.16+/-25.66)  
0.7% +/- 0.09 
(7.01+/-1.09) 
0.0004 
(<0.0001) 
 
 Vδ2pos 2.06 % +/- 0.5 
(44.1+/-13.8) 
3.07% +/- 0.64 
(43.7+/-8.9) 
0.09 
(0.472) 
 
  
Note, value  denote ean  and standard error for each subset as a percentage of total T cells and, 
in brackets, absolute numbers per µl of blood. 
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4.5.5 Identification of naive and memory γδ T-cell subsets 
Having observed the differences in γδ T cell subset repertoire by CMV carriage and age, 
we asked whether this population consists of naive or memory cells. To answer this 
question the expression of LFA-1 and CD45RA by Vδ2pos and Vδ2neg γδ T cells was 
measured by flow cytometry. Accordingly three major cell subsets were identified 
namely; Naive (LFA-1low CD45RAhigh), Memory “normal” also called TEM (LFA1high 
CD45RAlow), Memory “revertant” (LFA-1high CD45RAhigh) also denoted as TEMRA. 
Figure 4.5 demonstrates gating steps for identifying these cell subsets.  
Representative examples of these cells subsets based on sub-gating on Vδ2pos or Vδ2neg 
γδ T cells in CMV-seropositive and CMV-seronegative donors are shown in Figure 4.6 
(A and B). While Vδ2pos cells were overwhelmingly CD45RAlow memory cells in both 
CMV-seropositive and CMV-seronegative donors (Fig. 4.6B), Vδ2neg cells showed a 
distinct naive/memory profile (Fig. 4.6A), which appeared to be linked to CMV status. 
For instance, in CMV-seropositive donors the Vδ2neg γδ T cells subset was skewed 
towards CD45RAhigh revertant memory cells, this coincided with reduced frequency of 
naive cells. Changes in the phenotype profile of γδ T cell subsets according to the CMV 
status are summarized in Table 4.3.  
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Figure 4.5: Steps for identifying phenotypic profiles for Vδ2pos and Vδ2neg γδ  T-cell 
subsets.  
PBMC were stained with anti-TCRγδ, Vδ2, LFA1 and CD45RA monoclonal antibodies. Flow 
cytometry plots show LFA-1 vs CD45RA staining of Vδ2pos and Vδ2neg γδ T-cell subsets. 
Therefore, each cell subset can be categorized into Naive (LFA-1low CD45RAhigh), Memory 
“normal” (LFA-1high CD45RAlow), Memory “revertant” (LFA-1high CD45RAhigh). 
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Figure 4.6: Influence of CMV carriage on naive and memory cell composition of γδ  T cell 
subsets  
Plots are illustrative example of γδ T cell subsets phenotyped according to expression of LFA-1 
vs. CD45RA from two CMV-seropositive donors (A) and two CMV- seronegative donors (B). 
Values indicate percentage of gated cells in each quadrant.  
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Table 4-3 Summary of effects of CMV status on phenotypic profiles of γδ T cell subsets  
 
Values denote median with lower and upper percentile  (in brackets) for each subset as 
an absolute numbers per µl of blood.  
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Summary of effects of CMV status on phenotypic profiles of γδ l subsets  
 
Phenotype 
 
T cell 
Subset 
 
CMV-neg 
(n=50) 
 
CMV-pos 
(n=50) 
 
P value 
(Mann-Whitney) 
 
Naive 
(LFA-1low CD45RAhigh) 
    
  
Vδ2neg 
3.08 
(1.51-7.39) 
3.93 
(1.75-7.55) 
0.5999 
(369.0) 
 
 Vδ2pos 0.32 
(0.17-0.48) 
 
0.28 
(0.15-0.54) 
0.5913 
(321.0) 
 
 
Memory “normal” 
(LFA-1high CD45RAlow) 
    
 Vδ2neg 1.47 
(0.96-3.01) 
 
1.63 
(0.81-3.62) 
 
0.8800 
(392.5) 
 
 Vδ2pos 21.39% 
 (10.29-44.55) 
 
14.31% 
(9.18-20.29) 
0.0561 
(243.0) 
 
 
Memory “revertant” 
(LFA-1high CD45RAhigh) 
    
 Vδ2neg 2.72 
(1.43-6.31) 
 
6.60 
(2.624-18.06) 
0.0151 
(434.5) 
 Vδ2pos 5.28 
(2.07-11.60) 
 
2.75 
(0.90-5.80) 
 
0.0420 
(236.0) 
 
Values denote median with lower and upper percentile  (in brackets) for each subset as 
n absolute numbers per µl of bloo .  
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4.5.6 Age per se has its influence on the naive and memory Vδ2neg γδ  T cell 
subset repertoire  
Having observed substantial differences in frequency and also in absolute number of the 
memory revertant Vδ2neg γδ T cell subset between CMV-seropositive and CMV 
seronegative donors, the aim was to find out whether age per se has a role in configuring  
the phenotype of Vδ2neg γδ T cell, independent of CMV status. 
Therefore, the first step was to compare absolute numbers of both naïve and revertant 
memory Vδ2neg γδ T cells between different age group, independent of CMV status. This 
analysis showed that there was a significant decrease in absolute numbers of both naïve 
and revertant memory cells in the elderly (Figure. 4.7A and B) when compared with 
middle-aged and young donors (both p<0.05).  
The second step was to investigate the combined influences of both CMV carriage and 
age. As can be seen in Figure 4.7C CMV positivity was associated with reduced naive 
Vδ2neg cells in each group, but this only reached statistical significance in the elderly 
(p=0.01). Meanwhile, there was a significant increase in the absolute count of revertant 
memory cells in CMV-positive compared to CMV-negative donors in all age groups 
(Figure 4.7D). 
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Figure 4.7: Influences of age and CMV status on naïve and revertant memory Vδ2neg γδ T 
cells.  
Study cohort was categorized according to age into three groups; young, middle aged, and 
elderly. Absolute count of both naive (A) and revertant memory (B) Vδ2neg γδ T cells were 
compared between age groups, independent of CMV status. Then each age group was further 
subdivided according CMV status into CMV-seropositive and CMV–seronegative (marked as 
CMV+ and CMV- on x axis respectively) donors (chart C & D). Error bars indicate median with 
upper and lower interquartile, meanwhile asterisks denote P value (ns= not significant, *= 
p<0.05, **= p<0.001, and ***= p<0.0001). 
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4.5.7  Comparative analysis of Vδ2neg γδ T cell subset with virus-specific 
CD4+and CD8+ T cells 
Although memory Vδ2neg γδ T cells were higher in CMV-seropositive groups, there 
was considerable inter-individual variation within all age groups. It was questioned 
whether this variation was due to differences in frequencies of CMV-specific CD4+ 
and CMV-specific CD8+ T cells; both parameters also varying considerably between 
individuals in each group. CD4+ T cell frequency was based on IFNγ responses against 
CMV lysate and CD8+ T cell responses were based on responses against a peptide 
cocktail representing 6 immunodominant antigens (IE-1, IE-2, pp65, pp50, gB, pp150), 
which would cover 90% of responders. It is acknowledged that this would not give the 
complete CMV-specific T cell response, which could involve over 100 viral antigens 
(Sylwester et al., 2005), however this would be impractical to measure in a large 
cohort study such as this. The results (Figure 4.8) showed that frequencies of memory 
Vδ2neg γδ T cells did not correlate with the CD8+ T cell response (r2=0.034; p=0.847) 
or CD4+ T cell response (r2= 0.102; p=0.559). Some individuals had large Vδ2neg γδ 
memory T cell expansions and weak CMV-specific CD8+/CD4+ T cell responses; 
some had strong CMV-specific CD8+/CD4+ T cell responses and low frequencies of 
Vδ2neg memory cells, and some with high levels of all subsets.  
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Figure 4.8: Relation between Vδ2neg γδ memory T cell and CMV-specific αβ T cell 
frequencies in healthy donors 
Charts show the correlation between Vδ2neg γδ memory T-cells and CMV-specific CD8+ T-cells 
(A) and CMV-specific CD4+ T-cells (B) in CMV-seropositive donors. Values on each axis 
denote the percentage of each cell type as a percentage of the total T-cell repertoire. Significance 
(p) values at 95% confidence intervals are shown for each set of data. Correlations were 
determined using the non-parametric Spearman Rank test. 
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4.5.8 Phenotypic comparison of γδ T cell subsets and CMV-specific αβ T 
cells 
The above described similarity in phenotype between Vδ2neg γδ T cells and CMV-
specific CD8+ T cells led to further comparative studies. Previous studies have shown 
that CMV drives CD4+ and CD8+ T cells towards a highly differentiated Tem 
(CD45RAlow) and TEMRA (CD45RAhigh) phenotype (Appay et al., 2002, Pourgheysari et 
al., 2007). Since Vδ2neg γδ T cells were increased in CMV carriers and, in common with 
CMV-specific CD4+ and CD8+ T cells, also appeared to increase with age, it was 
hypothesized that these γδ T cells subset would also be driven towards a highly 
differentiated TEM/ TEMRA phenotype. Therefore the expression of CD27 vs. CD28 and 
perforin vs. granzyme B by γδ T cell subsets and CMV-specific αβ T cells in CMV-
seropositive and CMV-seronegative donors were compared. 
Figure 4.9A shows a representative example of Vδ2neg γδ T cells and Vδ2pos γδ T cells 
also CMV-specific CD4+ T cells and CMV-specific CD8+ T cells (Fig. 4.9B), analysed 
within a selected individual CMV-seropositive donor, and the phenotype of Vδ2neg γδ T 
cells and Vδ2pos γδ T cells in a typical CMV-seronegative donor (Fig. 4.8C). The 
complete data from CMV-seropositive and CMV-seronegative donors is shown in 
Figure 4.10. 
It is clear that Vδ2neg γδ T cells show remarkable similarity to CMV-specific CD8+ T 
cells in particular and CMV-specific CD4+ T cells to a lesser degree, but not to Vδ2pos 
γδ T cells. Vδ2neg γδ T cells in CMV-seropositive donors were composed of greater 
numbers of late memory (CD27lowCD28low) cells. In addition Vδ2neg γδ T cells contained 
higher levels of intracellular perforin and granzyme B than in CMV-seronegative donors, 
 177 
which probably indicates greater differentiation and functionality of Vδ2neg γδ T cells in 
terms of cytotoxicity.  
In contrast, Vδ2neg γδ T cells in CMV-seronegative donors (Fig. 4.9C) were mostly 
composed of TEM cells with less differentiated CD27highCD28high phenotype. Further 
contrast was displayed by Vδ2pos γδ T cells, which were almost exclusively 
CD27highCD28high, with considerable heterogeneity in perforin and granzyme B 
expression in both CMV-seropositive and seronegative donors. This indicates that CMV 
carriage leads to a profound change in phenotype of Vδ2neg γδ T cells but not Vδ2pos γδ 
T cells. See Figure 4.10 for complete data set analysis. 
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Figure 4.9: Phenotypic comparison of γδ T cell subsets and CMV-specific αβ T cells  
Flow cytometry plots of CD27 vs. CD28 and perforin vs. granzyme B staining of gated γδ T 
cells from PBMC of one CMV-seropositive (A&B) and one CMV-seronegative donor (C). The 
events shown are gated on T cell subsets indicated above each column of plots. For CMV-
specific αβ T cells, events are gated on CMV tetramer (A1-VTE) binding CD8+ T cells and ex 
vivo interferon-gamma producing CD4+ T cells after 6hr stimulation with CMV lysate at 37°C. 
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Figure 4.10: Level of differentiation and cytotoxicity ability of γδ T cell subsets. 
It summarizes differences in the level of differentiation (A&B) and cytotoxic capacity  (C) of 
Vδ2neg γδ T cells and Vδ2posγδ T cells in CM-seropositive (red triangles) and CMV-seronegative 
(blue triangles). Error bars indicate median with interquartile range, while asterisks denote P 
value (*= p<0.05, **= p<0.001, and ***= p<0.0001). 
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4.5.9 Dynamics of Vδ2neg γδ  T-cells in healthy donors over time 
Levels of herpesvirus-specific αβ T cells are reported to fluctuate over time (Crough et 
al., 2005). Thus it was interesting to learn if Vδ2neg γδ T cells displayed this behaviour 
by performing longitudinal analysis on a random selection of 6 CMV-seropositive and 
6 CMV-seronegative donors and two cases of primary CMV-infectious mononucleosis 
(IM) infection. Vδ2neg cell numbers varied modestly in healthy donors over time (see 
Figure 4.11A), mean 29.2% variation in CMV-seropositive and mean 35.7% in CMV-
seronegative donors, while CMV-IM patients showed a more dramatic reduction in 
absolute number of Vδ2neg γδ T cells in samples collected between 1 week post-
diagnosis and subsequent time points (Figure 4.11B). All healthy donors showed very 
stable phenotypes at each time point, but in CMV-IM Vδ2neg γδ T cells were initially 
composed of normal memory (TEM) and revertant memory (TEMRA) cells, and both 
CD27highCD28low and CD27lowCD28low cells during the early phase of infection. 
However, after 2 years Vδ2neg γδ T cells had shifted almost exclusively to the TEMRA 
phenotype with a concomitant shift to highly differentiated CD27lowCD28low cells (Fig. 
4.12). This change was more dramatic than those observed in healthy donors. In 
contrast, Vδ2pos γδ T cells were composed mainly of less differentiated 
CD27highCD28high CD45RAneg TEM cells both during acute infection and 3 years later 
(data not shown). 
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Figure 4.11: Dynamics of Vδ2neg γδ  T-cells in healthy donors over time  
Vδ2pos and Vδ2neg γδ T -cell numbers were measured in a longitudinal analysis of 6 CMV-
seropositive (top charts) and 6 CMV-seronegative healthy donors (bottom charts) (A), and also 
in 2 immunocompetent subjects diagnosed with primary CMV infection (B).  
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Figure 4.12: Dynamic changes in memory and TEMRA Vδ2neg γδ T cells  
Phenotypic changes in late memory and TEMRA cells were determined after a 12-month interval 
in 6 healthy donors (CMV-pos; red triangles, CMV-neg; green quadrangles) and 1 of the 
primary CMV patients (blue circle) (C). T1 represents 1 week post-diagnosis and T2 denotes 2 
years post-diagnosis for the primary CMV samples. Values shown indicate the percentage of 
Vδ2neg γδ T cells expressing the given phenotype. 
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4.5.10 Functional properties of Vδ2neg γδ T cells in virus-recognition assays  
4.5.10.1 In vitro generation of γδ T cell lines 
To confirm that Vδ2neg γδ T cells had CMV-specific reactivity, γδ T cell lines were 
generated in vitro. Briefly, this consisted of two steps; the first step was enriching γδ T 
cells of two selected donors, who were characterized by high frequencies of Vδ2neg γδ T 
cells. One of these donors was CMV-seropositive and the other CMV-seronegative. 
Here, PBMC were depleted of monocytes by plastic adherence and of Vδ2pos γδ T cells, 
αβ T cells, B cells and erythrocytes by magnetic selection using a special kit that 
contains a mouse monoclonal antibody cocktail specific for human Vδ2, TCRαβ, CD19, 
CD14. For more details see section 2.5.1 and 2.5.2. 
The second step was to establish γδ T cell lines by co-culture of enriched γδ T cells with 
irradiated PHA-activated allogeneic PBMC as feeder cells and stimulation with anti-
CD3 and recombinant interleukin 2 (rIL-2). Cultures were enriched further by depletion 
of αβ T cells prior to re-stimulation with feeder cells (after 3 to 4 weeks) followed by 
maintenance with media containing rIL-2. The absence of αβ T cells was confirmed by 
flow cytometry. As controls CMV-specific CD8+ T cell lines from CMV-seropositive 
donors were generated after stimulation with the cocktail of CMV-encoded peptide 
epitopes. Figure 4.13 demonstrates the steps of the functional assay.  
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4.5.10.2 Virus-recognition assays 
The outcomes of the previous step (4.5.10.1) was four cell lines namely; two CD8+ T 
cell lines (one from CMV-seropositive and one from CMV-seronegative), and similarly 
two Vδ2neg γδ T cells lines. Aiming to test their response to CMV each cell lines was co-
cultured either with uninfected human fetal foreskin fibroblasts (HFFF) or with HFFF 
that had been infected for 3-4 days with the AD169 or Towne strain of CMV (at a 
multiplicity of infection of 1:1) see section 2.5.4.  
Furthermore, to investigate if the responses of each cell line were through TCR receptors 
several blocking steps were performed. Herein, sets of T cells lines had been initially 
pre-incubated with anti-TCRαβ, anti-TCRVδ1, anti-TCRVδ2 or mouse isotype control 
monoclonal antibodies before they were co-incubated with mock and CMV-infected 
HFFF. 
In addition, aiming to test the ex-vivo effector function of Vδ2neg γδ T cells, PBMC from 
a CMV-seropositive was freshly isolated. A portion of these PBMC was used to test 
Vδ2neg γδ T cells enriched PBMC while the rest (unfractionated PBMC) was used to 
assess the αβ T cell response (as control). The schematic in Figure 4.13 summarize these 
steps of CMV-recognition assay.    
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Figure 4.13: Flow charts of functional assay 
This is to demonstrate the general scheme for determination of functional properties of Vδ2neg γδ 
T cells in virus-recognition assays. Basically, Vδ2neg γδ T cell and CD8+ T cell lines were 
generated from CMV-seropositive and CMV-seronegative healthy donors. This followed by co-
incubated them with either CMV-infected or mock-infected HFFF in presences and absence of 
different blocking monoclonal antibodies (anti-TCRαβ, anti-TCR γδ, anti-TCRVδ1, anti-
TCRVδ2 or mouse isotype). Finally, the ex-vivo effector function of Vδ2neg γδ T cell was 
investigated in Vδ2neg γδ T cells enriched PBMC and compared to αβ T cell response 
(unfractionated PBMC). 
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Results showed that T cell lines from both sets of donors (CMV-seropositive  and CMV-
seronegative) could produce cytokines after co-incubation with CMV-infected targets 
(using AD169 or Towne strains) but not against mock-infected targets (Figure 4.14A-B), 
as efficiently as CMV-specific CD8+ T cells (Figure 4.14C). This recognition could be 
blocked, either partially or completely, using the anti-Vδ1 monoclonal antibody but not 
with the anti-Vδ2 monoclonal antibody. This confirmed that Vδ2neg γδ T cells in these 
donors were indeed reactive against CMV, with Vδ1pos γδ T cells being a major 
component of this recognition. We also tested freshly isolated Vδ2neg γδ T cells, 
assumed to contain effector memory cells that were reactive against CMV-infected cells, 
for their ability to perform effector functions in ex vivo T cell assays. Figure 4.14E 
shows that fresh Vδ2neg γδ T cells do not produce IFNγ after co-incubation with CMV-
infected target cells. This was also the case when TNFα production was measured (data 
not shown), suggesting that Vδ2neg γδ T cells do not possess immediate effector function 
to the same degree as CMV-specific αβ T cells in our assay system. It was possible that 
the extremely efficient recognition of infected targets by virus-specific CD4+ and CD8+ 
T cells (Figure 4.14G-H) masked the true potential of the γδ T cell response. However 
this did not appear to be the case as antibody blocking or depletion of CD4+ and CD8+ 
T cells had no enhancing effect on the γδ T cells in the ex vivo assay (Figure 4.14F). 
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Figure 4.14: Recognition of virus-infected target cells by Vδ2neg γδ T cells.  
In vitro OKT3 expanded γδ T cell lines from a CMV-seropositive donor (A), γδ T cell lines from a CMV-
seronegative donor (B) and CD8+ T cell lines stimulated with CMV-peptides from a CMV-seropositive 
donor (C) and CMV-seronegative donor (D) were tested for the ability to recognise CMV-infected 
(AD169 strain) human fibroblasts. Partially class I HLA matched fibroblasts were used to allow for CD8+ 
T cell recognition as control effectors. Freshly isolated PBMC were also used for testing immediate 
effector function of γδ T cells from unfractionated PBMC of CMV positive donor (E) and γδ T cell 
enriched PBMC (CMV positive)(F).Ex vivo recognition of infected cells by CMV-specific CD4+ T cells 
(G) and CMV-specific CD8+ T cells (H) in PBMC were also tested. Data is pooled from 3 independent 
experiments showing IFNγ producing cells detected by flow cytometry. Values on y-axes indicate IFNγ 
production as the percentage of each T cell subset tested. Mock-infected targets were used as controls with 
anti-TCRαβ, anti-Vδ1 and anti-Vδ2 antibodies used to block recognition. 
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4.6 Discussion  
While presumed clinically benign, CMV infection in healthy humans appears to cause 
major perturbations in lymphocyte subsets over time (Looney et al., 1999, Almanzar et 
al., 2005, Chidrawar et al., 2009). It would appear that the current study is the first 
detailed account of how γδ T cell subsets are skewed by the combined effects of aging 
and CMV carriage in healthy individuals.  
The present study observed a dramatic shift towards increased levels of Vδ2neg γδ T cells 
with an effector memory cell phenotype in CMV-seropositive compared to CMV-
seronegative donors. Furthermore, a significant reduction in naive Vδ2neg γδ T cells was 
found with old age. CMV carriage was associated with reduced naive Vδ2neg cells 
numbers in each age group, reaching statistical significance in the elderly. These 
changes in Vδ2neg γδ T cells mirror those described for CD8+ T cells in elderly CMV 
carriers and thus advance understanding of the host-virus balance that is achieved during 
normal infection. The current studies also demonstrated Vδ2neg γδ T cells to be 
overwhelmingly Vδ1pos, in agreement with others (Pitard et al., 2008). Increased Vδ1pos 
γδ T cells have also been reported in HHV-8 infected persons (Barcy et al., 2008). 
Although HHV-8 status was not tested for, the very low UK prevalence of this virus 
would suggest it is unlikely to be associated with the observed difference in γδ T cell 
subsets. 
Vδ2neg γδ T cells exceeded 10% of total T cells in several middle-aged and elderly 
CMV-seropositive donors. Given the shared reactivity of Vδ2neg γδ T cells for tumour 
cells (Halary et al., 2005), immune responses against malignant cells in vivo may 
contribute towards these T cell expansions. However, the absence of such expansions in 
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CMV-seronegative donors suggests anti-tumor activity has a limited role. The above 
findings led us to test for intra-individual associations between Vδ2neg γδ T cell 
expansion and CMV-specific CD4+ and CD8+ T cells, which are also elevated in the 
elderly. No correlation was observed between frequencies of Vδ2neg γδ T cells and virus-
specific CD4+ T cells and CD8+ T cells within individuals. It is acknowledged that the 
methods used underestimate the total CMV-specific T cell response; CD4+ and CD8+ T 
cells are specific for a large number of (>100) CMV antigens (Sylwester et al., 2005), 
but this would be impractical to measure in a large cohort study such as used here. These 
CD4+/CD8+ responses are driven by both direct recognition of CMV-infected cells and 
indirect recognition by cross-presentation of antigens captured by professional antigen-
presenting cells (APCs). In addition, CD8+ T cell responses can also be directed against 
antigens expressed after reactivation from latency, and during latency itself (Blazquez et 
al., 2010). While Vδ2neg γδ T cells can be triggered by directly infected cells, it is 
unknown whether viral reactivation from latency or cross-presentation by APCs can lead 
to efficient stimulation. It will also be important to learn if CMV targets γδ T cells for 
immune subversion, as is the case for other T cells and for NK cells (Powers et al., 
2008). 
Vδ2neg γδ T cells and CMV-specific CD4+ and CD8+ T cells have similar characteristics, 
which are not shared by Vδ2pos γδ T cells. In particular, Vδ2neg γδ T cells were akin to 
CMV-specific CD8+ T cells; both are mainly TEM cells, including CD45RAhigh TEMRA 
cells, with a highly differentiated CD27lowCD28low phenotype. CD45RAhigh and 
CD45RAlow memory T cells are reported to indicate quiescent and recently activated T 
cells respectively (Carrasco et al., 2006). It could be that high CD45RA expression by 
 190 
Vδ2neg γδ T cells reflects non-recent activation of Vδ2neg γδ T cells as low levels (<15%) 
of CD38 and HLA-DR activation markers were observed in both cell types (data not 
shown). Vδ2neg γδ T cells also expressed high levels of perforin and granzyme B, similar 
to both CMV-specific CD8+ and CD4+ T cells, indicating cytotoxic functionality. In 
contrast, Vδ2pos γδ T cells were mostly CD45RAlow (CD45ROhigh), CD27highCD28high 
and heterogeneous for perforin and granzyme B expression. 
Highly differentiated Vδ2neg γδ T cells appeared to be very stable in number and 
phenotype during a three-year study period. Vδ2neg γδ T cells were also detected after 
primary infection in adults, though not at the very high frequencies described in 
pharmacologically immunosuppressed transplant patients (Dechanet et al., 1999b). In 
the acute phase the response was mainly composed of TEM (CD45RAlow) and TEMRA 
(CD45RAhigh) cells, but this response had rapidly contracted and shifted to an 
overwhelmingly TEMRA phenotype with a concomitant shift toward end-stage highly 
differentiated cells. In contrast no significant change in phenotype of Vδ2pos γδ T cells 
was observed. No doubt this analysis was weakened by limited patient numbers 
nevertheless the findings are consistent with those during acute infection in 
immunosuppressed CMV-infected transplant patients and CMV-infected newborns 
(Pitard et al., 2008, Knight et al., 2010, Vermijlen et al., 2010). 
Cytokines, such as IL-7 and IL-15, are known to support memory T cell survival and 
proliferation (Becker et al., 2002, Kaech et al., 2003, Purton et al., 2007) but their 
contribution to γδ T cell memory is unclear. While it was not possible to determine IL-
15R expression by flow cytometry IL-7Rh expression was detected by a minority of 
Vδ2neg γδ T cells (at similar levels described for CMV-specific CD8+ T cells), whereas 
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the majority of Vδ2neg γδ T cells T cells were IL-7Rhpos in CMV-seronegative donors. 
Most CD8+ T cells specific for persistent viruses are non-responsive to these cytokines 
unless also stimulated through the TCR, suggesting that antigen, and not cytokines, is 
the primary driving force behind T cell expansion (van Leeuwen et al., 2005, Shin et al., 
2007). Furthermore, TEMRA cells appear to be more long-lived than CD45ROpos TEM cells 
(Wallace et al., 2004). Thus it might be possible that Vδ2neg γδ T cell expansions are 
also driven more by TCR:ligand interactions than by cytokines and are maintained by 
increased lifespan rather than greater levels of proliferation. 
The reactivity of Vδ2neg γδ T cells against CMV-infected target cells was confirmed 
using in vitro expanded γδ T cell lines. Of particular note, this was also demonstrated 
using T cell lines expanded from CMV-seronegative donors. This indicates that CMV-
reactive Vδ2neg γδ T cells are present in CMV-seronegative donors, albeit at much lower 
precursor frequencies, and can be successfully expanded in vitro. This state of readiness 
provides support for these cells having a central role in the immune response after 
primary infection. However, it was not possible to demonstrate immediate effector 
activity in ex vivo assays, which was unexpected given the shared effector memory 
phenotype of Vδ2neg γδ T cells and virus-specific αβ T cells. Being a distinct T cell 
lineage αβ T cells may require an additional activation signal but the observed result 
could also be a reflection of the experimental conditions; CMV-infected fibroblasts, 
while able to sensitize virus-specific CD4+ and CD8+ T cells, may not have expressed 
sufficient levels of the ligand for optimal stimulation of freshly isolated Vδ2neg γδ T cells. 
This is supported by very recent work of Willcox and colleague, who have demonstrated 
that the TCR of γδ T cells (Vγ4Vδ5 clone) can directly bind endothelial protein C 
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receptor (EPCR), which is a major histocompatibility complex–like molecule  restricted 
to endothelial cells (Willcox et al., 2012). EPCR is upregulated after cellular 
transformation, with higher expression in carcinomas (Scheffer et al., 2002) and 
therefore, it can be considered as signature of cell stress. Nevertheless, this binding only 
occurs when costimulatory molecules are up regulated by CMV infection (Willcox et al., 
2012). This supports the notion that γδ T cells required a multimolecular stress signature 
composed of TCR ligand and costimulatory ligands. However, the single clone studied 
expressed an unusual Vδ5 encoded receptor, which may not be representative of the 
major Vδ1+ population of Vδ2neg γδ T cells.  
Another possible explanation of why freshly isolated Vδ2neg γδ T cells can not respond 
to CMV-infected fibroblasts is that they are driven to exhaustion as described for CMV-
specific αβ T cells in the elderly (Ouyang et al., 2004, Pawelec et al., 2005, Hadrup et 
al., 2006) and CD8+ cells with the CD28low/CD57high phenotype (Brenchley et al., 2003). 
Nevertheless, it is worth mentioning that there is contradictory evidence about the ability 
of highly differentiated CMV-specific αβ T cells to regain their ability to proliferate 
(Waller et al., 2007, Chong et al., 2008). Therefore, further work is necessary to clarify 
whether Vδ2neg γδ T cells show functional impairment in the elderly. 
It has to be noted that these experiments are based solely on circulating γδ T cells in the 
blood. As cells from mucosal sites, where Vδ2neg γδ T cells are likely to be functionally 
more active, have not been analyzed, some caution is warranted when assessing function. 
However, based on the knowledge that Vδ1pos cells are mainly located at epithelial 
tissues, it can be hypothesized that donors with high levels of Vδ2neg γδ T cells in the 
blood may have even higher levels of Vδ2neg γδ T cells at these sites possibly driven by 
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an elevated degree of localized viral replication. 
Studies of TCR usage by Vδ2neg γδ T cells populations show greater TCR restriction in 
CMV-seropositive individuals compared to CMV-seronegative controls (Dechanet et al., 
1999a, Pitard et al., 2008, Knight et al., 2010), indicating an antigen-driven selection of 
T cell clonotypes as observed for CMV-specific CD8+ and CD4+ T cells (Price et al., 
2005, Trautmann et al., 2005). Indeed, a recent study describes a public Vδ1 clonotype 
emerging during CMV infection in utero (Vermijlen et al., 2010). While TCR usage was 
not determined, it is tempting to speculate that public Vδ1 TCRs are also present in 
some donors. This clonal focusing may be driven by the selection of higher affinity 
TCRs (Price et al., 2005, Trautmann et al., 2005). Formal identification of the ligand(s) 
for the TCR of these γδ T cells would help answer some of these questions and also be 
of immense value for vaccine design, a major priority for CMV (Arvin et al., 2004), 
where the aim should be to elicit broad multi-specific immunity (Khanna and Diamond, 
2006). 
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5.1 Background 
Coronary Artery Diseases (CAD) (also called Ischemic heart diseases IHD) are the 
leading cause of death in adulthood worldwide. The pathological change behind these 
diseases is stenosis of coronary arteries due to atherosclerosis and plaque formation. It is 
multifactorial disease and there are several risk factors for atherosclerosis such as 
smoking, hypertension, diabetes mellitus, and hyperlipidemia (Ellenbogen, 1996). 
However, in recent years, there has been increasing focus on the role of chronic 
inflammation in the pathogenesis of atherosclerosis (Khan et al., 2011). One of the 
proposed causes of inflammation is chronic bacterial and viral infection. Although CMV 
was near the top of the causative agents list, there has been conflicting data as to whether 
CMV is a cause or an effect of atherosclerosis and CAD. 
There are several prior studies that have noted the importance of CMV in the etiology of 
CAD. For instances, in 1996 Zhou et al demonstrated that CMV carriage increased the 
risk of coronary artery restenosis by clot or plaque reformation after it had been removed 
during cardiac catheterization (Zhou et al., 1996). Subsequently, in 1998 Blum et al 
showed that high levels of anti-CMV IgG titre correlate positively with prevalence of 
coronary artery disease (Blum et al., 1998). Furthermore, Neumann and colleagues in 
2000 showed that there is a high risk of complication such as re-infarction, urgent re-
intervention and even higher rate of death in CMV seropositive patients in the thirty 
days post stent placement compared to CMV seronegative patients (Neumann et al., 
2000). In 2007 Gredmark et al utilized RT-PCR to show that there is a high rate of CMV 
replication in peripheral blood of patients with coronary disease compared with healthy 
controls (Gredmark et al., 2007). Nevertheless, in the same year Iriz’s group could not 
 196 
detect CMV infection by PCR when they examined aortic and internal mammary artery 
biopsy specimens from 33 patients who underwent open-heart bypass surgery (Iriz et al., 
2007). Contrary to expectations, Xanaki’s group were able to detect CMV DNA in 
endothelial cells of coronary arteries. However there was no significant difference in 
viral load in nonatherosclerotic tissues and atherosclerotic plaques in the group of 
patients who had bypass surgery (Reszka et al., 2008).  
No doubt such contradictory findings about CMV as a causative agent in CAD 
necessitates a sensible explanation for the CMV and CAD association. One possible 
explanation is based on the concept of immune system modulation such 
immunosenescence by chronic infection with CMV (see section 1.2.5 and 1.2.8 in 
general introduction). For instance, there is a considerable amount of evidence for 
continuous immune activation in CAD which is characterized by accumulation of 
immunocompetent cells in the arterial lesion and elevation of inflammatory markers in 
the circulation (Hansson et al., 1989, Caligiuri et al., 1998, Mazzone et al., 1999, 
Jonasson et al., 2002, Khan et al., 2011) and CMV is believed as the trigger antigen for 
this persistent immune activation. This is consistent with the fact that CMV is never 
cleared from the host, and enters into latency with poorly understood periodic 
reactivation and viral replication, which is controlled by reactivation of memory T cells 
(Sinclair and Sissons, 2006, Reeves and Sinclair, 2008, Sinclair, 2008). This notion is 
supported by the coexistence of inflammation and seropositivity for CMV as the most 
important predictor for reduced survival in CAD. In other words, patients who were 
CMV seropositive without coexisting inflammation did not show adverse prognosis 
(Zhu et al., 1999, Muhlestein et al., 2000, Simanek et al., 2011).   
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Besides the chronic CMV seropositivity and state of persistent inflammation, a third 
factor, leukocytes telomere length, has become an important component in 
understanding the relationship between infection and CAD. For instance, individuals 
with shorter telomeres in their peripheral blood leucocytes carry a higher risk of dying 
from cardiovascular disease (Samani et al., 2001, Nowak et al., 2002, Cawthon et al., 
2003, Yamada, 2003, Brouilette et al., 2007). On the other hand, CMV seropositive 
patients, but not healthy controls, exhibit accelerated telomere shortening of their 
cytotoxic T lymphocytes (CTLs) (Spyridopoulos et al., 2009, van de Berg et al., 2010, 
Spyridopoulos, 2011).  Over time, the persistent antigen exposure would induce not 
only temporary change in T cell activation markers but also with each cell division 
cycle, the telomere becomes shorter until the cell reaches the terminal effector stage 
(Blasco, 2005) and permanent alteration in the T cell phenotype pattern could occur 
(Effros et al., 1996, Monteiro et al., 1996, Valenzuela and Effros, 2002, Fletcher et al., 
2005). In immunologica1 terms this stage is known as the immunosenescence stage 
(Kaszubowska, 2008). This stage is characterized by poor response of the immune 
system to antigens and is associated with morbidity and mortality (Alonso-Fernandez 
and De la Fuente, 2011, Stankiewicz and Stasiak-Barmuta, 2011). Relation between 
CMV carriage and immunosenescence is reviewed in section 1.2.7 and 1.2.8 in the 
introduction chapter. 
It is worth mentioning that the quality of the immune response mounted against an 
antigen depends not only on the frequency of T cells reactive against that antigen but 
also on their functional pattern (Betts et al., 2006, Darrah et al., 2007, Seder et al., 
2008). In this regard, far too little attention has been paid to the relationship between 
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the change in the magnitude of CMV specific T cell response and prognosis in 
coronary artery disease patients.  
Hypothesis 
Here it is hypothesized that persistent subclinical CMV reactivation in ischemic heart 
disease patients leads to a stage of immunosenescence that particularly affects CMV 
specific T cells. Based on the observation that CMV specific T cells comprise a 
relatively large percentage of the memory T cell pool, the functional quality of CMV 
specific T cells must be an important factor in the morbidity and mortality in coronary 
heart diseases. 
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5.2 Aims  
It is not known whether the frequency and functional integrity of CMV reactive T cells 
in patients with coronary artery disease (CAD) differ from those of otherwise healthy 
subjects, and whether CMV specific T cells in CAD show premature signs of 
exhaustion that are represented as oligo-functionality, which in this thesis is referred to 
concurrent expression of two or less of the measured markers by CMV-specific T cells. 
Hence the aim is to determine differences in the magnitude of T cell responses to 
CMV in CAD and age-matched healthy volunteers by 8-colour flow cytometer. 
5.3 Plan of investigation 
To achieve the current project aims a plan of analysis was designed to include five 
steps, see Figure 5.1. The initial step was to carry out optimization experiments, this 
followed by determination of the study population CMV status. Finally, in two 
separate steps both the frequency and the functional integrity of CMV specific T cells 
and non-CMV specific T cells were measured ex-vivo in all patients and results were 
compared with age-matched seropositive healthy adults.  
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Figure 5.1: Schema for investigation steps  
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5.4 Results  
5.4.1 Study population  
Samples were recruited from the Cardiology Department, Newcastle Freeman Hospital. 
The patient cohort consisted of 57 patients (age 45-65 years) diagnosed with coronary 
artery disease (CAD) (also known as ischaemic heart disease IHD). 26 of them 
suffered acute myocardial infarction (AMI) while the rest were in stable post 
myocardial infarction stage (PMI). The patients selected lacked any history of cancer, 
inflammatory disease, immune disorders or severe comorbidity. However, all of them 
were on Aspirin (75-150 mg), Beta-blocker and statins. As a control group 40 age-
matched healthy volunteers were used. Ethical approval was obtained from the ethics 
committee of Freeman Hospital and University of Liverpool.  
5.4.2 CMV status of study population 
To address the aims it was necessary to confirm the CMV status of the cohort of blood 
donors. This involved the use of two complementary methods; serological method 
utilizing ELISA and αβ T cell responses against CMV measured by flow cytometry.  
The serological part was carried out by collaborators in the Freeman Hospital, Newcastle. 
They utilized an ELISA technique to detect CMV specific IgG in serum (data not 
shown). Out of 57 patients tested there were 28 CMV-seropositive donors according to 
this assay. As this was not a quantitative assay, information on the level of CMV-
specific antibodies could not be generated. 
T cell responses against CMV antigens were tested by using CMV lysate plus an 
inclusive CMV peptide pools, as this has been shown to be a good way to confirm CMV 
carriage (Kern et al., 2000). These pools spanned the entire amino acid sequences of the 
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HCMV pp65, major immediate early (IE-1) proteins and DYS/VTE. They comprised of 
15-amino acid peptides with at least nine overlaps between neighboring peptides. 
 T cell responses were measured by staining PBMC with antibodies against T cell 
markers (CD4 and CD8) and then against intracellular cytokines IFNγ, TNFα, IL-2. 
Figure 5.2 shows representative examples of donors tested for T cell responses against 
CMV antigens. The increase in the proportion of any of the mentioned cytokine 
production by CD4+ T cell or CD8+ T cell was used to decide whether there was 
response or not, an example of the formula that used to calculate this proportion is 
shown below. Since not all CMV seropositive donors (based on ELISA) showed T cell 
responses the conclusion on CMV status was made using both assays; see Table 5-1 
below. 
 
 
An example applying the above formula on pt007 is shown below. 
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responses against CMV antigens. The increase in the proportion of any of the mentioned 
cytokine production by CD4+ T cell or CD8+ T cell was used to decide whether there 
was response or not, an example of the formula that used to calculate this proportion is 
shown below.  
 
 
 
 
 
Since not all CMV seropositive donors (based on ELISA) showed T cell responses the 
conclusion on CMV status was made using both assays; see Table 5.1 below. 
Table 5-1: Examples of CMV status of donors tested in this study 
 
Donor ID 
 
Clinical condition*  
 
CMV-specific antibodies 
(ELISA) 
 
IFN-γ response after CMV stimulation** 
(Flow cytometry) 
 
CMV status 
P001 AMI 
 
? 0.9% Positive 
P003 AMI + 1.58% Positive 
P007 AMI + 1.53% Positive 
P008 AMI + 0.6% Positive 
P009 AMI _ 0.1% Negative 
P010 PMI + 0.1% Positive 
P028 AMI + 0.1% Negative 
P016 PMI + 1.67% Positive 
P044 AMI _ 0.0% Negative 
P051 PMI  + 2.1% Positive 
P058 PMI - 2.3% Positive 
* AMI= Acute Myocardial Infarction, PMI= Post Myocardial Infarction 
**IFN-γ response is calculated after subtracting the response against mock lysate 
Frequency of CMV-specific CD4+ or CD8+ T cells based on IFNγ production= 
                             % IFNγpos  (CD4+ or CD8+) T cells events in response to mock.  
    Subtracted from 
     % IFNγpos  (CD4+ or CD8+) T cells events in response to CMV-antigen  
 
%  CMV specific  CD4 T cells out of total CD4+ T cell in CMV stimulated tube 
                                (i.e IFNγ+ CD4+ T cells)
 (0.751/45.05)X 100 ≃1.66
(0.0406/61.34)X100 ≃ 0.066%  CMV specific  CD4 T cells out of total CD4+ T cell in mock stimulated tube  
(−)
 Frequency of CMV-specific CD4+ T cell≃ 1.59
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Table 5-1 : Examples of CMV status of donors tested in this study 
 
* AMI= Acute Myocardial Infarction, PMI= Post Myocardial Infarction 
**IFNγ response is calculated after subtracting the response against mock lysate.  
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responses against CMV antigens. The increase in the proportion of any of the mentioned 
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**IFN-γ response is calculated after subtracting the response against mock lysate 
Frequency of CMV-specific CD4+ or CD8+ T cells based on IFNγ production= 
                             % IFNγpos  (CD4+ or CD8+) T cells events in response to mock.  
    Subtracted from 
     % IFNγpos  (CD4+ or CD8+) T cells events in response to CMV-antigen  
 
-
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Figure 5.2: Representative flow cytometry plots of negative and positive blood donor 
responses against CMV antigens. 
This figure shows two representative results of patient’s responses against CMV. The upper 
groups of plots are for a CMV seronegative patient (Pt 044) while the lower are from a CMV 
seropositive patient (Pt 007). PBMC were stimulated for 10 hours at 37°C followed by surface 
staining for CD4 and then intracellular staining for IFNγ, , TNFα , and IL-2. The frequencies 
shown in the quadrants refer to the percentage of total lymphocytes. 
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Figure5.2: Representative flow cytometry plots of negative and positive blood donor 
responses against CMV antigens. 
This figure shows two representative results of patient’s responses against CMV. The upper 
groups of plots are for a CMV seronegative patient (Pt 044) while the lower are from a CMV 
seropositive patient (Pt 007). PBMC were stimulated for 10 hours at 37°C followed by surface 
staining for CD4 and then intracellular staining for IFNγ, , TNFα , and IL-2. The frequencies 
shown in the quadrants refer to the percentage of total lymphocytes. 
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5.4.3 Optimization of the ICS assay 
Since eight-colour flow cytometry for intracellular cytokine staining (ICS) on frozen 
peripheral blood monocyte (PBMC) is potentially demanding, a preliminary set of 
standardization steps was carried out before doing actual experiments on the patients’ 
samples. Therefore, in addition to the ordinary optimization steps such as, choosing 
which fluorochromes and use of isotype monoclonal antibody controls to each marker 
and titration of antibody quantity to reduce the background noise, the following were 
done: 
1- Incorporation of eight to ten hours PBMC rest period. 
2- Addition of DNase to the growth media during washing steps and    
subsequent   incubations. 
3- Selection of appropriate cytokine secretion inhibitors to be used in ICS. 
5.4.3.1 PBMC rest period and the addition of DNase to the culture medium 
It is known that freezing and thawing is very stressful to PBMC. Therefore incorporating 
a resting period for PBMC before commencing stimulation and ICS steps is favourable 
(Gauduin et al., 2004, Nomura et al., 2008). In addition, using DNase during washing 
steps was found to remarkably decrease PBMC stickiness (Lamoreaux et al., 2006, 
Horton et al., 2007). Thus, both of these approaches were adopted in the current study. 
However, the length of the PBMC resting period is not precisely determined and it 
varies according to the purpose of the experiment; besides, the possible effects of DNase 
on the ICS assay are unknown. It was therefore essential to optimize the length of 
PBMC resting period and to determine the appropriate concentration of DNase needed 
to be used in the ICS assay. Herein, flow cytometry was used to determine the level of 
IFNγ production by CD4+ and CD8+ T cells upon stimulation with CMV antigens in the 
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presence of different concentrations of DNase and for different incubation periods. The 
initial step was to find the optimal concentration of DNase to be used; to do that four 
vials of frozen PBMC from healthy donors known to be CMV-seropositive were thawed. 
One vial was washed with and cultured in RPMI medium alone (concentration 1-2×106 
PBMC/1 ml medium). Meanwhile, the other vial was aliquoted into three test tubes each 
contains 1-2×106 PBMC in 1 ml medium; three different concentrations; 1:10, 1:100 and 
1:1000 of DNase in RPMI medium were used for washing and incubation of these 
aliquots. After resting at 37 OC in a 5% CO2 incubator for fifteen hours, cells were 
washed twice with FACS buffer then recounted and any cell aggregations or clumps 
were removed.  This was followed by staining with FITC conjugated anti-CD4 and PE 
conjugated anti-CD8 monoclonal antibodies. Finally, fixation, permeabilization and 
intracellular staining of IFNγ with anti IFNγ APC conjugated monoclonal antibody were 
preformed (For more details see section 2.4.3.).  
The preliminary observation was that the DNase treated samples showed higher yields 
of PBMC. In addition, there was notable reduction in the background staining in mock-
stimulated tubes treated with DNase. Nonetheless, there was no significant change either 
in T cell subsets frequency or in the level of IFNγ in CMV stimulated tubes (Figure 5.3). 
The next step was to determine the optimum duration for resting of PBMC without 
stimulation and in the presence of DNase. Therefore, resting of cells for six, ten and 
fourteen hours were carried out before stimulation and ICS steps. There were no 
remarkable differences in levels of cytokine production (data not shown). However, for 
convenient scheduling ten to fourteen hours (i.e. overnight) were chosen as an optimal 
incubation period. 
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Figure 5.3: DNase does not interfere with the cytokine detection assay. 
It demonstrates the response of CD4+ and CD8+ T cells (left and right panels of plots, 
respectively) to mock and CMV antigens in the presence of different DNase concentrations. The 
top row of plots show the response of T cells to mock, whereas the low three rows of plots reveal 
T cells responses to CMV antigens. The Y-axis represents T cells frequency while the X-axis 
demonstrates IFNγ production in both CD4+ and CD8+ T cells. Labels and numbers to the left 
of the Y-axis show the stimulus type and DNase concentration used in each set of experiments. 
! 14!
Figure 0.3: DNase does not interfere with the cytokine detection assay. 
It demonstrates the response of CD4+ and CD8+ T cells to mock and CMV antigens in the 
presence of different DNase concentrations. The top row of plots show the response of T 
cells to mock, whereas the low three rows of p ots reveal T cells responses to CMV antigens. 
The Y-axis represents T cells frequency while the X-axis demonstrates IFNγ production in 
both CD4+ and CD8+ T cells. The panels to the left of the Y-axis show the stimulus type and 
DNase concentration used in each set of experiments. 
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5.4.3.2 Golgi Stop containing monensin enhances the CD107 mobilization assay detection threshold. 
Appropriate measuring of T cells response should include assessment of the ability of 
cells to kill (cytotoxic capability). This can be achieved either by directly measuring 
intracellular cytotoxic granule contents such as perforin and granzymes or indirectly by 
measuring degranulation marker such as CD107a or  CD107b. Implementing the last 
option necessitated the use of Golgi Stop containing monensin besides brefeldin-A 
(BFA). Aiming to find out the effects of cytokine secretion inhibitor on the ICS assay, 
PBMC from a CMV-seropositive donor were aliquoted into four test tubes. One of the 
tubes was stimulated with mock infection while the others were stimulated with CMV 
antigens. Immediately after stimulation, PBMC were stained with FITC conjugated anti-
CD107a/b monoclonal antibody in the presence or absence of monensin, followed by 10 
hours incubation in growth media containing co-stimulatory antibodies (pure anti CD28 
and anti CD49d) and BFA. On day two the surface and intracellular staining were 
carried out and flow cytometric analysis done.  Figure 5.4 is an illustrative example of 
how monensin could dramatically enhance the detection threshold of the CD107 
mobilization assay. 
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Figure 5.4: Golgi stop containing monensin increases the sensitivity of CD107a detection.  
Illustrative example of the influence of Golgi stop containing monensin on the level of CD107a 
expression of CMV stimulated T cells. PBMC incubated with mock (top row of plots) and CMV 
(second and third rows of plots) labelled with anti-CD107a monoclonal antibody. Monensin was 
used with the mock infection and in the lower plots only. Here, the Y-axis of each plot denotes 
either CD4+ or CD8+ T cell frequencies while the X-axis shows the level of CD107a expression. 
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5.4.4 Concurrent measurement of five separate T cell functions 
To determine the polyfunctionality of CMV specific T cell responses, simultaneous and 
independent measurements of CD107a mobilization and MIP1β, TNFα, IFNγ, and IL-2 
production were carried out. The gating scheme for identification of polyfunctional T 
cells is shown in Figure 5.5. Briefly, PBMC from a CMV seropositive CAD patient were 
stimulated with a mixture of IE-1 and pp65 CMV peptides and CMV lysate for 
approximately 10 hours in the presence of co-stimulatory antibodies, Golgi inhibitor and 
anti CD107a monoclonal antibody. This was followed by intracellular staining with anti 
MIP1β, IFNγ, TNFα, and IL-2 monoclonal antibodies to determine the functional 
capacity of T cells. In this subject, both the CMV specific CD4+ and CD8+ T cells 
demonstrated each of the five functions. For instance, the percentage of CD4+ T cells 
that produced CD107a was 2.31%, while for other cytokine production it ranged from 
0.6% to 2.13%. In contrast, the frequency of CD107a+ CD8+ T cells were 1.45 of the 
gated PBMC (plots not shown); with other functions having slightly lower frequency 
ranges than for CD4+ T cells.  
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Figure 5.5: Detection of five T-cell functions and characterization of CMV-specific T cell 
polyfunctionality in coronary artery disease.  
This portrays gating steps for identification of multifunctional CD4+ T-cell responses. The top 
two plots illustrate the progressive gating strategy used to identify the lymphocyte population. 
Meanwhile, the bottom panels represent results of the five functional responses of the CD4+ T 
cells to CMV antigens.  The histogram summarizes the 32 possible polyfunctional combinations 
of CMV specific CD4+ T cells. Data demonstrated are from a CMV-seropositive patient with 
coronary artery disease.  
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5.4.5 CMV specific CD8+ T cells in patient groups exhibit higher levels of 
inflammatory cytokines compared to the control group. 
Determination of CD8+ T cell responses to CMV by measuring the frequency of a single 
marker independent of other functional markers showed that the patient group usually 
demonstrated a higher frequency of responding CD8+ T cells compared to controls 
(Figure 5.6). This difference was obvious among IFNγ and TNFα positive CD8+ T cells 
where P values were <0.05 and < 0.01 respectively. Since the patient group consists of 
two categories of patients, namely patients with Acute Myocardial Infarction (AMI) and 
patients with stable Post Myocardial Infarction (PMI), then it would be more rigorous to 
compare these subgroups of patients to each other rather than only to healthy donors 
(Figure 5.7).  Statistically significant differences in frequency of TNFα+ CD8+ T cells 
can be seen between PMI and control groups (P<0.01) and in CD8+ IFNγ+ double 
positive T cells between AMI and control groups (P<0.05).  
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Figure 5.6: CD8 T-cell responses to CMV antigen in control and patient groups.  
Scatter dot plot comparing the frequency of CMV specific CD8+ T cells out of total CD8+ T 
cells between patients with coronary artery disease (CAD) and control groups, note both groups 
here are CMV seropositive. Blue triangles denote control groups, while red triangles represent 
patient groups. The bars indicate the medians with interquartile ranges. The X-axis indicates 
which function was measured (MIP1β, IFNγ, TNFα, and IL-2) while the Y-axis indicates the 
percentage of specific CD8+ T cells out of total CD8+ T cells.  Note, asterisks at the top of the 
plot indicate the significance of the difference between the groups, see figure label. 
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Figure 5.7: Comparison of the frequencies of CD8+ T cell responses to CMV antigens 
among different patient subgroups.  
Comparison between the frequencies of CMV specific CD8+ T cells out of total CD8+ T cells 
(Y-axis) in coronary artery disease  (CAD) patient subgroups and the control group. From right 
to left, the color-coded bars are referring to: patients with acute myocardial infarction (AMI), 
patients with stable post myocardial infarction (PMI) and control group respectively. The height 
of bars and error bars indicate the median and upper-quartile range respectively. The four 
functions measured, MIP1β, IFNγ, TNFα, and IL-2 are shown on the X-axis, and the asterisks at 
the top of bars refer to the significance of the difference between the groups (see figure legend).  
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5.4.6 Similarity in the frequency of CMV specific CD4+ T cells in patient 
and control groups. 
Although the response patterns of CD4+ T cells to CMV antigens in patient and control 
groups were similar to that of CD8+ T cells, there were no significant differences in 
frequencies of CMV-specific CD4+ T cells between patient and control groups. For 
instance, the independent measurement of five functional markers in CD4+ T cells after 
stimulation with CMV antigen revealed no substantial variation between the patient and 
control groups (Figure 5.8). Furthermore, no statistical difference emerged even when 
the patient groups were clinically categorized into their subgroups (AMI and PMI) and 
comparison preformed at the level of these subgroups (Figure 5.9).  
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Figure 5.8: Resemblances in frequencies of CMV specific CD4+ T cells of patient and 
controls groups. 
Figure demonstrates the similarity between patient and control group (red and blue triangles 
respectively) considering the percentage of CD4+ T cells that respond to the CMV antigens (Y-
axis) by expressing one of the functional markers; MIP1β, IFNγ, TNFα, and IL-2 (X-axis). The 
bars are indicating the median with interquartile range. 
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Figure 5.9: Comparing the frequency of CD4+ T-cell responses to CMV antigen in patient 
subgroups (AMI &PMI) and the control group.  
Comparison of the frequency of CMV specific CD4+ T cells out of total CD4+ T cells 
(Y-axis) among AMI, PMI and control groups (red, blue, and clear-pattern bars 
respectively). The height of bars and error bars indicate the median and upper-quartile 
range respectively. Despite the apparent differences within some clusters, particularly 
for IFNγ and IL-2, no statistical differences were found. 
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5.4.7 Measurement of T cell functional capacity based on Boolean gating of 
different functional markers 
Aiming to measure the full complexity of T cell response Flowjo software (version 
9.4.10;Mac) was used to produce an array of Boolean gates of five response markers, 
which include CD107a, MIP1β, IFNγ, TNFα, and IL-2. This resulted in the generation 
of 32 possible combinations of these five functions (Figure 5.5). With such a large 
database it was essential to use database organizing software. Thus, PESTLE software 
was utilized to reorganise the data and correct any non-specific background responses by 
subtracting the mock responses (negative control) from both the CMV antigen and 
mitogen (CON A as a positive control) responses. Finally, data were exported to a 
special program called SPICE 5 (Simplified Presentation Incredibly Complex 
Evaluations) (Roederer, 2011) where graphs and some statistical work were produced. 
Notably, most of the intracellular stains were satisfactory; nevertheless, CD107-FITC 
was substandard with high background levels. Therefore, CD107 was purposely 
excluded from the Boolean gates to prevent any statistical biases. Consequently, CD107 
will neither appear in graphs nor is included in the statistical analysis. Accordingly the 
number of possible combination automatically was reduced to 15 instead of 32 
combinations. 
5.4.8 CD8+ T cell response to CMV is mostly limited to cell populations 
with restricted functionality 
Investigating the functional hierarchy of CMV specific CD8+ T cell response in both 
patient and control groups (Figure 5.10) showed that most responses were restricted to a 
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single functional marker. For instance, in the patient group, CD8+ T cell responses were 
mainly dominated by cells that only produce MIP1β followed by TNFα and with less IL-
2 preponderance. Meanwhile in the control group IFNγ and TNFα monofunctional cells 
were positioned second in the order just after MIP1β; again IL-2 secreting cells were the 
least frequent. In addition, some of the responding populations exhibited multifunction 
patterns that mostly segregated to 3 or less simultaneous functions. The percentage of 
contribution of each of these combinations in total CD8+ responding cells was 
comparable and ranging from 0.4% to 4% of total CD8+ T cells response with the 
exception of the MIP1β+ IFNγ- TNFα+ IL-2+ CD8 T cell combination which was 
approaching zero. Interestingly, the CD8+ T cell response pattern in control groups was 
very similar to that of patient groups and there were no statistical significant differences 
between the two groups.  
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Figure 5.10: Comparison between CD8+ T cell functional capacity in patients with 
coronary artery disease (CAD) and healthy controls.  
The graph demonstrates the percentage contribution of each of the fifteen possible combinations 
of CMV specific CD8+ T cell in response to CMV antigen (Y-axis). Red and blue vertical bars 
represent the median of these combinations in coronary artery disease patient and healthy CMV 
carriers, respectively. Each combination of the four functions that involves; MIP1β, IFNγ, TNFα, 
and IL-2 is colour coded as a small square below the X-axis. For simplicity, the fifteen 
combinations were regrouped according to how many chemokine/cytokines were produced 
simultaneously into four major groups. Horizontal bars of different colours below the x-axis 
were used to portray these major groups. The integrated table below the graph provides the P 
value differences between patient and control groups of each combination based on the Mann-
Whitney test. 
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5.4.9 Permutation analysis of the patient and control groups demonstrates 
similar patterns of CD8+ T polyfunctional response to CMV antigens.   
The fifteen possible combinations of functions were represented in pie charts (Figure 
5.11a) where each slice in the pie charts symbolizes one of the fifteen combinations. 
Therefore, the colour of each slice matches the colour of the square below the X-axis in 
the histogram in Figure 5.10. Statistically, the comparison of distributions from 
individual categories in these complex datasets is subjected to Type 1 statistical error. 
Therefore, it would be reasonable to reduce the number of comparisons by replacing the 
fifteen functional combinations with four major function groups. The first group 
includes CD8+ T cells that express only one function (1+). The second group comprises 
responding cells with a combination of any two functions (2+); meanwhile the third and 
fourth groups represent, respectively, any three or four function combinations.  
Thereafter, the pie chart was reproduced using only the four major groups (Figure 5.11b). 
Each section in the new pie chart was colour-coded thus it matches corresponding 
horizontal bars in the histogram in Figure 5.10. Furthermore, for clarification purposes, 
arcs were added to each pie chart, where each arc symbolizes a single function. The 
overlap between arcs determines the pattern of polyfunctionality. By performing a 
permutation comparison between every pair of pies we found that there was no 
significant difference (p=0.1375) between the patient and control cohorts.  
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Figure 5.11: Comparison of the pattern of polyfunctionality of CMV specific CD8+ T cells 
in CAD patients and healthy donors.  
(a) Pie charts represent the entire pattern of multifunctional CD8+ T cells among patients and 
controls groups. Each slice in the pie charts represents one of the fifteen possible combinations 
of the four functions (MIP1β, IFNγ, TNFα, and IL-2). Therefore, colours of slices match the 
colours that are given to the square below the bars in Figure 5.10. The pie charts (b) are 
duplicates of the pie charts in (a), however the fifteen functional combination sectors were 
replaced by the main four groups i.e CD8+ T cells having one function (1+), two functions (2+), 
three functions (3+), and four functions (4+). Therefore, there are only four different colours, 
which were given the same colours as corresponding horizontal bars in Figure 5.10. For 
clarification purposes, arcs were added to each pie chart, where each arc symbolizes a single 
function. The overlap between arcs defines the pattern of polyfunctionality.  
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5.4.10 Similarity between the patterns of polyfunctionality of CD4+ T cell 
responses and CD8+ T cell responses to CMV antigen.  
Regardless of the magnitude of the responses, the CD4+ T cell responses to CMV 
antigens showed a very similar pattern to those of CD8+ T cells. In both situations the 
response that predominates is with cells that express only one function. For instance 
MIP1β and IFNγ single responding cells compose just less than the half of all responses. 
Meanwhile, the summation of polyfunctional cells (two or more functions) constitutes 
less than 30% of the responding cells (Figure 5.12).  
Comparing side-by-side CD4+ T cells response of CAD patient and controls showed no 
statistical difference between any compared pairs of data, see integrated table in Figure 
5.12. Furthermore comparing the two groups using permutation analysis confirmed no 
dramatic difference in the quality of the CD4+ T cell response (p=0.24), where the 
polyfunctional cells represent approximately 25% of responding cells in both patient and 
control groups, see pie chart Figure 5.12.  
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Figure 5.12: Comparison of the quality of CD4+ T cells responses to CMV antigens in CAD 
patient and control groups.  
As in Figure 5.10 the bar chart compares the 15 possible function combinations in patients and 
controls. The table shows the statistical differences (P value) of this comparison based on the 
Mann-Whitney test. The pie charts demonstrate the pattern of the whole difference between the 
four major function categories.    
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5.4.11 Patients with stable post myocardial infarction preferentially maintain 
highly functional CMV-specific T cells compared to patients with 
Acute Myocardial Infarction. 
Clinically, the patient cohort comprises of two categories of coronary artery disease 
patients, i.e. AMI and PMI. Consequently, it was investigated whether the pattern of 
CMV specific T cell polyfunctionality was related to the disease categories.  
The initial observation was that the permutation analysis of the CMV specific CD4+ T 
cell functional pattern in the PMI patient group preserved high functionality compared to 
both AMI patients (P= 0.001) and the control group (P= 0.005), see pie chart in Figure 
5.13. In this context, the difference between PMI and AMI seems to be a result of 
differences in cells with any two and any three functional combinations (red and green 
sectors respectively of the pie charts in Figure 5.13). Furthermore, this difference was 
particularly significant when comparison was made at the level of MIP1β+ IFNγ- 
TNFα+ and IL-2+ combinations (one-way ANOVA test, P< 0.05). In addition, there 
were significant differences in MIP1β-, IFNγ-, TNFα+, IL-2+ CD4+ T cells and 
MIP1β+, IFNγ-, TNFα- IL-2+ CD4+ T cells  combinations (P<0.01 and P<0.05 
respectively).  In contrast, the difference in CD4+ T cell quality between the PMI group 
and the control group is mainly due to monofunctional cells, for instance, while there 
were more IL-2 and TNFα single producer cells in the PMI group, the control group had 
more MIP1β and IFNγ single producer cells. Besides, there is a slightly higher 
preponderance in three functional combinations and statistically significant differences 
in MIP1β+, IFNγ-, TNFα- IL-2+ CD4 T cells (P<0.05). 
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Figure 5.13: Comparing the quality of CD4 + T cell response to CMV antigens in CAD 
patient sub-groups (AMI and PMI) and the control group.  
The histogram compares 15 functional combinations of CMV specific CD4+ T cells in acute 
myocardial infarction (AMI) and patients with stable post myocardial infarction  (PMI) and 
healthy controls  (black and grey and blue bars respectively). Asterisks at the top of bars refer to 
the significance of the difference between the groups (based on one-way ANOVA test and 
Dunn's Multiple Comparison post Test). For instance one asterisk means P< 0.05, while two and 
three asterisks symbolize P<0.01 and P<0.001 respectively. The pie charts demonstrate the 
pattern of polyfunctionality. The differences in the pattern were tested by permutation and are 
presented as P values under the charts.  
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Contrasting with CD4+ T cells, permutation analysis of the CMV specific CD8+ T cell 
features between PMI, AMI and the control group showed no substantial variances (see 
pie charts in Figure 5.14). Nevertheless, the comparison at the level of paired groups 
revealed several statistical differences; see histogram Figure 5.14. An example of that is 
remarkably high frequency of four functions positive CD8+ T cells in PMI comparing to 
the control group (P<0.05). Besides, PMI showed a greater level of MIP1β+ IFNγ+ 
TNFα- IL-2+ CD8+ T cells comparing to both AMI and the control group.  
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Figure 5.14: Comparing the quality of CD8+ T cell responses to CMV antigens in IHD 
patient sub-groups (AMI and PMI).  
Similar to Figure 4.13, the histogram compares 15 functional combinations of CMV specific 
CD8+ T cells in AMI, PMI, and control groups. The significant differences are indicated with 
asterisks. The pie charts demonstrate the pattern of the whole differences between the four major 
functional categories with a permutation test.  
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5.4.12 In addition to CMV seropositivity, coronary heart disease per se might 
have an impact on T cell quality. 
 Having observed differences in the patterns of functionality in response to CMV 
antigens between patients and controls, particularly in CD4+ T cells, it was hypothesized 
that, regardless of the CMV status, these differences in T cell quality might be a 
consequence of coronary heart disease itself and not the effect of CMV carriage.  
Aiming to prove or disprove that it was investigated if the same differences could be 
identified between diseased and healthy control groups who were CMV seronegative. 
This time a mitogen (CON A) was used to trigger T cell responses rather than CMV 
antigens.  
The pie charts in Figure 4.15 summarize the permutation analysis of CD4+ and CD8+ T 
cell responses to mitogen in AMI, PMI, and control groups. Interestingly, there were 
significant differences in CD4+ and CD8+ T cell responses between PMI, AMI and 
control groups. However, these differences related to single functional cells, such as 
only IFNγ+ and IL-2+ producing cells (represented as red and blue arcs in the pie charts 
respectively)  (Figure 5.15) rather than differences in the polyfunctional cells. For 
instance the red, green, and yellow slices, which symbolize 2+, 3+, and 4+ functional 
combinations and their corresponding overlapped arcs are very similar in all groups.     
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Figure 5.15: Comparison of the quality of T cell responses to mitogen in CAD patient sub-
groups and the control group.  
The pattern of T cell responses to Mitogen (CON A) in CMV seronegative patient and control 
groups. The top row of pie charts shows the differences in CD4+ T cell responses while the 
bottom row demonstrates CD8+ T cell responses in the same groups. The blue sector of the pie 
indicates the percentage of single function cells in the total response while the red, green, and 
yellow portions represent the polyfunctional cell percentages. Each pie chart arc symbolizes a 
single function and the overlap between arcs determines the pattern of polyfunctionality. A 
permutation test was used to show the differences between these groups and differences are 
presented as P values under the charts.  
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5.4.13 Polyfunctional CMV specific T cells produce more cytokine on a per 
cell basis. 
Having shown a high polyfunctionality of CMV specific T cells in the PMI group 
compared to both the AMI and control groups, it was investigated if there was any 
association between the degree of functionality and the amount of the chemokine/ 
cytokine produced per cell. The median fluorescence intensity (MFI) of each of the four 
markers within the fifteen functional combinations was calculated (Figure 5.16). Here it 
is shown that there was a direct relationship between the polyfunctionality and the 
expression levels of cytokines. In other words, the higher the functionality the higher the 
chemokine/cytokine levels. For instance, the MFI of IFNγ in 4+ polyfunctional CMV 
specific CD4+ and CD8+ T cells was approximately 3-fold and 2.5-fold higher, 
respectively, compared to mono-functional CMV specific CD4+ and CD8+ T cells. A 
similar trend was seen in all other chemokine/cytokines (Figure 5.17) the only exception 
was the IL-2 secretion level, which was remarkably high in both CD4+ and CD8+ T 
cells with two concurrent functions compared to those displaying three or four functions.  
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Figure 5.16: IFNγ median fluorescence intensity (MFI) is higher in polyfunctional CMV 
specific T cells.  
A representative example of the IFNγ-MFI overlay of cells producing different cytokine 
combinations in CD4+ T cells (upper plot) and CD8+ T cells (lower plot).  The IFNγ-MFI of 
each functional combination was colour coded and represented as a histogram. (See figure label)  
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Figure 5.17: CMV specific polyfunctional T cells express higher levels of cytokines than 
CMV specific monofunctional cells.  
Each graph shows median fluorescence intensity (MFI +/- SEM) of MIP1β, IFNγ, TNFα, and 
IL-2 in CMV specific T cells (CD4+ and CD8+; left and right column of plots respectively). The 
Y-axis  indicates MFI levels and the X-axis shows T cells expressing one, two, three or four 
cytokines. 
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5.5 Discussion 
The purpose of this project was to investigate the relationship between CMV specific T 
cell responses and coronary heart disease. Thus the polyfunctionality of CMV specific T 
cells in CAD patients was compared to that in healthy controls. The objective was to 
measure a panel of chemokine/cytokines including; CD107a, MIP1β, IFNγ, TNFα, and 
IL-2 utilizing flow cytometry and intracellular cytokine staining (ICS). It is worthy to 
mention that, there is no consensus about which markers should be used for these 
purposes and justifications for selecting this panel of markers that were used in this 
project is discussed elsewhere (see section 7.1.3). Indeed, measuring such a relatively 
large panel of cytokines technically necessitates several optimization steps before 
commencing actual experiments (Gauduin et al., 2004, Lamoreaux et al., 2006, Horton 
et al., 2007, Nomura et al., 2008).   
5.5.1 The importance of optimization steps 
Taking into consideration that the accuracy of the ICS assay is highly dependent on the 
condition of the PBMC after being thawed, two strategies were used to improve PBMC 
condition. The first strategy was to add DNase to the washing media during media 
exchange steps and during resting periods as well as during the stimulation step of ICS. 
This step was based on previous studies which shown that using DNase during washing 
steps remarkably decreased PBMC stickiness (Darzynkiewicz et al., 1994, Lamoreaux et 
al., 2006). The second strategy was to incorporate a resting period for PBMC before 
commencing the stimulation and ICS steps.  
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Since the use of DNase was novel in this laboratory, it was essential to confirm that the 
proposed DNase concentration did not interfere with the ICS assay. Therefore a set of 
optimization experiments was performed. The first observation from these experiments 
was an improvement in the yield of PBMC, which was reflected by increased numbers 
of cells harvested from frozen samples washed with DNase. This illustrates the benefit 
of minimizing the PBMC loss caused by clumping of cells together, and thus physically 
removing them during sample filtration. It is known that the freeze-thaw process is very 
stressful to PBMC and can lead to damage of cells and release of DNA, which can cause 
adherence of cells and occurrence of PBMC stickiness phenomena.  
The second observation was that incorporation of a PBMC resting period and including 
DNase in the ICS protocol led to a remarkable reduction in background staining for 
cytokines in the mock samples. This was of particular importance because the response 
of CMV stimulated samples was determined by subtraction of the background staining 
in the mock sample. In other words, this means an increase in the assay specificity and 
sensitivity. A possible explanation might be that the resting of PBMC for a long enough 
period in the presence of DNase gives more time to destroy any potential apoptotic cells 
and eliminate any released DNA by DNase. Thus, this will reduce the nonspecific 
binding of monoclonal antibody to DNA during the ICS step.  
5.5.2 Determining which functions to measure of the T cell response 
Before discussing further, it is essential here to clarify exactly the meaning of some 
terms. For instant single cytokine producing cell or single function cells refer to cells that 
produce or express only one cytokine or function that was measured in this project. For 
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example the frequency of IFNγ single producing cells means the frequency of cells in 
the population that only produce IFNγ but not other measured markers. Nevertheless, it 
should be emphesised that these cells might be still able to produce other cytokines that 
are not included in the measured panel such as IL-17, and IL-4.  Meanwhile, the 
frequency of IFNγ producing cells (without prefix ‘Single’ or ‘Mono’) means the 
frequency of all those cell producing IFNγ regardless if they express other functions or 
not. ’Polyfunctional’ or ’multifunctional’ will be used to describe cells that can produce 
more than a single cytokine simultaneously. 
Stereotypically, the magnitude of the CMV specific T cell response is defined by 
measuring the frequency of antigen-specific T cells based on expression of certain 
specific effector function such as IFNγ and TNFα productions (Khan et al., 2004, Sester 
et al., 2005, Sund et al., 2010). Nonetheless, measuring of a single parameter 
independent of other markers might not always precisely describe the magnitude of the 
T cell response (Ouyang et al., 2003b, Darrah et al., 2007, Nebbia et al., 2008). 
Particularly if we take into consideration that T cell response to a stimulus is not only 
restricted to effector function but also involves the ability to proliferate or induce 
proliferation and modulation of other cells of the immune system so that any proper 
description of T cell function should cover these aspects.  
Therefore aiming to define an appropriate measure of T cell response quality, 
experiments were designed to involve a panel of different activation markers. However, 
due to limitations in the ability of flow cytometry to detect only eight colours, in this 
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thesis measuring the components CD107a, MIP1β, IFNγ, TNFα, and IL-2 was thought 
to give a comprehensive picture of the quality of the antigen-specific T cell response. 
Returning to the optimization aspect of this project and as mentioned in the Aims, one of 
the targets was to characterise the cytotoxic activity of CMV specific T cells. Therefore 
the CD107 mobilization assay was adopted. This assay works by detecting the transient 
surface expression of CD107a or CD107b (LAMP-1/LAMP-2 respectively) that takes 
place during T cell degranulation following antigenic stimulation. This assay involves ex 
vivo addition of a protein transport inhibitor to stimulated lymphocytes. This leads to 
blocking of the intracellular protein transport and accordingly accumulation of cytokine 
inside the cells and also prevents the quick reinternalization of CD107 molecules after 
degranulation. Therefore, it will enhance the detectability of both cytokine-producing 
cells and expression of CD107 by flow cytometry. Brefeldin A (BFA) and monensin are 
the cytokine secretion inhibitors that are most commonly used in ICS. However, they 
have been found to have different effects on ICS, particularly the duration of incubation 
and cytokines that are required to be detected (Nomura et al., 2008). For instance, the 
viability of monensin treated cells is significantly decreased when exceeding 18 hours 
incubation compared with Brefeldin A, which is less toxic to the cells (O'Neil-Andersen 
and Lawrence, 2002). Nevertheless, monensin must be included in the protocol as it is 
required to prevent acidification of lysosomes and endosomes and is consequently 
preferable for inhibition of CD107 reuptake than Brefeldin A. Taking into consideration 
the advantages and disadvantages of both reagents the decision was made to use both of 
them concurrently. The question, which needed to be asked here, is that, is it possible to 
use both inhibitors simultaneously without affecting the accuracy of the assay? To 
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answer this question, levels of CD107a and IFNγ were measured in the presence and 
absence of monensin, (see Section 5.4.3.2). It was found that stimulating PBMC in the 
presence of monensin for approximately 12 hours improved the CD107 detection 
threshold without affecting the ICS assay. 
5.5.3 Justification for using a special statistical analysis software  
Aiming to measure the full complexity of the T cell response, an array of Boolean gates 
of response markers, which include MIP1β, IFNγ, TNFα, and IL-2, was generated. The 
result of this was 15 possible combinations of these functions. For appropriate analysis 
of such polychromatic flow cytometry data’ special programs called PESTLE and 
SPICE v5 (Simplified Presentation of Incredibly Complex Evaluations, Version 5) were 
used (Roederer, 2011).  
Statistically, since the data was continuous, unpaired and does not follow Gaussian 
distribution, then all statistical tests used were nonparametric; this included the Mann 
Whitney test (in case of comparing two independent variables) and the Kruskal-Wallis 
test (variant of One-Way ANOVA test) followed by Dunn’s post-test in cases where 
more than two variables were compared. 
One of the simplest ways to determine differences in the whole pattern of T cell 
functionality is to represent data as pie charts, followed by comparing each portion of 
certain pie charts to its corresponding portion in other pie charts. Nevertheless 
comparison of distributions from individual categories in these complex datasets might 
lead to Type 1 statistical errors. In other words it can lead to mistaken identification of a 
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difference as being statistically significant. This comes from the large number of 
comparison all of the distributions simultaneously. To overcome this a permutation test 
was adapted that can be done by the SPICE program. Basically SPICE compares the size 
of each category (each "slice") between the two distributions. It sums up the differences 
over all categories (all slices) to determine the overall difference. This overall difference 
is used in the permutation test. Differences were considered statistically significant when 
p<0.05. 
The current study showed that the percent T cells expressing a single function 
independently of other functions was significant higher in the patient group compared to 
controls. This was particularly relevant when considering IFNγ or TNFα positive CMV 
specific CD8+ T cells, see (Section 5.2.5). However, the pattern of responding cells was 
approximately similar in both the patient and control groups. For instance, the highest 
frequency of responding CMV reacting cells usually dominated by those cells producing 
MIP1β followed by TNFα or IL-2 and then IFNγ. This finding seems to be consistent 
with the earlier observation, which showed correlation between high inflammatory 
cytokine levels and coronary artery disease (Caligiuri et al., 1998, Jonasson et al., 2002, 
Simanek et al., 2011). Furthermore it might suggest that repeated reactivation of CMV 
specific CD8+ T cells can act as a source of inflammatory cytokines.  
Interestingly, examining the T cell response of each donor individually demonstrated 
that no functional marker was consistently expressed in all responding cells which might 
suggest that it is not appropriate to rely on measuring each function independently of 
other to determine the response.  This is supported by the same observation in many 
HIV studies that confirm that measuring individual effector cytokines may be an 
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inefficient indicator of the T cell response (Betts et al., 2006, Kim et al., 2009b). 
Therefore, we carried out Boolean gating of the four cytokines to compare all possible 
combinations of the four functions. In this regard, the current study indicates that the 
majority of T cell responses, irrespective of the donor status (patient or healthy), are 
characterized by low functionality. Most responding cells are restricted in expressing 
only one chemokine or cytokine, and only less than 30% of the response can be 
considered as multifunctional with very few donors having T cells expressing four 
functions concurrently.  
Considering the patient cohort consisted of two substantially different groups in the 
spectrum of coronary heart disease; namely AMI and PMI then it was more appropriate 
to investigate them as different groups rather than as a single combined group. 
Interestingly, subdividing patients into AMI and PMI revealed several significant 
differences in their T cell response quality. An example of this is the high frequency of 
2+ and 3+ functional CMV specific CD4+ T cells and 4+ functional CMV specific 
CD8+ T cells in PMI compared to AMI. Furthermore, the permutation analysis showed 
that PMI preferentially maintains highly functional CMV-specific T cells, particularly 
CD4+ T cells, compared to patients with AMI and to controls (Section 5.4.11). For 
instance, comparing PMI to AMI showed that in PMI there were higher frequencies of 
CD4+ T cell populations that have one of the following chemokine/ cytokine profiles 
(MIP1β+, IFNγ-, TNFα-, and IL-2+), (MIP1β-, IFNγ-, TNFα+, and IL-2+) or (MIP1β+, 
IFNγ-, TNFα+, and IL-2+).  
Interestingly, all of these profiles are characterized by the absence of IFNγ and the 
presence of IL-2 plus any other functions. This might suggest the importance of a 
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positive IL-2 and negative IFNγ T cell profile as a prognostic factor in coronary artery 
disease in CMV carriers.  Supporting this view are the studies by Sinclair et al (Sinclair 
et al., 2006) who observed significantly lower numbers of CMV-specific T cells that 
express IL-2 in subjects with active CMV retinitis. Furthermore Gattinoni and 
colleagues (Gattinoni et al., 2005) demonstrated that the frequency of effector T cells, 
characterised by strong cytotoxic function and IFNγ production, are paradoxically 
correlated with the control of cancer growth in a cancer immunotherapy model. 
Additionally the results of this study is consists with the model of Pantaleo et al 
(Pantaleo and Harari, 2006, Harari et al., 2009) that proposed that IL-2 production in the 
absence of IFNγ by antigen specific T cells is a signature for viral clearance. Meanwhile 
dominance of IFNγ in the absence of IL-2 is associated with chronic non-controlled 
disease whereas synchronized secretion of both of them by the same cell is seen in 
chronic controlled infections (Figure 5.18).  
Contradictory to the findings of the current study, Casazza et al showed that the salient 
features of virus-specific CD4+ T cells in chronic CMV infection characterise by the 
simultaneous production of MIP1β, TNFα, and IFNγ in the absence of IL-2 (Casazza et 
al., 2006). Nonetheless, in their study day used only eight PP65 CMV epitopes. 
Meanwhile in the current experiments comprehensive CMV peptide pools were used for 
this purpose. These pools covered the entire amino acid sequences of the HCMV pp65, 
major immediate early (IE-1) proteins and DYS/VTE. Therefore the Casazza group 
work might reflect only the functional profile for CMV pp65 specific CD4+ T cells. 
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Figure 5.18: Pantaleo and Harari model for functional signatures (IFNγ and IL-2) of virus-
specific CD4+ and CD8+ T cells to clinical monitoring of virus-associated disease 
This Figure illustrates the possible fate of the cytokine profile of T cells during infection. The 
primary viral infection is usually dominated by an IFNγ signature of CD4+ and CD8+ T cells 
(depicted in blue) with a small number of IL-2 secreting cells (depicted in yellow). After primary 
infection, there are three possible outcomes: virus elimination associated with a dominant IL-2 
signature of the T cell response, establishment of chronic controlled infection associated with a 
multifunctional T cell response, and establishment of chronic non-controlled infection associated 
with the persistence of a dominant IFNγ signature. In the case of chronic controlled infection, 
reactivation of viral replication will be marked by a rapid shift from a multifunctional to a 
dominant IFNγ signature. In the case of non-controlled infection, suppression of viral replication 
for example by treatment will be marked by a shift from a dominant IFNγ to a multifunctional 
signature. Figure adopted from (Pantaleo and Harari, 2006) 
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As mentioned earlier, three functional 
patterns of antigen-specific CD4+ and CD8+ 
T-cell responses — dominant IL-2 secretion 
and proliferation, multifunctional (that is, 
secretion of both IL-2 and IFNγ, prolifera-
tion and cytotoxic activity for CD8+ T cells) 
and dominant IFNγ secretion and cytotoxic 
activity — have been identified in associa-
tion with different antigen loads23,25,26. 
These different functional CD4+ and CD8+ 
T-cell populations are not contained within 
a single phenotypic population but are dis-
tributed within multiple phenotypic T-cell 
populations24–26. Typical examples are 
represented by the distribution of IL-2-
secreting, dual IL-2- and IFNγ-secreting 
and IFNγ-secreting CD4+ and CD8+ T cells 
within the antigen-specific cell populations 
defined by CD45RA and CCR7 (TABLE 2). 
With regard to CD4+ T cells, central mem-
ory (CD45RA–CCR7+) T cells mainly con-
tain IL-2-secreting cells and, to a lesser 
extent, dual IL-2- and IFNγ-secreting 
cells; effector memory (CD45RA–CCR7–) 
T cells, contain all three cytokine-secreting 
populations and terminally differentiated 
(CD45RA+CCR7–) T cells mainly contain 
IFNγ-secreting cells. Similarly, CD45RA–
CCR7+ and CD45RA–CCR7– CD8+ T cells 
contain both dual IL-2- and IFNγ-secreting 
and IFNγ-secreting cells, whereas 
CD45RA+CCR7– cells contain only IFNγ-
secreting CD8+ T cells.
Recent studies have also found a correla-
tion between phenotypically defined popu-
lations — for example, in vivo expanded 
CD8+CD45RA+CCR7–CD27– and 
CD8+CD127+ T-cell populations — and 
better control of viral replication in different 
models of viral infection (such as non-
progressive and/or slowly progressive HIV-1 
infection and CMV infection)11,22,25,55–57. 
However, unlike the changes in T-cell func-
tion that occur in different viral infections, it 
is not clear whether quantitative measures in 
distinct phenotypic T-cell populations can 
function as markers of disease activity that 
are of sufficient sensitivity to detect changes 
in viral load.
T-cell functions in clinical monitoring
Our observations of the three main func-
tional patterns of antiviral CD4+ and CD8+ 
T-cell responses and their correlation with 
different levels of antigen load and viral 
replication provide the scientific rationale 
Figure 3 | Application of functional signatures of virus-specific CD4+ 
and CD8+ T cells to clinical monitoring of virus-associated disease 
activity. In this model, we propose that functional signatures of T-cell 
responses can accurately reflect the patterns of interleukin-2 (IL-2) and 
interferon-γ (IFNγ )-secreting CD4+ and CD8+ T-cell responses observed 
during primary HIV-1 and cytomegalovirus (CMV) infection (acute anti-
gen exposure with high antigen load); influenza virus infection (antigen 
clearance); chronic CMV, Epstein–Barr virus, herpes simplex virus (HSV) 
and HIV-1 infection in long-term non-progressors (protracted antigen 
exposure and persistence with low antigen load); chronic progressive 
HIV-1 infection (antigen persistence with high antigen load); HIV-1 sup-
pressi n after antiretroviral therapy (shift from high to low antigen load); 
and interrupted antiretroviral therapy for HIV infection (acute antigen 
re-exposure with high antigen load). 
Table 2 | Cytokine-secreting T-cell populations defined by CD45RA and CCR7
T-cell phenotype T-cell function
IL-2-secreting IL-2 and IFNγ-secreting IFNγ-secreting 
Antigen-specific CD4+ T cells
CD45RA–CCR7+ + –/+ –
CD45RA–CCR7– –/+ + +
CD45RA+CCR7– – –/+ +
Antigen-specific CD8+ T cells
CD45RA–CCR7+ – +* +
CD45RA–CCR7– – +* +
CD45RA+CCR7– – – +
*The proportion of dual IL-2- and IFNγ-secreting T cells is higher in the CD45RA–CCR7+ than CD45RA–CCR7– CD8+ 
T-cell populations. CCR7, CC-chemokine receptor 7; IL-2, interleukin-2; IFN-γ; interferon-γ.
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Having observed this shifting in T cells response post myocardial infarction towards 
polyfunctionality raised a question about the role of coronary artery disease in modelling 
patterns of T cell response. One might argue that changes in CMV specific T cell 
functionality is a part of global phenomenon in CAD affecting the whole memory T cell 
pool. Consequently, one can propose that ischaemic heart disease per se might cause 
changes in the whole T cell response including the CMV specific one. To address this 
possibility we investigate the T cell response of CMV seronegative cohorts to mitogen 
(Section 5.4.12). In this context, it was shown that the differences in cell quality among 
the patient subgroups and between them and the control group were mainly due to 
differences in magnitude of monofunctional cells and not as a consequence of shifting to 
polyfunctionality.  
Rationally we expected that the capability of one cell to secrete numerous cytokines 
simultaneously might negatively affect the amount of these cytokines expressed per cell. 
Interestingly, opposite to expectation, CMV specific polyfunctional T cells were found 
to be capable of expressing larger quantities of cytokines compared to CMV specific 
monofunctional cells. For example, amounts of IFNγ and TNFα produced by each 
polyfunctional cell were about 2.5 to 3 times higher than the levels of these cytokines in 
monofunctional cells. In other words, the level of each cytokine positively correlated to 
the number of functions expressed per cell. The only exception to this rule was the level 
of IL-2, which was secreted more by double functional than polyfunctional cells. This 
might be explained by the role of IL-2 being to maintaining T cell proliferation in early 
immune responses to antigen.  This again supports the notion that polyfunctional cells 
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are more efficient effector cells than the monofunctional cells. Therefore, one can 
propose that even small differences in the frequency of polyfunctional cells might be 
biologically important and could have a major influence on the quality of antigen 
specific immune responses. 
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6 Prospective Study of Immunity to Varicella Zoster 
Virus During Treatment For Acute Lymphoblastic 
Leukaemia (All) In Children 
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6.1 Background 
Varicella zoster virus (VZV) is a cytopathic human herpes virus that causes chickenpox 
(varicella) upon primary infection. This is followed by persistent infection in the body in 
a dormant state, termed as latency, from which the virus may reactivate to cause shingles 
(zoster) (Arvin, 2001). More severe disease symptoms occur in persons with a weak 
immune system such as children with immunodeficiency, pregnant women and elderly 
persons, suggesting that the virus is successfully kept in check by immune mechanisms 
in healthy persons with normal immune function.  
In a recent epidemiological study in the UK and Ireland 112, children have been 
identified with severe complications of chickenpox and six deaths, over a 13-month 
period from November 2002 (0.82/100,000 children/year) (Cameron et al., 2007). Four 
deaths were in children with underlying medical conditions although not ones usually 
associated with high varicella mortality. Furthermore, the development of chickenpox in 
immunocompromised children was found to be not only associated with considerable 
morbidity but also with increased mortality rate. For instance, the overall mortality rate 
from varicella in children with cancer has been reported in the late 1980’s to be as high 
as 7% (Feldman et al., 1975, Feldman and Lott, 1987). However, the subsequent 
introduction of therapeutic acyclovir shortens the cutaneous course of the infection and 
reduces the risk of dissemination and a more serious illness (Feldman and Lott, 1987, 
Nyerges et al., 1987). 
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It was previous practice on the Regional Oncology Unit at Alder Hey to give 
prophylactic oral acyclovir to all immunocompromised patients following contact with 
VZV.  In 2003, the practice was changed in accordance with National Guidelines 
(RCPCH, 2002) and prophylaxes only were given to patients without varicella zoster 
immunoglobulin G (VZV IgG) detected at diagnosis.  
Taking into consideration that at least 70% of all patients in the Oncology Unit at Alder 
Hey had VZV IgG detected at diagnosis of their malignancy suggesting previous 
infection with chickenpox, led to a reduction in the prescription of prophylactic 
acyclovir and a considerable cost saving. However, between July 2001 and July 2007, 
40 patients with a malignancy in the Oncology Unit at Alder Hey were diagnosed with 
chickenpox. Nine of these 40 patients were found to have VZV IgG detected at 
diagnosis of their malignancy (Manley et al., 2008). The primary diagnosis of all nine 
patients was acute lymphoblastic leukaemia (ALL) and all developed chickenpox 
between November 2004 and July 2007. None of these patients had clinically 
dermatomal shingles and no patient received prophylactic acyclovir, as their chickenpox 
occurred following the change in practice in 2003. 
Eight of these nine patients had their VZV IgG rechecked either at the time or after the 
episode of chickenpox. Five of the patients showed loss of VZV IgG at the start of their 
chickenpox and three patients showed a further decline in VZV IgG at some time after 
the event. All these cases of chickenpox occurred in the second or third year of 
chemotherapy.  
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Indeed, the development of chickenpox in immunocompromised children, who were 
thought to have adequate protection, is a worrying occurrence and needs to be 
investigated.  
Usually, protection against herpes zoster is correlated with the antibody-mediated 
immune response through measurement of VZV-specific antibody by ELISA. However, 
in view of the importance of T cells in recognition of intracellular viral antigens, it has 
been argued that this form of immune response is of equal or even greater importance 
than antibody responses (Heininger and Seward, 2006).  
This is supported by the observation that the decline in the T cell response coincides 
with higher levels of viral reactivation (Asanuma et al., 2000). Therefore, the current 
study proposes the investigation of antibody-mediated responses against VZV alongside 
T cell anti-viral immune responses. 
Research question 
To determine whether there is loss of immunity to varicella in children with ALL 
treated with the current national protocol ALL 2003, as a result of the 
immunosuppressive therapy by studying VZV-specific B and T cell immunity. 
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6.2 Aims 
To determine the importance of B or T cell mediated immunity to protect against 
VZV infection and reactivation during chemotherapy in patients with ALL. 
Furthermore, to evaluate whether the loss of VZV-specific B and/or T cell mediated 
immunity might be utilized as a risk predictor for VZV reactivation in patients who 
were considered to be protected. Therefore, the following two steps were carried out:  
1. Monitoring the change in the levels of VZV IgG as indicator of B cell function. 
2. Assessing any changes in the VZV-specific T cell immune responses through 
measuring cytokine profiles. 
6.3 Plan of Investigation 
6.3.1 Study population 
6.3.1.1 Control group 
Since having healthy children, as a control group was ethically unattainable, healthy 
adult donors were used. The main purpose of that was to optimize different assays used 
in this project. 45 donors aged from 18-40 years were recruited for this purpose.  
Therefore, in this chapter whenever ‘adult healthy controls’ are mentioned it refers to 
this group unless otherwise mentioned. 
6.3.1.2 Patient group and sampling time point 
This work involves children diagnosed with acute lymphocytic leukaemia (ALL) and 
treated according to the ALL 2003 protocol. Both newly diagnosed patients and patients 
already undergoing chemotherapy were included. Table 6-1 summarises the patient 
group characteristics.  
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The number of blood samples that were taken from each patient depended on two main 
factors. Firstly, the stage of treatment at which any patient enrolled into the study, the 
second is the type of the chemotherapy regimen. For instance, at diagnosis, a patient 
would receive either Regimen A or Regimen B, dependent on age and presenting white 
cell count. However, for a variety of reasons, a patient might be transferred at any point 
to Regimen C. Furthermore, the length of each regimen is also dependent on the gender 
of the patient. Hence, fewer samples were taken from girls as they complete treatment at 
week 112 in Regimen A, week 114 in Regimen B and week 118 in Regimen C. In 
contrast, boys will complete treatment at week 164 in Regimen A, week 166 in Regimen 
B and week 170 in Regimen C. Therefore, the goal was to collect five samples from 
girls and seven samples from boys. 
Table 6-1: Age and gender distribution of the leukaemic children group 
 
 
 
 
 
 
 
< 3 years 3 to 5 years > 5 years Total
Male Female Male Female Male Female Male Female
5 5 10 11 15 28 44 30
10 21 43 74
Age at study 
entry
Gender
Number
Total
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6.4 Statistical analysis 
Unless otherwise mentioned all data were presented as median with interquartile range 
and Mann Whitney test was applied with 95% confidence intervals to test differences 
between different donor groups. All P values were two-tailed and modified for multiple 
comparisons according to the Holm-Bonferroni correction. Receiver-Operator 
Characteristic (ROC) curve, was used to determine the cut off point of positivity and 
negativity in ICS assay based on the trade-off between the high sensitivity and high 
specificity.  
6.5 Results 
6.5.1 Testing the study cohort for VZV status 
To address the aim of monitoring VZV-specific B cell changes, all serum samples from 
patient groups were sent to the Department of Clinical Microbiology, Aintree Hospital 
Foundation NHS Trust for VZV IgG determination where 1 ml of serum/plasma was 
examined by ELISA using a Diamedix Immunosimplicity (Is)-VZV IgG test kit (IVAX 
Diagnostics, Inc., Miami, FL). Index values were recorded to represent a quantitative 
measure of VZV IgG antibody levels, with a level of less than 16 EU/ml indicating no 
immunity, level 16-19 EU/ml considered as equivocal and ≥20 signifying immunity to 
varicella.  Regarding the healthy adult control group, 45 consenting volunteers were 
recruited to donate 20 ml of blood. After separating the PBMC buffy layer, plasma was 
used for quantitative VZV IgG ELISA using a Diamedix Immunosimplicity (Is)-VZV 
IgG test system (Cat. No.  720-380; 96 tests). An illustrative example of the ELISA test 
from healthy donors is shown in Figure 6.1, for more details see section 2.3.1.3. 
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Figure 6.1: An illustrative example of a VZV specific IgG ELISA test  
The picture is of the 96-well ELISA microplate that was used to detect VZV-specific IgG 
antibody. Each sample was replicated in two adjacent wells and the average of absorbance 
reading from both wells was calculated. The Table presents results of ELISA and the 
numbers indicate the concentration of VZV-specific IgG antibody as EU/ml calculated by 
the formula below the table. The conclusion for the VZV immunity is colour coded, see the 
table legend for each colour code. 
1 2 3 4 5 6 7 8 9 10 11 12
A 1.504 2.012 0.061 0.059 1.187 1.383 0.06 0.059 0.063 0.068 0.918 1.004
B 1.771 1.708 1.21 1.268 0.054 0.065 0.071 0.066 0.325 0.378 1.641 1.665
C 1.517 1.426 1.105 1.3 1.534 1.407 0.053 0.052 0.982 0.87 1.16 1.213
D 1.193 1.152 1.365 1.29 0.07 0.075 0.054 0.053 0.294 0.42 0.706 0.707
E 0.831 0.844 1.614 1.56 1.516 1.476 1.184 1.274 0.055 0.055 1.574 1.402
F 0.531 0.556 1.097 1.216 1.076 1.176 0.056 0.059 1.39 1.379 0.051 0.057
G 0.333 0.325 1.479 1.473 0.051 1.027 0.131 0.135 1.824 1.607 0.056 0.059
H 0.245 0.229 0.056 0.058 0.71 0.67 1.452 1.5 1.53 1.439 0.966 0.91
1 2 3 4 5 6 7 8 9 10 11 12
A 1.504 2.012 3.05 2.95 59.35 69.15 3 2.95 3.15 3.4 45.9 50.2
B 1.771 1.708 60.5 63.4 2.7 3.25 3.55 3.3 16.25 18.9 82.05 83.25
C 1.517 1.426 55.25 65 76.7 70.35 2.65 2.6 49.1 43.5 58 60.65
D 1.193 1.152 68.25 64.5 3.5 3.75 2.7 2.65 14.7 21 35.3 35.35
E 0.831 0.844 80.7 78 75.8 73.8 59.2 63.7 2.75 2.75 78.7 70.1
F 0.531 0.556 54.85 60.8 53.8 58.8 2.8 2.95 69.5 68.95 2.55 2.85
G 0.333 0.325 73.95 73.65 2.55 51.35 6.55 6.75 91.2 80.35 2.8 2.95
H 0.245 0.229 2.8 2.9 35.5 33.5 72.6 75 76.5 71.95 48.3 45.5
calicula9on<<
(EU/ml<ofcalibrator</<absorbance<of<calibrator)<X<absorbanceof<sample=<EU/ml<of<sample<
<
<
EU/ml<
<16.0<<<<<<<<<<<=5Nega:ve5for5an:@HSV1&25IgG5
<
<16.0K19.0<=5Equivocal55for5an:@HSV1&25IgG5
<
<20.0<<<<<<<<<<<=P5osi:v5for5an:@HSV1&25IgG5
<
Blank 
Negative control 
Positive control 
Positive sample 
Calibrator 
Negative sample 
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(100µl of Sample Diluent). This followed by Incubate at room temperature (18-30°C) for 
30 minute. After discarding contents of the wells they were washed 3 times with Wash 
Solution. Next 100µl of Conjugate was added to each well and plate was incubating at 
room temperature (18-30°C) for 30 minutes. Followed by wash step as in above. 
Subsequently 100µl of Substrate Solution was added to each well and incubate at room 
temperature for 30 minutes. Finally 100µl Stop Solution was added to each well and the 
absorbances was read at 450/600-630 nm. The results was presented as EU/ml (ELISA 
Units/ml) which can be calculated using the following formula: 
 
Results can be interpreted according to the following values 
Table 2-3; Interpretation for VZV –ELISA value  
EU/ml                   Interpretation 
<15.0 EU/ml Nonreactive (Negative) for anti-VZV IgG: 
Presumed non-immune to VZV 
15.0-19.9 EU/ml Equivocal 
No conclusion on the immunity of VZV ≧20.0 EU/ml Reactive (Positive) for anti-VZV IgG: 
Presumed immune to VZV 
 
 
 
 
 
EU/ml of sample =
EU/ml of Calibrator
Absorbance of Calibrator
X Absorbance of sample
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6.5.2 Choosing the appropriate VZV- antigen for optimal T cell response    
Based on the literature so far, most of the work on VZV T cell responses, particularly 
CD4+ T cell responses, were based on Limiting Dilution Responder Cell Frequency 
assay (RCF assay) (Asano et al., 1993). Different antigens from different companies 
such as East Coast Biologics and ABI Company were used for this purpose (Klein et al., 
2006, Jones et al., 2007). However, there is insufficient data concerning using these 
antigens in short term stimulation assays such as ICS assay. Therefore, the initial step 
was to investigate the competence of these antigens to generate an adequate T cell 
response that can be measured by assays developed in this project.  
Briefly, 20ml of blood was taken from six consented adult volunteers. Four of them 
were VZV seropositive (having detectable levels of anti-VZV IgG antibody by ELISA) 
while the other two were seronegative. The immune responses were measured by 
detecting an increase in intracellular cytokines (IFNγ and TNFα) by flow cytometry. In 
addition to East Coast Biologics and ABI companies reagents another two different 
vaccine antigens from Varivax (Merck, NJ, USA) and Varilrix (GlaxoSmithKline, 
Rixensart, Belgium) were also tested in the current study. The efficiency of these 
antigens to serve as a good stimulator was determined by achieving a significant 
detectable responder T cell population. For details, see chapter 2, section 2.4.3.  
The result of this experiment demonstrates that these different antigens can specifically 
trigger VZV-specific T cell responses, however, there was very mild non-significant 
difference in term of frequency of T cell response. This was true even when a mixture of 
all antigens was used to stimulate PBMC. Indeed, using one of the vaccines would be 
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more cost effective. Therefore, Varilrix vaccine (V.R) vaccine was used for rest of all 
experiments.  
Since the full activation of T cells necessitate two signals (Signal 1 is through the TCR-
MHC-peptide interaction and signal 2 is through the CD28:CD80/CD86 interaction), the 
requirement for T cell co-stimulation was also tested. Here anti-CD28 and anti-CD49d 
was added to each tube at the beginning of the incubation, the flow cytometric analysis 
showing that the T cell response against V.R vaccine could be enhanced by using of 
these co-stimulators. Therefore, in all subsequent assays these antibodies were integrated 
to detect the maximum possible response.  A representative example of T cell response 
using V.R vaccine in adults is shown in Figure 6.2. 
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Figure 6.2: T cell responses in healthy donors to Varilrix vaccine   
 Flow cytometry plots showing T cell responses against Varilrix (VR) vaccine in PBMC of two 
VZV-seropositive healthy donors (HD078 & HD0173). Values shown in right upper quadrants 
indicate frequencies of the T cell subset producing cytokine (IFNγ) out of total lymphocytes. In 
both donors there was a stronger CD4 T cell response. 
Mock stimulated VZV stimulated
CD4
CD8 
IFNγ
T cell
HD078
Mock stimulated VZV stimulated
CD4
CD8 
IFNγ
T cell
HD173
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6.5.3 Differentiation between positive and negative T cell responses to VZV 
antigen    
Similar to most laboratory tests reliant on visualization, one of the disadvantages of flow 
cytometry is the lack of a clear-cut discriminant value that distinguishes between 
positivity and negativity. This is particularly important when the difference is very small. 
To avoid possible subjective error in interpretation of results, besides the VZV-
stimulated tube, a mock-stimulated tube was also used with each patient test. 
Furthermore, aiming to define clear parameters for positivity and negativity, the index of 
the increase in the frequency of cytokine producing cell was measured. This includes 
calculating any increase in the ratio of VZV-specific T cells in VZV-stimulated and 
Mock-stimulated tube using the formula below.  
 
 The interpretation of results was that any donor with VZV T cell immunity that 
exceeded a certain threshold was considered VZV-immunized. The threshold level was 
estimated using a receiver-operator characteristic (ROC) curve, see Figure 6.3. Basically, 
this test helps to visualize and understand the trade-off between the high sensitivity and 
high specificity. For instance, in this project, the response of CD4+ T cells to VZV was 
considered genuine if the frequency of responding cells in VZV-stimulated was higher 
than the response in the mock tube by at least 77%. This threshold was selected based on 
the best combination of sensitivity of 85% (95% CI=66.27% to 95.81%) and specificity 
A= cytokine+ T cell % of total lymphocyte in VZV-stimulated tube
B=cytokine+ T cell % of total lymphocyte in Mock-stimulated tube
A
B
X 100 VZV T cell immunity = if  the result ≥ the selected threshold  
indicates positive immunity
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of 72.73 % (95% CI=66.27% to 95.81%) with likelihood ratio of 3.12. A similar 
approach was carried out to calculate the threshold for VZV-specific CD8+ T cells, 
which was an increment of 30% at sensitivity of 75% (95% CI=53.29% to 90.23%) and 
specificity of 60 % (95% CI=24.24% to 87.84%) with likelihood ratio of 1.88. 
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Figure 6.3: ROC-curve for VZV-specific T cell response in healthy donors. 
Shows a representative example of how to the select the optimal threshold to differentiate 
between true responses and background based on sensitivity and specificity. ROC-curves 
(A) for both CD4 and CD8+ T cells were created by plotting the ratio of increase in VZV-
specific T cell in VZV-seronegative and VZV-seropositive healthy donors. Graph (B) 
shows comparison between VZV-seropositive and seronegative group regarding the 
increment in the ratio of CD4 and CD8 VZV-specific T cell (right and left graph 
respectively). Columns and error bars indicate median with interquartile range respectively.  
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6.5.4 T cell response to VZV antigens in children with acute lymphocytic 
leukaemia 
After optimizing the VZV-ICS assay in healthy controls, the next challenge was to 
investigate if the same assay would work in leukaemic children who were on 
chemotherapy including high doses of immunosuppressive drug such as 
prednisolone.  
Since most patients were suffering from lymphopenia, besides the limited volume of 
blood sample that was permitted to be taken (8-12 ml/time-point), it was mandatory 
to downscale the PBMC number used per tube. Therefore, instead of the usual 
number of 0.5-1×106 PBMC per test only 0.1-0.3 ×106 PBMC per tube was used. 
Indeed, this necessitated downscaling of all other reagents including the quantity of 
VZV antigen, co-stimulator, and Brefeldin-A to optimal concentrations. Besides the 
low number of PBMC there was another issue, which is the effect of chemotherapy 
on the cell viability. Therefore, the goal was to process the samples as quickly as 
possible after they had been collected.  
 Examples of T cell responses to Mock, VZV antigen, and OKT3 in leukaemic 
children are shown in Figure 6.4. CD4+ T cells and to less extent CD8+ T cells 
showed an increase in production of IFNγ and TNFα after stimulation with V.R 
vaccine and after stimulation with OKT3 as positive control compared to the mock 
tube (negative control). 
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Figure 6.4: Illustrative example of T cell response to different antigens in ALL children. 
This illustrates the CD4+ T cell response (upper two rows of plots) and the CD8+ T cell 
response (lower two rows of plots) by measuring levels of intracellular cytokine (IFNγ and 
TNFα) in response to different stimuli including; Mock, VZV antigen, and OKT3. Numbers 
inside the quadrants indicate the frequency of different lymphocyte subsets as % of total 
lymphocytes. 
CD8
IFNγ
CD8
TNFα
CD4
IFNγ
CD4
TNFα
Mock VZV OKT3
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6.5.5 Both VZV-specific CD4+ and CD8+ T cell responses can be detected 
in healthy individuals by CFSE proliferation assay 
Taking into consideration that T cell response to antigen is not only restricted to 
effector function but also includes the ability to proliferate or to induce proliferation 
in other cell subsets, the aim here was to investigate the ability of VZV-specific 
CD4+ and CD8+ T cells to proliferate in response to VZV antigen (V.R vaccine) 
utilizing a CFSE proliferation assay. PBMC from healthy control donors with good 
ICS assay response were used for standardizing this assay. Briefly, after isolation of 
PBMC in the standard way the PBMC: media concentration was corrected to 1×106 
PBMC/ml then CFSE stain was added at appropriate concentration. This was 
followed by incubation with different antigens including; PBS (as Mock), V.R 
vaccine, CMV lysate, influenza vaccine, and OKT3 (as positive control). For more 
details about this technique, see section 2.4.4. 
A representative example is shown in Figure 6.5. It demonstrates that VZV specific 
CD4+ T cells and to a lesser degree CD8+ T cells can proliferate in response to 
VZV antigen. The level of proliferation was similar to that induced by influenza 
vaccine. However compared to the CMV and OKT3 response it was much weaker.  
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Figure 6.5 A representative example of CD4+ and CD8+ T cell proliferation response in a 
healthy donor.  
PBMC dot plots show the proliferation of CD4+ T cells (left column of plots) and CD8+ T 
cell (right column of plots) in the same healthy donor. Different antigens were used 
including; mock, V.R vaccine, CMV lysate, influenza and OKT3. The frequency of each 
cell subset is shown inside of each dot plot quadrant.  
CD8
CFSE
CD4
CFSE
Okt3
Influenza 
vaccine
CMV
lysate
Mock
VZV
vaccine
OKT3
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6.5.6 Implementation of proliferation assay in leukaemic children 
  
Since as mentioned above regarding viability and the low number of lymphocytes in 
patients samples, it was predicted that establishment of the proliferation assay in 
leukaemic children would not be an easy task. Therefore, the first step toward 
achieving this aim was optimising this assay to work with few numbers of cells in 
healthy control adults. The goal was to start with as low a number of PBMC as 
possible. Hence, downscaling of initial PBMC count from 1-2 x 106/ ml and V.R 
vaccine concentration of 10µl per culture well (2 ml final volume) into 0.1-0.2x106/ 
ml and V.R vaccine concentration into 1µl per culture well (0.5ml final volume) 
was carried out. Results of this experiment are demonstrated in Figure 6.6.  Here, T 
cell proliferation was achievable even with the use of 0.2x106/ ml PBMC and 1µl 
V.R vaccine per culture well (0.5ml final volume). 
Despite the achievement in downscaling of the proliferation assay to be applicable 
to low lymphocyte numbers, applying this assay in leukaemic patients was 
successful only in a few instances. The high nonspecific background in mock tubes 
led to difficulty in interpretation of results. One example of the few relatively 
successful experiments is shown in Figure 6.7. 
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Figure 6.6: Downscaling of T cell proliferation assay   
Panel of plots are the proliferation assay of CD4+ and CD8+ T cell responses to VZV 
vaccine in healthy donors. Initial PBMC count, V.R vaccine concentration and the final 
volume per each culture well used for each panel are shown in the table below.  
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Figure 6.6: Downscaling of T cell proliferation assay   
Panel of plots are the proliferation assay of CD4+ and CD8+ T cell responses to VZV 
vaccine in healthy donors. Initial PBMC count, V.R vaccine concentration and the final 
volume per each culture well used for each panel are shown in the table below.  
 
 
Panel of 
plots  
Initial PBMC count     
per ml 
VZV antigen (V.R vaccine) 
concentration µl/ml 
Final volume /well 
A 1x106 10 1 
B 0.5x106 5 0.5 
C 0.2 1 0.5 
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Figure 6.7: An example of a proliferation assay in leukaemic children. 
Plots and accompanying histograms are an illustration of mock (left column) and VZV-specific 
(right column) CD8 and CD4 T cell proliferation assays (upper and lower panel of plots 
respectively) in a leukaemic patient (ALL036). The Table is a summary of some statistical 
values generated from the histograms. Proliferation Index: indicates the total number of 
divisions divided by the number of cells that went into division; % Divided denotes The 
percentage of cells from the original sample, which have divided, and Replication Index means 
the average number of cell divisions that a cell in the original population has undergone and is 
equal to (Proliferation Index) X (% Divided). 
 
Unstimulated VZV antigen
CD4
CFSE
CD8
Donor/ALL36 CD4 T cells CD8 T cells
Antigen Mock VZV Mock VZV
Proliferation Index 1 1.08 1 1.32
%Divided 8.75 7.68 14.4 24
Replication  Index 1.09 1.09 1.14 1.52
Significant difference in 
T cell response NO YES
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6.5.7 History of chickenpox might infer the VZV T cell immune status 
In normal situations a history of previous VZV infection is usually associated with long-
lived B and T cell protection; whether this association is also true in context of 
leukaemia is not well known. To address that, the association between the histories of 
VZV in leukaemic children was compared to both the ELISA results (as indicator of B 
cell function) and ICS assay results (as indicator of T cell function). See Tables 6-2 and 
6-3. Fisher’s exact test confirms the presence of an association between history and 
serology of VZV p<0.0001. However, the association between history of VZV infection 
and T cell immunity was less significant.  
Table 6-2: Association between VZV infection history and B cell immunity 
 
Table 6-3: Association between VZV infection history and T cell immunity 
 
Association between previous 
history of VZV and VZV-
ELISA results
VZV-ELISA
VZV-positive VZV-Negative  Equivocal
History of 
VZV infection
in 70 patients
Positive= 41 30 7 4
Negative= 29 3 21 5
Total 33 28 9
Comments 
Fisher's exact test P<0.0001 
Sensitivity= 90%  
Specificity =75%
Association between previous 
history of VZV and VZV-
specific T cell response
VZV-specific T cell response 
VZV-positive VZV-Negative  Equivocal
History of 
VZV infection
in 70 patients
Positive= 41 24 17 0
Negative= 29 7 20 2
Total 31 37 2
Comments 
Fisher's exact test P=0.0125
Sensitivity= 77%  
Specificity =54%
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6.5.8 Change in the CD4:CD8 T cell ratio in leukaemic children. 
In the current study, basic lymphocyte counting showed that most leukaemic 
children had lymphopenia (median with upper and lower interquartile = 0.6 (0.4-
0.9) x106/ml of blood. This level of lymphocyte numbers is substantially low 
compared to both the normal range in healthy children (age group of 1-18yr) of 3.1 
(2.3-3.15) x106/ml and to healthy adult controls (current study) of 2.0 (1.6-2.5) x106.  
Considering that, it was not clear whether this reduction in the total lymphocyte 
count was affecting the whole T cell population, whether it was associated with 
proportionate reduction in different T cell subsets or a decrease in only one T cell 
subset more than the other. To investigate this, both frequency and absolute 
numbers of CD4+ and CD8+ T cell were measured by flow cytometry and then the 
CD4:CD8 T cell ratio was calculated.  Figure 6.8 illustrates steps to identify CD4+ 
and CD8+ T cells in healthy adults and leukaemic patients. Meanwhile Figure 6.9 
displays the percentage and ratio of these subsets in patient groups comparing both 
healthy adult controls and healthy children (reference range obtained from previous 
study (Schatorje et al., 2012)). 
Interestingly there was a significant difference (P < 0.0001) in the CD4:CD8 T cell 
ratio in leukaemic children compared to healthy control adults of current study, 
which also seems to be present even when compared to healthy children Figure 6.9.  
However, it is not clear if this difference is attributable to the expansion in CD8+ T 
cells or reduction of the CD4+ T cell population. 
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Figure 6.8: Identifying frequencies of CD4 and CD8+ T cells 
This demonstrates an illustrative example of CD4 T cell and CD8 T cell frequency in a healthy 
control (HD 078) and leukemic children (ALL 23 and ALL30). Firstly, an original gate was 
drawn around the lymphocyte population on the FSC and SSC plot followed by sub-gating on 
CD4+ and CD8+ populations to identify CD4 T cell and CD8 T cell frequencies in the original 
gate.  
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Figure 6.9: Comparison between distributions of total CD4+ and CD8+ T cell in healthy 
controls and leukaemic children. 
Pie charts demonstrate the percentage of CD4+ and CD8+ T cells in peripheral blood of leukaemic 
children, healthy adult controls and healthy children. The Table summarises the differences in the 
absolute lymphocyte counts, as well as differences in the frequencies and CD4:CD8 T cell ratios.  
Values denote the median with upper and lower quartiles. P values were calculated using the 
Mann-Whitney test with 95% confidence intervals.  
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6.5.9 Significant reduction in the absolute numbers of CD4+ and CD8+ T 
cells in leukaemic children.  
The change of CD4:CD8 T cell ratio in association with lymphopenia might suggest that 
there was a disproportionate reduction in CD4+ and CD8+ T cells. However, it is not 
clear, if this difference could be attributed to expansion in CD8+ T cells after reduction 
of the CD4+ T cell population or as a consequence of reduction in both populations that 
was more profound in CD4+ T cells. To answer this a comparison between absolute 
numbers of CD4+ and CD8+ T cells in leukaemic children and healthy control was 
carried out (Figure 6.10). 
Although, apparently there was a high frequency of CD8+ T cells in patient samples, the 
comparison of absolute numbers showed that both CD4+ and CD8+ T cells were 
significantly less in leukaemic patients. This might support the proposal that there was 
unbalanced CD4+ and CD8+ T cell populations reduction that probably affected CD4+ 
T cells more than CD8+ T cell populations. 
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Figure 6.10: Comparing frequency and absolute CD4+ and CD8+ T cell numbers in 
leukaemic children and healthy adult controls. 
The graph displays differences in the frequencies (A) and absolute counts (B) of T cell 
populations in healthy adult controls (CD4 and CD8; yellow and red spots respectively) and 
leukaemic children (CD4 and CD8; blue and green squares respectively). (ns= not significant, *= 
p<0.05, **= p<0.001, and ***= p<0.0001). 
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6.5.10 VZV-specific T cell distribution is comparable in healthy controls and 
leukaemic children. 
Having observed the disproportionate shrinking of the total T cell population this led to 
another question about whether VZV-specific T cells follow the same pattern of 
distribution as the total T cells or not. To answer this question the frequencies of VZV-
specific CD4+ and CD8+ T cells were identified and the ratio between them was 
calculated in VZV seropositive patients and control groups. Here flow cytometry and ICS 
assays were utilised to measure the response of T cells to VZV antigen by detecting any 
increase in intracellular cytokine. Note, here both anti-IFNγ and anti-TNFα monoclonal 
antibodies were conjugated to the same flurochrome, hence, any increase in either of these 
cytokines will indicate VZV specificity. 
Interestingly, opposite to expectation, the frequency of VZV-specific CD4+ and CD8+ T 
cell in leukaemic children (median; 0.42 and 0.16 respectively) was very similar to that 
median of frequency of VZV-specific CD4+ and CD8+ T cell seen in healthy adult 
controls (0.53 and 0.22 respectively). Furthermore, there was no significant difference in 
the CD4:CD8 ratio between both groups (p>0.05). See Pie charts and integrated table in 
Figure 6.11.   
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Figure 6.11: Comparison between healthy controls and leukaemic children VZV-specific T 
cell distribution. 
Pie charts show the percentage of VZV-specific CD4 and CD8+ T cells out of total lymphocytes 
in both leukaemic and control groups.  The Table summarises the comparison between the two 
groups. Values denote the median with upper and lower quartiles. P values were calculated using 
the Mann-Whitney test with 95% confidence intervals.  
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6.5.11 VZV-specific T cell response in healthy and patient groups has a 
different cytokine profile.  
 
Although there was a similarity in the frequency of VZV-specific T cells between 
patient and control groups, the subcategorizing of these cells according to type of 
cytokine profile against VZV antigen revealed various differences. This time each 
cytokine (IFNγ and TNFα) was stained with a different flurochrome. Accordingly, the 
VZV-specific T cell population was sub-classified into four subsets that include: 
IFNγ+/CD4, TNFα+/CD4, IFNγ+/CD8, and TNFα+/CD8 VZV-specific T cells.  
The VZV T cell response in healthy populations is characterized by dominance of 
IFNγ+/CD4+ T cells, which comprise approximately two thirds of responding T cells 
see Figure 6.12(A). In contrast, the chief population in the patient group was 
TNFα+CD4+ T cells (47% of responding T cells). Meanwhile, the VZV-specific CD8+ 
T cell population in both the control and the patient groups consisted of slightly larger 
TNFα+CD8+ T cell populations.  
Since the difference in the frequency of VZV-specific T cells does not necessarily 
indicate a difference in the absolute numbers of VZV-specific cells, a comparison in the 
absolute count of these subsets per microlitre of blood between the patient group and 
healthy adult control group was carried out (Figure 6.12,B).   The only significant 
difference was between IFNγ+/CD4 T cell populations, which were remarkably low in 
the patient group (median, interquartile; 0.2, 0.1-0.6) per 1µ of blood compared to the 
healthy control group (median, interquartile; 0.79, 0.3-1.4). 
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Figure 6.12: Difference in cytokine profile of VZV specific CD4 and CD8+ T cells in 
healthy adult controls and leukaemic children. 
Pie charts (A) demonstrate the percentage of contribution of each subset of the VZV specific T 
cell response in healthy control and leukaemic children (ALL). Each colour denotes a different 
subset of cells: blue =IFNγ+/CD4, green =TNFα+/CD4,  yellow =IFNγ+/CD8, and  red 
=TNFα+/CD8  VZV specific cells. The graph (B) shows the differences in the absolute counts of 
these subsets per 1µl of blood in healthy controls and patients (ALL). The top of each column 
indicates the median with error bars showing the interquartile range; ns= not significant, *= 
p<0.05, **= p<0.001, and ***= p<0.0001). 
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6.5.12 Sub-classification of leukaemic children according to VZV clinical 
infection.   
 
Having observed the difference in the cytokine profile between healthy control and 
patient groups, and taking into consideration that not all leukaemic children experienced 
VZV infection, it was reasonable to ask if there were differences in the quality of T cell 
response to VZV within the patient group. In other words, is there any specific T cell 
profile that might play a role in protection against or susceptibility to a new VZV 
infection or reactivation? Note, the quality of T cell response here is referred to the 
frequency of the responding cells as well as their cytokine profile.  
To answer this question, firstly the patient groups were classified according to the 
history of pre-leukemic VZV infection into two groups: patients with positive history 
(n=41 patients) and those with negative history (n=29). Postulating that the positive 
history group are VZV immunized (see section 6.5.7), they were subdivided into three 
subgroups; this included (Group A) which includes leukaemic children who had no 
clinical VZV infection during the chemotherapy and their ELISA were negative for 
VZV antibodies, they are only 5 patients. Group B involved leukaemic children who had 
no clinical VZV infection during the chemotherapy but their ELISA were positive for 
VZV antibody (23 patients). Finally, Group C comprised children who experienced 
clinical VZV infection regardless of the serology (13 patients).  
Since the aim was to compare the T cell profile in relatively VZV protected leukaemic 
children to that of susceptible leukaemic children, each group was selected according 
certain criteria.  For instance, in the ‘no clinical VZV infection’ groups (group A and B), 
only those patients who achieved advanced chemotherapy maintenance cycles, such as 
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cycle 8, 10, or EOT (End Of Therapy) with no VZV infection were included. Meanwhile, 
group C includes any patient who had chickenpox or herpes zoster regardless of the 
stage of the treatment. However, for group C only the sample preceding an episode of 
clinical VZV infection was considered.  For instance, if a patient developed VZV 
between maintenance cycles 2 and 4, the T cell profile during cycle 2 would be 
considered for this comparison. Meanwhile, the sample taken during acute infection and 
the cycle 4 sample (post infection) would not be included for this purpose. 
The basic initial comparison was to compare the absolute counts of lymphocytes, 
total CD4 T cells, and total CD8 T cells. In addition, the difference in CD4:CD8 T cell 
ratio between groups was determined. These are summarised in Table 6-4. 
Table 6-4: Classification of leukaemic children with positive history of VZV infection into 
three subgroups 
 
 
Leukaemic children Group A Group B Group C
 Statistical Differences 
between 
Group C and 
History of pre-leukaemia 
VZV infection
Yes Yes No / Yes
clinical chickenpox 
or herpes zoster during  
chemotherapy
No No Yes
 Group A Group B
ELISA for VZV 
antibody negative positive negative or positive
Absolute total 
lymphocyte count 
 per µl of blood
590
(500-970)
450
(300-690)
900
(490-1740)
p>0.05 p<0.05
Absolute CD4 T cell 
count 
 per µl of blood
280
(205-351)
141.6
(69.8-264.3)
205.8
(151-633) p>0.05 p>0.05
Absolute CD8 T cell 
count 
 per µl of blood
 200
(121-319)
101.6
(48.82-188)
200
(93-489)
p>0.05 p>0.05
CD4:CD8 ratio 1.2
(0.71-0.32)
1.59
(1.04-2.04)
1.29
(0.90-1.8)
p>0.05 p>0.05
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6.5.13  Decrease in the frequency of VZV-specific CD4+ T cells in VZV 
clinically diagnosed group (group C) 
Considering that no statistical difference, neither in frequencies nor in the ratio of total 
CD4+ and CD8+ T cells between patient subgroups was observed, the next step was to 
compare the VZV-specific T cell profiles of these patient subgroups. This involved 
investigating the difference in CD4:CD8 T cell ratio of the VZV-specific population, as 
well as the difference in cytokine profiles between these subgroups.  
 The most interesting finding was the inverted ratio of VZV-specific CD4:CD8 T cell in 
leukaemic children with clinical VZV infection (Group C). For instance, this ratio was 
0.72 in group C compared to 2.12 and 1.2 in group A and B respectively, see Figure 6.13 
(I).  Furthermore, in contrast to the dominance of TNFα producing CD4+ T cells in 
group A and B, approximately one third of VZV-specific T cells in group C was 
attributed to CD8+ T cells that mainly produce IFNγ, see Figure 6.13 (II). 
In addition to the difference in VZV-specific T cell profile there were also differences in 
the absolute numbers. For instance, comparison between group C on one hand and 
groups A and B on the other hand showed a remarkably low absolute count of VZV-
specific IFNγ+ CD4+ T cells in group C (median, interquartile; 0.12, 0.06-0.26/ µl 
blood). This difference was only statistically significant when group C was compared to 
group A (p<0.05), see Figure 6.13(III).  
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Figure 6.13: VZV-specific T cell profile in subgroups of leukaemic children 
This compares T cell response to VZV antigen in leukaemic children subgroups, where Group A 
and B denote patient with no clinical infection and VZV-ELISA was negative and positive 
respectively. Group C includes patients with clinical infection. Pie charts (I) show the frequency 
of VZV-specific CD4 and CD8+ T cells in these groups. Meanwhile, Pie charts (II) demonstrate 
the cytokine profile of each group. The graph (III) compares the absolute count of each T cell 
subset in these subgroups. Note, ns= not significant, *= p<0.05, **= p<0.001, and ***= 
p<0.0001. 
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6.5.14 Monitoring of the loss of VZV-specific B and T cell immunity in 
leukaemic children. 
Since the main goal of the current study was to identify a reliable immune risk profile 
that can predict leukaemic children who might be at higher risk of VZV new infection 
and/or reactivation, therefore, loss of either humoral and /or cellular immunity preceding 
VZV infection was proposed.  Thus, the dynamic change in the VZV-specific T cell 
response and VZV-specific IgG antibody titre were measured. Table 6-5 below 
summarizes changes in the VZV immune status according to both assays. 
Table 6-5: Summary of VZV-immune status of leukaemic children. 
 
*Note, ‘inconclusive’ includes both equivocal results and results if only a single time point 
per patient was tested.  
 
Throughout the follow up of the cohort population, thirteen patients had clinical VZV 
infection and only four of them suffered from clinically diagnosed herpes zoster. 
Furthermore, approximately half of them have no history of VZV infection prior to 
leukaemia, which might suggests a primary infection.  
 
VZV-Immunity Acquired (Negative ➡ Positive)
Lost
(Positive ➡ Negative)
No change
Inconclusive
(Negative ➡ Negative) (Positive ➡ Positive)
 T cell
(ICS assay) 11 8 22 15 18
B cell
(ELISA) 6 4 15 25 24
Both T and B 
cell 2 2 10 8 52
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6.5.15 Inversion in the VZV specific CD4:CD8 ratio might be a warning sign 
preceding appearance of clinical VZV.  
 
Here, dynamic changes in VZV-specific B and T cell immunity in three different 
patients who experienced clinical VZV infection during chemotherapy course are 
presented. The first patient (ALL09) is an example of VZV primary infection 
(chickenpox), meanwhile, ALL23 and ALL24 are representative examples of 
reactivation (herpes zoster). See Figure 6.14.   
Starting with ALL09, who is a male of 3yrs old with no history of VZV and was 
seronegative, he developed chickenpox two weeks after cycle 10. It was speculated that 
the actual viral infection and changes in the immune system might have started just 
around cycle 10. Herein, despite the lymphopenia (0.63X106/ml of blood) the level of 
VZV-specific T cells became detectable with a remarkable increase in the frequency of 
IFNγ+/CD8+ T cells. Nevertheless, there was no similar increase in the count of 
IFNγ+/CD4+ T cells, which possibly led to inversion of the CD4:CD8 T cell ratio. As 
predicted the VZV-specific IgG antibody titre was low at cycle 10 and surged up just 
around the time of appearance of clinical VZV.  
 The scenario in patient ALL23 was slightly different, as he initially had a primary 
infection and then reactivation while he was under chemotherapy. The first infection was 
between cycle 6 and 8, seemingly a primary infection as the patient had no prior history 
of chickenpox and his VZV-ELISA was negative. The second infection occurred near 
the end of therapy and clinically it affected multi-dermatomes, which perhaps supports 
the possibility of reactivation of latent virus. Since the period between cycle 6 and 
primary infection was more than 4 months then the immune profile at cycle 6 might not 
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be correlated to the primary infection. In contrast, only 4 weeks were separating cycle 10 
from the second infection, therefore, the changes in immune profile might be related to 
VZV reactivation.  
In cycle 8, which was three weeks after the primary infection there was a remarkable 
increase in the count of TNFα+/CD4 and TNFα+/CD8+ T cells. In contrast the counts of 
IFNγ+/CD4 and IFNγ+/CD8+ T cells during cycle 8 were very similar to their counts 
during the primary infection. However, for both IFNγ and TNFα producing T cells the 
CD4:CD8 ratio of VZV specific T cell was maintained above 2.0.  
In cycle 10, with the exception of TNFα+/CD4+ T cells that dropped from their previous 
spike, there were increases in the counts of all other VZV-specific T cells. However, 
there was a remarkable change in the CD4:CD8 ratio of these cells. 
Interestingly, in contrast to the T cell response, the anti-VZV IgG antibody titre steadily 
increased throughout the course of therapy and even before the appearance of the second 
infection. 
Lastly, patient ALL24, who had a history of chickenpox before he developed leukaemia, 
was also VZV seropositive at beginning of the study. Between cycle 2 and 4 he 
developed herpes zoster. Similar to ALL23 there was inversion in the ratio of both 
TNFα+/CD4: TNFα+/CD8 and IFNγ+/CD4: IFNγ+/CD8 VZV-specific T cells in the 
sample preceding the appearance of infection.  
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Figure 6.14: Changes in the level of VZV-specific T cell and anti VZV antibody titre in 
leukaemic children. 
This demonstrates the dynamic variations in different subsets of VZV-specific T cell compared 
to changes in anti VZV IgG antibody titre during different cycles of chemotherapy (X axis) in 
three leukaemic patients.  Left column of graphs shows the change in the absolute count of these 
cells (y axis). Meanwhile, the right column of graphs display changes in the VZV-specific 
CD4:CD8 ratio according to IFNγ or TNFα secretion. 
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6.6 Discussion  
The aim of this project was to find out the reasons behind the high incidence of VZV 
new infection and reactivation in leukaemic children under chemotherapy.  Since the 
prevention of new infection and/or control of latent virus needs integration of different 
arms of the immune system, loss of VZV-specific B cell humoral immunity and/or T cell 
mediated immunity was hypothesised as a reason for this susceptibility. Furthermore, 
identification of an immune risk profile that can help in predicting leukaemic children 
who might be at high risk of VZV would be of great benefit.  Therefore, anti-VZV IgG 
antibody titre (as indicator of B cell immunity) and VZV-specific T cell absolute count/ 
frequency and cytokine profile were monitored throughout this study.  
In the current project more focus was given to T cell immunity including frequency, 
absolute count, and ratio of VZV-specific CD4+ and CD8+ T cell as well as their 
cytokine profile. This was based on several clinical observations that proposed T cells  
are more important than humoral immunity in recovery from VZV acute infection 
(Arvin, 2000, Schmader, 2001, Baiker et al., 2010). Furthermore, the importance of 
helper CD4 T cells in activation of B cell and antibody class switching is well 
established (Parker, 1993). 
In most previous studies, the determination of VZV-specific T cell mediated immunity 
was usually carried out using proliferation assays (Giller et al., 1986, Haining et al., 
2005), which need several days of in-vitro PBMC incubation with VZV antigen. In the 
current study, applying such assays was impractical as cell viability, which is very 
crucial for such kind of assay, might be severely compromised by the cytotoxic 
chemotherapy. Therefore, an intracellular cytokine staining assay (ICS assay), which is 
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quick ex-vivo with short-term incubation periods, was optimized for present project. In 
addition, several strategies were introduced to improve the cell viability, for instance to 
avoid any toxic effect of drugs blood sampling was scheduled to be taken just before the 
chemotherapy cycle and samples were processed on the day of collection.  
The T cell response in healthy control adults to VZV lysate from two different 
companies (East Coast Biologics and ABI companies) and two live attenuated VZV 
vaccines (Varivax and Varilrix) were tested in the current study. Both VZV-specific 
CD4+ and to a lesser extent CD8+ T cell responses were detectable by both ICS and 
proliferation assays. Nevertheless, implementation of proliferation assays in leukaemic 
children was confounded by both low cell viability and high background proliferation of 
nonspecific cells.  N.b. in the ICS assay the T cell response was considered positive if 
the cytokine production of T cell stimulated by VZV antigen exceeded that of the mock 
response by 77% for CD4+ T cells and 30% for CD8+ T cells. 
The current study confirms that VZV-T cell responses in adult healthy controls and 
leukaemic children were characterised by a predominance of CD4+ T cells which 
represent almost two thirds of the T cell response compared to CD8+ T cells which only 
comprise less than one third.  This was somewhat unexpected as viral clearance relies 
heavily on CD8+ T cell functions, however, an increasing body of evidence has 
highlighted the importance of CD4+ T cells in directly regulating antiviral responses 
through proinflammatory cytokines acting in both a direct and indirect manner (Davis et 
al., 2008). In accordance with these results, previous research demonstrated a similar 
observation (Arvin, 1996, Abendroth et al., 2000, Jones et al., 2006, Haberthur et al., 
2011). In addition, this might be explained by the high ability of VZV to evade CD8+ T 
 286 
cell recognition through down regulation of MHC class I compared to the ability to 
escape CD4+ T cell recognition (Cohen, 1998, Abendroth and Arvin, 2001, Abendroth 
et al., 2010). In addition, there might be an underestimation of CD8+ T cells because 
VZV antigen used in the majority of studies (including present study) is poorly 
presented through MHC class I (Abendroth and Arvin, 2001). Several VZV antigens 
have been identified as targets of CD4+ T cell compared to the partial understanding of 
VZV-specific CD8+ T cell specificity. For instance, CD4+ T cells were found to be able 
to recognize immediate early antigens, such as IE62, IE63, ORF4, and ORF10, and late 
antigens that included gB, gC, gI, gH, and gI surface glycoproteins (Arvin et al., 1986, 
Bergen et al., 1991, Arvin et al., 2002).  
One of the interesting observations of the present study was the change in the total 
CD4:CD8 T cell ratio in leukaemic children, which might be explained by unbalanced 
CD4+ and CD8+ population reduction that probably has more influence on CD4+ than 
CD8+ T cells. Such inversion in the ratio might have its importance as an immune risk 
indicator. This is supported by the fact that inversion in the CD4:CD8 T cell ratio is 
associated with morbidity and mortality in the elderly and considered as an 
immunosenescence indicator (Huppert et al., 2003, Wikby et al., 2005, Cretel et al., 
2011).   
Having seen such changes in the total CD4:CD8 ratio, the anticipation was to discover a 
similar change in the ratio of VZV-specific T cells. Surprisingly, opposite to expectation, 
the frequency of VZV-specific CD4+ and CD8+ T cells in leukaemic children was very 
similar to that seen in the healthy adult controls. Furthermore, there was no significant 
difference in the CD4:CD8 ratio (VZV-specific) between both groups. This finding 
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might suggest that leukaemia affects mainly naïve and effector cells while the pool of 
memory cells, including VZV-specific memory T cells, is preserved. In support of this 
suggestion is the work by Haining and colleagues (Haining et al., 2005) who showed 
that the antigen-specific T-cell memory is preserved in children treated for acute 
lymphoblastic leukemia.  
Considering the relative stability of the VZV IgG titre during leukaemia and having seen 
no difference between healthy controls and leukaemic children regarding the frequency 
of VZV-specific T cells, the question here is, why leukaemic children are not protected 
against VZV, in other words what is the reasons behind the frequent reactivations of 
latent VZV. To answer this question, the cytokine profile of VZV-specific T cells was 
investigated. Taking in consideration that the T cell response to VZV has a TH1 profile 
with little or no production of TH2 cytokines (Watson et al., 1995, Abendroth et al., 
2000, Vossen et al., 2004); the two cytokines that were selected for measuring in this 
project were IFNγ and TNFα.  Surprisingly, the current study demonstrates a significant 
reduction in the absolute numbers of VZV-specific IFNγ+CD4+ T cells, which seemed 
to be replaced by an expansion of TNFα+CD4+ T cells in leukaemic children. This 
finding might be of particular importance as there is evidence that supports a clear link 
between the early production of IFNγ but not TNFα (nor other Th1 cytokines) and the 
nature of the cellular immune response, and disease outcome in a virus model (Chaudhri 
et al., 2004). Indeed this finding raises the possibility that inappropriate cytokine 
responses may be the cause of increased susceptibility to VZV infection in leukaemic 
children. However, since not all leukaemic children experienced VZV infection during 
the chemotherapy course, then it was reasonable to ask if there was any cytokine profile 
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that might be associated with VZV clinical infection. Therefore the patient group was 
sub-classified into three groups including a sub-group that had clinical VZV infection 
(group C) and groups with no clinical VZV infection  (groups A and B), see Table 6-6 
for detailed description of these groups.  
Interestingly, the current study showed remarkably low absolute counts of VZV-specific 
IFNγ+ CD4+ T cells in group C. Furthermore, there was inversion of the ratio of VZV-
specific CD4:CD8+ T cells that produce IFNγ. Based upon that, it seems conceivable to 
propose that both the reduction in the absolute counts of VZV-specific IFNγ+ CD4 T 
cell and/ or inversion of the VZV-specific CD4:CD8 (IFNγ producer) T cell ratio are an 
immune risk profile for VZV infection in leukaemic children.  
However, it was not clear, whether these changes in immune profile preceded clinical 
VZV infection by a sufficient period and thus could be used as predictors for VZV 
reactivation, or that they took place just around the time of clinical appearance of VZV 
and therefore it were not appropriate for this purpose. Since the VZV incubation period 
can be 1 to 3 weeks before appearance of clinical manifestation (Arvin, 2000), that 
might mean actual viral replication might start a few weeks before clinical diagnosis. 
Therefore, it can be speculated that the changes in the immune system, particularly T 
cell immunity, may also precede the clinical manifestation. Nevertheless, according to 
the literature the T cell response is only detectable after the start of the clinical 
symptoms. However, most of these studies used proliferation assays to measure the 
VZV cell-mediated immunity with insufficient data on the ICS assay that is employed in 
this project. However, in the current study, prospective follow up of a couple patients 
who were VZV seropositive and had clinical VZV infection (most likely reactivation), 
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confirmed the proposal that the second infection was typically preceded by a drop in the 
VZV-specific IFNγ+ CD4 T cell absolute count with inversion in the CD4:CD8 ratio of 
VZV-specific T cells that produced IFNγ.    
 
In contrast, the level of anti-VZV IgG antibody titre was high even before reactivation of 
VZV and it showed no correlation with T cell immunity. This might suggest that VZV-
specific cellular immunity is more important than humoral immunity in preventing VZV 
reactivation. This notion was supported by clinical observations, for instance, children 
suffering from acquired immune deficiency syndrome (AIDS) have a significantly 
higher risk of progressive VZV reactivation (Gershon et al., 1997, Adityan et al., 2009), 
in contrast, children with agammaglobulinaemia usually have no increase in the risk of 
VZV infection (Webster et al., 1988). Therefore, it might be inappropriate to rely only 
on VZV-specific IgG antibody titre as an indicator for protection against VZV.  
Furthermore, since the changes in antibody titre do not immediately reflect those in B 
cells, in other words it takes a while for antibody levels to drop even in the absence of 
the secreting B memory cells, this might be another reason for not considering VZV-
specific IgG titre as an indicator of B cell protection in the context of leukaemia.  
Therefore, implementation of other technique such as Fluorescent Antibody To 
Membrane Antigen assay  (FAMA) and Time-Resolved Fluoro Immune Assay (TRFIA) 
assay to determining the VZV-specific B cell immunity (Dickson et al., 1995), are being 
optimized by our collaborator Professor Judy Breuer and her colleagues at University 
College, London. Furthermore, incorporating VZV-specific ELISPOTs in the current 
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study is being considered as well.  
As discussed in previous chapters, the control of CMV carriage is associated with 
marked changes in the immune system. This heavy investment in the response against a 
single virus may compromise T cell repertoire diversity and the ability to respond to 
other pathogens. Therefore, it can be hypothesised that carriage of CMV can be 
detrimental also to the immunocompromised host by suppressing heterologous VZV-
specific immunity. This notion can be supported by earlier observations that showed 
CMV infection could reduce prevailing levels of immunity to another persistent virus 
such as Epstein-Barr virus (EBV) (Khan et al., 2004). Furthermore, in agreement with 
that, in solid organ recipients, CMV replication was found to increase the viral load of 
other viruses, such as hepatitis C virus (HCV) (Razonable et al., 2002). However, in 
context of ALL in children, this might be debatable as the incidence of CMV infection 
in this age group is relatively low in developed countries. Furthermore, the influences of 
CMV on the immune system seem to be related to duration of CMV carriage, in other 
words it is age related with older subjects being more severely affected. Nonetheless, 
investigating the impacts of simultaneous CMV infection upon immunity to other 
pathogens in ALL children is highly recommended. Moreover, another important 
question that might need to be addressed here is; what is the effect of VZV status on 
CMV immunity? This question is based on the conceivable role of HHV-6 and HHV-7 
as copathogens in the direct and indirect illnesses caused by CMV(Razonable and Paya, 
2002). 
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This thesis set out with the aim of understanding the balance between the immune 
system and two common herpesviruses chronic infection, namely CMV and VZV. It was 
designed initially to explore the influence of chronic cytomegalovirus infection on the 
immune system of healthy subjects, particularly T cell immunity. Then, the impact of 
immune modulation by this virus on the sequelae of coincident coronary artery disease 
was investigated. 
Meanwhile, the purpose of the VZV study was to determine the importance of adaptive 
immunity (B or T cell mediated immunity) in protection against VZV reactivation in 
children with acute lymphocytic leukaemia receiving chemotherapy. Besides, it 
evaluated whether the loss of VZV-specific B and/or T cell mediated immunity might be 
utilized as a risk predictor for VZV reactivation in patients who were considered to be 
protected.  
To achieve these aims, four different projects were run simultaneously. However, since 
each project was independent of other, the results of each project were discussed in 
detail separately in its related chapter. Therefore, the purpose of this part of the thesis is 
to draw general conclusion from these four projects.  
7.1 CMV work 
7.1.1 Imprint of chronic CMV on the immune system of healthy subjects. 
Initially, a pilot study was carried out aiming to explore simultaneously influences of 
CMV chronic infection on different lymphocyte subsets. Contrasting with most previous 
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studies this study considered these influences in the same subjects. The most obvious 
finding emerging from this study is that, compared to CMV-seronegative donors, the 
CMV-seropositive cohort exhibited a remarkable increase in the frequencies of CD28neg 
CD4+ (Error! Reference source not found.), CD28neg CD8+ T cells (Error! 
ference source not found.), NKG2Cpos NK Cells (Figure 3.10) and Vδ2neg γδ T cells 
(Error! Reference source not found.). In addition, this study confirms, to some extent, 
hat these concurrent changes in phenotype are probably restricted to CMV infection and 
are not general phenomena that might occur with any chronic latent viral infection (see 
section 3.4.3). Furthermore inter-donor association analysis showed no statistically 
significant correlation between these subsets, which suggests independency of these cell 
subsets in controlling of CMV chronic infection, see section 3.4.5.  
Indeed, participation of all of these subsets of lymphocytes in keeping CMV under 
control raises awareness of the major burden on the immune system of this virus. 
Furthermore, it might imply that development of a successful vaccine against CMV 
should consider activating all these subsets. Finally, in the current thesis results of this 
pilot study served as a basis for further investigations in chapters four and five. 
7.1.2 Association between high frequency of Vδ2neg γδ T cells and CMV is 
age related  
Since the importance of γδ T cells, principally, Vδ2neg subsets, in CMV infection has 
been studied only recently, and due to the real gap in knowledge about these cells, more 
investigation of this lymphocyte subset was carried out in this thesis. Based on the fact 
that the persistent nature of CMV infection is thought to drive the accumulation of large 
CD4+/CD8+ T cell expansions over time, the target of the current work was to test the 
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hypothesis that Vδ2neg γδ T cell expansions occur more frequently in CMV carriers of 
older age and also to examine whether there are similarities between the phenotype and 
properties of Vδ2neg γδ T cells and that of αβ T cells. The present study has shown 
increased levels of Vδ2neg γδ T cells with advance in age in CMV-seropositive compared 
to CMV-seronegative donors.  
Furthermore, it has demonstrated the Vδ2neg γδ T cell phenotype is very similar to that of 
CMV-specific CD4+ and CD8+ T cells. In particular, Vδ2neg γδ T cells were akin to 
CMV-specific CD8+ T cells; both are mainly TEM cells, including CD45RAhigh TEMRA 
cells, with a highly differentiated CD27lowCD28low phenotype in Vδ2neg γδ T cells (see 
section 4.5.8). Moreover, Vδ2neg γδ T cells were found to express high levels of perforin 
and granzyme B, indicating cytotoxic functionality of this T cell subset. 
In addition, the reactivity of Vδ2neg γδ T cells against CMV-infected target cells was 
confirmed using in vitro expanded γδ T cell lines. Taken together, this state of readiness 
provides support for these cells having a central role in the immune response early in 
primary infection. However, it was not possible to demonstrate immediate effector 
activity in ex vivo assays, which was unexpected given the shared effector memory 
phenotype of Vδ2neg γδ T cells and virus-specific αβ T cells. Taking into consideration 
that the majority of Vδ2neg γδ T cells are located in peripheral tissues, these results 
suggest that, Vδ2neg γδ T cells can be triggered directly by infected cells, while viral 
reactivation from latency or cross-presentation by APCs can lead to efficient stimulation.  
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7.1.3 CMV in coronary artery disease (CAD) 
The purpose of this part of the project was to investigate the possible role of subclinical 
reactivation of latent CMV in coronary artery disease. Therefore differences in the 
magnitude of T cell responses to CMV antigens in CAD and age matched healthy 
controls were tested by flow cytometry. While a variety of definitions of the term 
“quality of T cell responses” have been suggested, in this chapter of the thesis, it refers 
to both the frequency as well as the pattern of T cell responses against CMV antigens. 
The “pattern of function” is related to how many functions the CMV–specific T cells 
can perform simultaneously, which ranges from mono to multifunctional (Betts et al., 
2006, Darrah et al., 2007, Seder et al., 2008). Therefore, the description of T cell quality 
included three aspects: effector function, proliferation ability, and cytotoxic capability. 
However, since there is no consensus about which markers should be used for these 
purposes, the justification for selecting the panel of markers that was used in this project 
is discussed in the following paragraphs.  
Undoubtedly IFNγ should be included in the panel as correlation between the frequency 
of IFNγ producing cells and clearance of various pathogens, particularly viruses, is well 
established (Ouyang et al., 2003b, Khan et al., 2007). Nevertheless, several observations 
showed that the frequencies of IFNγ producing cells do not adequately reflect the level 
of protection (Elias et al., 2005, Duvall et al., 2008). The ability of TNFα to mediate the 
killing of infected cells independently of IFNγ makes it second in the list of cytokines 
that are proposed to be measured (Herbein and O'Brien, 2000, Chan et al., 2003, Simon 
et al., 2005).  
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The third cytokine in the panel was IL-2, which has a major role in promoting the 
proliferation of CD4+ T cells and CD8+ T cells (Williams et al., 2006, Sester et al., 
2008). In addition, it enhances the activation of NK cells, which contribute to infection 
eradication.  
Regarding cytotoxicity, there are two ways to measure the capability of T cells to kill, 
particularly CD8+ T cells. These are either by directly measuring intracellular cytotoxic 
granules contents such as perforin and granzymes or indirectly through measuring a 
degranulation marker, CD107a/b (Betts et al., 2003). Again due to limitation in the 
number of flow cytometer channels it was decided to use the CD107a immobilization 
technique to measure the cytotoxic activity. To make coverage of all aspects of T cell 
response quality more complete, a chemokine was added to the proposed panel. MIP1β 
(CCL4) was selected, in view of the possible role of this chemokine in immunity against 
CMV. For instance, MIP1β was found to be capable of inhibiting HIV-1 infection by 
binding with the HIV-1 co-receptor CCR5 (Cocchi et al., 1995). Recently, CMV latent 
memory T cells were found to have a distinct cytokine signature characterized by high 
MIP1β expression (Kim et al., 2009a). In addition it plays important role in linking 
innate and adaptive immunity through its potent chemo-attracting function for 
monocytes and NK cells. Therefore, measurement of the components CD107a, MIP1β, 
IFNγ, TNFα, and IL-2 together can give a more comprehensive picture of the quality of 
the antigen-specific T cell response. 
The most striking observation of this study was the monofunctional restriction of most 
responding CMV specific T cells in coronary artery patients. Interestingly, no one 
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chemokine/cytokine was consistently expressed in all CMV reactive donors, suggesting 
that measuring one cytokine might be not sufficient to assess the magnitude of the T cell 
response. Additionally, and in contrast to expectation, neither IFNγ nor TNFα were the 
most frequent cytokines produced by stimulated T cells, instead MIP1β was the 
predominant cytokine in term of frequency (see section5.4.8). This might be of 
particular importance in assays that rely on measuring IFNγ alone such as ELlSPOT 
assays, which may seriously underestimate the actual frequency of antigen-specific T 
cells. Hence, it can be proposed that MIP1β is a more sensitive marker than IFNγ and 
TNFα for specific T cell activation. 
 With in the CAD group the most obvious differences between AMI (acute myocardial 
infarction) and PMI (stable post myocardial infarction) patients were in the distributions 
of polyfunctional CMV specific CD4+ T cells that were characterized by the absence of 
IFNγ but expression of IL-2 plus any other function. This cell subset was significantly 
higher in the PMI group, see section 5.4.11. This might suggest the importance of IL-2 
as a stability factor in coronary artery disease in CMV carriers. An implication of this is 
the possibility that the presence of (IFNγ- IL-2+) CMV specific CD4+ T cells could be 
used as an immune biomarker in CAD patients. In other words, absence of this 
functional pattern could be used to identify CMV-seropositive CAD patients at risk of 
developing AMI and hence to help development of novel strategies for future treatment 
and prevention. 
7.1.4 Should CMV be eradicated?  
Having seen all of these significant alterations in the immune system of CMV carriers, 
this could lead to the general feeling that CMV is bad for our health! Thus, preventing 
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infection by vaccination or even eliminating the established infection with antiviral drug 
such as ganciclovir may be desirable. This idea was augmented by proposing a link 
between CMV chronic carriage and high incidence of many infectious diseases in the 
elderly. One mechanism that sheds light on the association between CMV and morbidity 
in the elderly is the remarkable shrinkage in the available naïve T cell repertoire. This is 
attributed to the consequence of competition for 'immunological space' by dysfunctional 
CMV-specific T cell clones and other novel antigen-specific cells (Ouyang et al., 2004). 
However, It might be debated that expanded CMV-specific T cell clones have some 
beneficial effects, for instance, severe CMV infection is rarely reported in the immune-
competent (Effros, 2005). Furthermore, the presence of high frequencies of highly 
differentiated (CD28low) CD8+ T cells post transplant has been correlated to low risk of 
acute graft rejection (Colovai et al., 2003, Nickel et al., 2009) which might suggest a 
suppressive effect of these cell subsets (Liu et al., 1998). Nevertheless, this suppressive 
role can be responsible for failure of influenza vaccination in the elderly (Effros et al., 
2005, Song et al., 2010). 
Therefore, as a personal opinion, eradication of chronic CMV infection might be a 
reasonable goal only in certain circumstances when virus activation can be devastating. 
An example of that is post bone marrow transplant. There is, therefore, a definite need 
for a novel CMV vaccine. However a successful vaccine has to be able to mimic the 
response to the natural infection (Lambert et al., 2005), which in CMV incorporates all 
arms of the immune system.  Taking into consideration that the burden of natural CMV 
infection is related to its influences on the immune system rather than to its direct tissue 
damage, then it is reasonable to argue against this vaccine. Furthermore, to date, there is 
 299 
no approved CMV vaccine though there is an encouraging report that CMV vaccination 
can prevent CMV primary infection in pregnant seronegative mothers (Pass et al., 2009). 
The ambition for a novel CMV vaccine that can eradicate CMV infection from society 
may be achievable one day. However, the impact of that will remain an open question 
for more debate.  
7.1.5 Novelty of CMV work 
The influences of CMV infection on different arms of the immune system have been 
extensively studied, this was reviewed elsewhere (Khan, 2007). This includes the 
influences on the lymphocyte subsets that are studied in this thesis, namely highly 
differentiated  (CD28low) αβ T cells, NKG2Cpos NK cell, and Vδ2neg γδ T cells. However, 
the originality of this thesis is related to the exploring of changes in these lymphocyte 
subsets in the same subject. And according to the best of our knowledge it is the first 
study that addresses the correlation between; conventional (αβ), non-conventional (γδ) T 
cells  (both are adaptive immune system) and NK cells (innate immune system).  
Although the CMV seropositivity and the expansion of Vδ2neg γδ T cells has been 
established in both immunocompromised subjects (Dechanet et al., 1999a, Knight et al., 
2010) and immunocompetent subjects (Pitard et al., 2008), the current study is the first 
detailed account of how γδ T cell subsets are skewed by the combined effects of aging 
and CMV carriage in healthy individuals.  
In the context of influence of CMV status on the immune system of the diseased, the 
current study showed for the first time that there is a difference in the CMV-specific T 
cell profile of AMI and PMI patients. Therefore, this study has gone some way towards 
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suggesting the influence of CMV chronic infection on the immune system as an 
aetiological factor in ischemic heart diseases rather than CMV as direct causative factor.  
 
 
7.1.6 Limitations of current CMV work 
These conclusions should be considered in the light of some limitations. For example, 
the initial pilot study (chapter 3) was limited by the ability of the flow cytometer to 
detect only four colours, preventing comprehensive phenotyping and sub-classification 
of lymphocytes. Another limitation was the age of the cohort, which was between 20-60 
years, while it is known that CMV has more prominent effects in the age group over 60 
years. In addition, with a small sample size of primary acute CMV infection work (only 
two cases were accessible), caution must be applied, as findings might not be 
transferable to larger populations.  
While an 8-colour flow cytometer was available for the CAD project (chapter 5), the use 
of frozen samples for functional assays might be a drawback. In addition, the lack of 
phenotypic markers to differentiate memory from effector T cell subsets is another 
limitation.  
7.1.7 Future work on CMV  
No doubt formal identification of the ligand(s) for the TCR of γδ T cells would help in 
answering many important questions of immense value for vaccine design, a major 
priority for CMV (Arvin et al., 2004), where the aim should be to elicit broad multi-
specific immunity (Khanna and Diamond, 2006). It will also be important to learn if 
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CMV targets γδ T cells for immune subversion, as is the case for other T cells and for 
NK cells (Powers et al., 2008). 
Recently, Vδ2neg γδ T cells from CMV+ kidney transplant patients were found to 
express the IgG Fc receptor CD16 and to show enhanced function in the presence of 
anti-CMV antibody (Couzi et al., 2012). This emphasizes the potential for collaboration 
between Vδ2neg γδ T cells and IgG in mediating antibody-dependent cellular cytotoxicity. 
It would be of interest to study CD16 expression by Vδ2neg γδ T cells in leukaemia 
patients with or without VZV reactivation in relation to antibody titres.  
Given the shared reactivity of Vδ2neg γδ T cells for CMV and epithelial tumour cells 
(Halary et al., 2005) and the greater incidence of cancer in the elderly, this finding has 
great significance. Indeed, CMV seropositivity and increased numbers of Vδ2neg γδ T 
cells coincide with lower risk of cancer in a long-term follow up of kidney transplant 
patients (Couzi et al., 2010). Further independent studies of CMV status and Vδ2neg γδ T 
cells in cancer patients are thus a major priority for the future. 
Studying the role of CMV in CAD has thrown up many questions in need of further 
investigation. For instance, additional experimental investigations are needed to 
establish whether CMV viral load correlates with polyfunctionality and T cell quality 
during acute myocardial infarction. Indeed, correlating changes in telomere length to 
CMV polyfunctionality is another potential area for research. In addition, a longitudinal 
cohort study to monitor the dynamic changes in cytokine profile during and after acute 
myocardial infarction would be of great help in understanding the role of CMV infection 
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in coronary artery diseases. Furthermore, supplementary information on the role of other 
common latent viral infection such as herpes zoster is also needed. 
 
 
 
7.2 VZV work 
The main aim of the VZV study was to find an explanation for the high incidence of 
VZV reactivation in leukaemic children. Furthermore, as a secondary aim, it was tried to 
establish an immune risk profile that could help in identification of leukaemic children 
who might be at risk of VZV reactivation. The change in both VZV-specific B cell 
responses (through measuring of VZV-specific IgG titre by ELISA) and frequency and 
cytokine profile of VZV-specific T cell were monitored in this prospective study.     
One of the more significant finding to emerge from this study is the significant reduction 
in the absolute count of VZV-specific IFNγ+ CD4+ T cells in those leukaemic children 
group who developed clinical VZV infection (see section 6.5.13). This reduction was 
associated with an inversion in the CD4:CD8 ratio of VZV-specific T cell populations 
that produce IFNγ. It was possible to detect this profile during acute infection and even a 
few weeks before appearance of infection in a previously naturally immunized patient 
(see section 6.5.15). This may lead to the proposal that both the reduction in the absolute 
counts of VZV-specific IFNγ+ CD4 T cells and/ or inversion of the VZV-specific 
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CD4:CD8 (IFNγ producer) T cell ratio are an immune risk profile for VZV reactivation 
in leukaemic children.   
 Contrasting with T cell responses, VZV-specific IgG was detected post primary 
infection in most patients; however, there was no clear association between the VZV-
specific IgG antibody titre and VZV reactivation. In general, therefore, it seems that 
VZV-specific IgG antibody titre might be an inappropriate indicator for protection 
against VZV reactivation in the context of leukaemia.  
7.2.1 Novelty of VZV work 
The VZV work was original theoretically and methodologically. For instance, to the best 
of our knowledge, the current VZV study is the first prospective longitudinal study that 
has explored B cells and/or T cells as a possible immunological defect behind the high 
incidence of VZV reactivation in children with ALL. Methodologically, the ICS assay 
was modified by using whole attenuated viral vaccine as stimulus instead of using 
peptides mix; also the assay was optimized to work with limited numbers of cells in 
immune compromised patients. 
7.2.2 Limitations of current VZV study 
A number of important limitations need to be considered in VZV project. First, it is 
worth noting that this clinical study is still running, and since only few patients have 
completed their chemotherapy course, the data presented in this thesis can be considered 
as preliminary. In addition, it is admitted that the absence of age matched healthy 
controls is one of the weaknesses of this project. Therefore, recruiting healthy children 
from those children who were admitted for elective surgery such as tonsillectomy might 
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be an option. Furthermore, the current study was limited by the gap in knowledge about 
other lymphocytes such as NK cells and unconventional T cell subsets.  
7.2.3 Future work on VZV 
What is now needed is continuous recruitment of more patients and monitoring them for 
a longer period. Furthermore, the use of ultra sensitive and highly specific assays such as 
TRFIA, FAM and ELISPOT would be of great importance in assessing B cell immunity 
(O'Ferrall, 1954, Baba and Shigeta, 1986). In addition, further investigation and 
experimentation into the role of innate immunity, particularly of NK cells is strongly 
recommended. It has been shown that the NK cell KIR B haplotype, which contains 
several activating receptors, is associated with increased protection against CMV 
reactivation after bone marrow stem cell transplantation (Cook et al, 2006). It would be 
of interest to examine KIR genotypes in leukaemia patients who do or do not 
subsequently become infected with VZV.     
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